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Cationic antimicrobial peptides (CAMPs) are a key component of the innate immune 
system of many organisms, including humans. They target invading pathogens in a variety 
of ways often integrating into, and permeabilising, bacterial cell membranes and causing 
cell death. In response, bacteria have developed a variety of CAMP resistance mechanisms, 
including those based on ATP-binding cassette (ABC) transporters such as Sap and Yej, 
which are the subject of studies described herein. ABC importers use an extracellular 
substrate binding protein (SBP) to recognise substrates and deliver them to a cognate 
membrane complex for uptake into the cell. A primary aim of this study was to unravel the 
structural basis of CAMP binding by the SBPs, SapA and YejA. CAMPs are larger than 
conventional peptides handled by ABC transporters and usually contain secondary 
structure. 
SapA from diverse bacterial species proved to be insoluble. Moreover, phylogenetic 
analysis carried out here suggested to us that SapA is in fact a dipeptide binding protein. 
YejA from E. coli was purified and crystallised and its structure determined by X-ray 
diffraction methods, revealing the protein in the closed conformation with an endogenous 
undecapeptide, LGEPRYAFNFN, bound in a spacious cavity enclosed by two protein lobes. 
Remarkably this peptide is derived from sequence close to the N-terminus of YejA itself. 
LGEPRYAFNFN was shown via thermal shift assays and mass spectrometry to bind 
specifically to YejA. Other ligands of variable length derived from the N-terminus of YejA 
were also shown to bind to YejA; all possess the core motif EPRYAFN. We have so far been 
unable to demonstrate binding of CAMPs to YejA. This data leaves open the intriguing 
possibility that Yej function may be regulated by proteolytic processing of the extended N-
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1.1 Antimicrobial resistance 
Antibiotics have undoubtedly saved the lives of millions of people worldwide and were 
seen as wonder drugs for much of the 20th century. They were considered to be magic 
bullets which selectively targeted disease causing microbes without harming the host. 
Many people thought they would stop communicable disease. The 1950s to the 1970s was 
considered the golden era of antibiotic discovery. However, Fleming was quick to caution 
about the misuse of antibiotics and the potential for resistance to emerge (Zaman et al., 
2017).  
Antibiotics work with the immune system to clear the body of pathogens and work in a 
multitude of ways including inhibiting the synthesis of the bacterial cell, proteins and DNA 
and membrane disorganisation. Over the last 60 years, millions of metric tons of new 
classes of antibiotics have been manufactured. As demand for antibiotics has increased 
across all sectors, it has allowed for cheaper off-label drugs, helping to spread resistance 
(Zaman et al., 2017).  
Antibiotic resistance can develop very quickly (Figure 1.1) and has been found in every 
country (World Health Organisation, 2018). 2 million people a year in the US are infected 
with antibiotic resistant bacteria resulting in the death of 23,000 people, this is a huge 
strain on the healthcare system (CDC, 2018). In 2016 the Wellcome Trust put out a report 
on antimicrobial resistance that predicted that by 2050 10 million people a year would die 
of antimicrobial resistant infection, more than are predicted to die of cancer, costing over 
$1 trillion per year in healthcare fees worldwide (Wellcome Trust, 2016). However, with the 
improvements in information technology people are more aware than ever of antibiotic 
resistance, its causes and how to prevent it (Zaman et al., 2017).  
A whole host of mechanisms are employed by bacteria to resist antibiotic killing as well as a 
range of methods of acquiring those resistance traits. Acquisition of different resistance 
mechanisms can be split into three categories; innate, acquired or adaptive. Another major 
contributor to the development of antibiotic resistance is the natural mutation rate of 
bacteria. As mutations occur they can bring costs or benefits to the bacteria, those which 
are beneficial are commonly maintained and spread throughout the population via various 
means, sometimes these mutations are antibiotic resistance (Schroeder, Brooks and 




Figure 1.1. Timeline of antibiotic discovery and resistance development. 
Shortly after the discovery of a new antibiotic, resistance develops. Now, due to the 
discovery void, there are fewer new antibiotics coming through the pipeline and so fewer 





Innate resistance is the natural ability of a bacterium to resist the activity of a particular 
antibiotic or antimicrobial due to the inherent structure or functional characteristics of the 
organism (Figure 1.2). This is also sometimes known as insensitivity to particular antibiotics 
and antimicrobials. Innate resistance mechanisms can include a lack of affinity for the 
antibiotic; inaccessibility of the antibiotic to the bacterial cell; extrusion of the antibiotic 
from the cell or enzymes which inactivate the antibiotic. These resistance mechanisms are 
commonly due to the fact that the bacteria themselves produce antibiotics so these 
mechanisms are a form of self-immunity that can be employed against other similar 
antibiotics or a simple mutation which enables an efflux pump to now recognise an 
antibiotic (Schroeder, Brooks and Brooks, 2017).  
Acquired resistance is categorised as the ability of a bacteria to not only survive antibiotic 
stress but to also acquire resistance under antibiotic selective pressure, for example via 
horizontal gene transfer (Schroeder, Brooks and Brooks, 2017). Acquired resistance is 
commonly spread through horizontal gene transfer (Figure 1.3), this is the passing of 
genetic information from one bacteria to another and contrasts with vertical gene transfer 
in which genetic information is passed on to the next bacterial generation via chromosome 
replication and cell division. Horizontal gene transfer allows the rapid passage of genetic 
information between multiple different bacterial cells and allows the passing of genetic 
information between different bacterial species, one of the reasons antibiotic resistance is 
spreading so quickly. There are three mechanisms of horizontal gene transfer; (i) 
transformation; (ii) transduction and (iii) conjugation (Von Wintersdorff et al., 2016). 
Transformation (Figure 1.3) is the process by which bacteria take up, integrate and express 
pieces of exogenous DNA from their environment (Griffith, 1928). It is therefore possible 
for bacteria to become resistant to antibiotics if they use this natural transformation 
process to pick up pieces of DNA encoding antibiotic resistance. This transformation 
process has been shown to transfer resistance genes between bacteria of the same and 
different species (Alexander, Hahn and Leidy, 1956).  
Transduction (Figure 1.3) involves bacteriophages transferring genes between bacteria that 
are advantageous to their bacterial hosts, this in turn promotes their own survival and 
propagation (Modi et al., 2014). As with transformation these bacteriophage transported 
genes are integrated and expressed within the new bacterial host. Gene transfer agents are 
very similar to bacteriophage, however they are host cell derived and contain only 




Figure 1.2. Mechanisms of innate antibiotic resistance. 
Diagram depicting the different forms of innate resistance. An example of a β-lactam 
antibiotic targeting a penicillin binding protein (PBP), antibiotic A can enter the cell via a 
porin and reach its target, inhibiting peptidoglycan synthesis. Antibiotic B is removed from 
the periplasm via an efflux system, so is unable to reach its target and antibiotic C is not 
able to pass through the outer membrane so cannot target the PBP. Innate resistance is 




Figure 1.3. Mechanisms of horizontal gene transfer. 
Methods by which bacteria acquire resistance via horizontal gene transfer. Image taken 




random segments of DNA found in the host bacteria (Marrs, 1974; Von Wintersdorff et al., 
2016).   
Finally, conjugation (Figure 1.3) is the direct transfer of DNA via cell-to-cell contact 
between bacteria. This DNA transfer occurs through conjugative machinery such as pili and 
the DNA transferred is often a plasmid or a transposon. Antibiotic resistance genes are 
often encoded on plasmids and transposons, making conjugation an important mechanism 
of spreading antibiotic resistance. Conjugation is considered the most likely mechanism of 
antibiotic resistance spread via horizontal gene transfer due to the fact that the DNA is 
more protected from the external environment than the DNA in transformation and the 
host range is larger than that of bacteriophage transduction (Norman, Hansen and 
Sorensen, 2009; Von Wintersdorff et al., 2016).  
Lastly, adaptive resistance is a temporary increase in the ability of a bacterium to survive a 
particular antibiotic assault or environmental niche resulting from alterations in gene or 
protein expression brought about by an environmental trigger. In the case of antimicrobial 
resistance the environmental trigger would be the presence of the antimicrobial itself. The 
intrinsic antimicrobial resistance mechanism in the bacteria that is triggered by the 
antimicrobial can include biofilm formation, efflux pump regulation, changes in cell 
morphology and permeability and antibiotic inactivation via enzymes (Schroeder, Brooks 
and Brooks, 2017). 
1.2 Bacterial cell envelope 
The bacterial cell envelope is a complex and multi-layered barrier which protect the 
bacterium against the external environment whilst also providing the cell with structure 
and rigidity. Most bacterial cell envelopes fall into one of two major categories, Gram-
negative and Gram-positive, which have very different envelope architecture (Silhavy, 
Kahne and Walker, 2010).  
1.2.1 Gram-negative cell envelopes 
The Gram-negative cell envelope consists of three distinct layers; the outer membrane 
(OM), the peptidoglycan cell wall and the cytoplasmic or inner membrane (IM). Between 
the OM and the IM is the periplasm, an aqueous cellular compartment (Silhavy, Kahne and 
Walker, 2010).  
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The OM is the outermost layer of the Gram-negative cell envelope and is a lipid bilayer 
(Figure 1.4). The inner leaflet of the OM consists of phospholipids, whereas the outer 
leaflet contains glycolipids such as lipopolysaccharide (LPS). LPS is notorious for causing 
endotoxic shock common with septicaemia caused by Gram-negative pathogens. 
Therefore, the human innate immune system is highly sensitive to the presence of LPS. LPS 
is critical in the barrier function of the OM and consists of a glucosamine disaccharide 
attached to six or seven acyl chains, a polysaccharide core and an extended polysaccharide 
chain (O-antigen). Lipid A is a hydrophobic lipid component of LPS which anchors the LPS to 
the OM. The acyl chains of the LPS are predominantly saturated. This facilitates tight 
packing and provides an effective barrier against hydrophobic molecules. The OM also 
contains proteins, the majority of which form β-barrels and act as porins, allowing the 
passive diffusion of molecules such as polysaccharides and peptides across the OM. These 
OM porins limit the diffusion of hydrophilic molecules larger than 700 Da or so. This 
coupled with the nature of the LPS makes the OM a selective and effective permeability 
barrier. As a result, Gram-negative bacteria are generally more resistant to antibiotics than 
Gram-positive bacteria (Silhavy, Kahne and Walker, 2010).  
The peptidoglycan is a rigid exoskeleton formed of repeating units of the disaccharide N-
acetyl glucosamine-N-acetyl muramic acid. These repeating units are crosslinked by 
pentapeptide side chains. It is this peptidoglycan layer which gives bacteria their 
characteristic cell shape, such as rods in the case of Escherichia coli. In Gram-negative cells 
the peptidoglycan is located in the periplasm where it is anchored to the OM via the 
lipoprotein Lpp (Silhavy, Kahne and Walker, 2010). 
The periplasm harbours the periplasmic binding proteins which function in the transport of 
solutes, such as sugars and amino acids, across the inner membrane (Silhavy, Kahne and 
Walker, 2010). 
The IM of bacterial cells performs all of the membrane-associated functions of eukaryotic 
organelles such as energy-production, lipid biosynthesis, protein secretion and transport. 
The IM is formed of a phospholipid bilayer (Figure 1.4), in E. coli the major phospholipid 
components are phosphatidyl ethanolamine and phosphatidyl glycerol (Silhavy, Kahne and 




Figure 1.4. The structure of the Gram-negative bacterial cell envelope. 
The Gram-negative cell envelope includes an outer membrane, a periplasm and a thin layer 
of peptidoglycan. LPS = lipopolysaccharide, OMP = outer membrane protein, LP = 





1.2.2 Gram-positive cell envelopes 
The Gram-positive cell envelope structure differs in a number of key ways from the Gram-
negative cell envelope structure. The most obvious difference is that Gram-positive 
bacteria do not contain an outer membrane. Due to the fact that the OM indirectly 
stabilises the IM in Gram-negative bacteria the peptidoglycan layer is relatively thin. To 
enable Gram-positive bacteria to withstand the turgor pressure, they are surrounded by a 
peptidoglycan layer that is many times thicker than that of Gram-negative bacteria (Figure 
1.5). Long anionic polymers, called teichoic acids, are threaded through the peptidoglycan 
layers. Teichoic acids are comprised of glycerol phosphate, glucosyl phosphate, or ribitol 
phosphate repeats. The surfaces of the Gram-positive bacterial cell envelope can be 
decorated with proteins with functions analogous to those found in the periplasm of Gram-
negative bacteria (Silhavy, Kahne and Walker, 2010).  
Gram-positive bacterial peptidoglycan structure is similar to that of Gram-negative bacteria 
in that it is composed of a disaccharide repeat. The difference in the structure comes from 
the different crosslinks between the glycan strands, which can differ between bacterial 
species. Another major difference is that in Gram-negatives the peptidoglycan layer is a few 
nanometres thick whereas in Gram-positives the layer can be 30-100 nm thick and 
composed of many overlapping layers of peptidoglycan (Figure 1.5) (Silhavy, Kahne and 
Walker, 2010).  
Teichoic acids are anionic polymers which fall into two groups, wall teichoic acids, which 
are coupled to peptidoglycan and lipoteichoic acids, which are anchored to the cell 
membrane (Figure 1.5). Due to their anionic character, they bind cations and contribute to 
cation homeostasis, this in turn influences the rigidity and porosity of the cell wall (Silhavy, 
Kahne and Walker, 2010).  
1.3 Cationic antimicrobial peptides (CAMPs) 
Innate immunity is the first line of defence for many organisms against invading pathogens. 
As many species have evolved they have maintained the innate immune system as a rapid 
broad-spectrum defence mechanism against pathogens. A major component of the innate 
immune system is cationic antimicrobial peptides (CAMPs), which in recent years have 
been highlighted as possible alternatives to antibiotics (Hancock and Lehrer, 1998). CAMPs 
are <100 residue amphipathic molecules with a variety of different antimicrobial effects 




Figure 1.5. The structure of the Gram-positive bacterial cell envelope. 
The Gram-positive cell envelope contains a thick layer of peptidoglycan and no outer 





being constitutively expressed by epithelial cells. Although they come in many different 
sizes and with a variety of secondary structures, the common feature of the CAMPs is that 
they are highly cationic. There are a number of different categories of CAMPs, including 
defensins, cathelicidins and histatins (Pasupuleti, Schmidtchen and Malmsten, 2012). 
Defensins are long (18-45 residues) cationic peptides with three disulphide bonds linking six 
conserved cysteines. They were first discovered in human neutrophils (Ganz et al., 1985a; 
Selsted et al., 1985a) and have since been found in insects (Saito et al., 1995), mammals 
(Ganz et al., 1985b; Selsted et al., 1985b) and plants (Thomma, Cammue and Thevissen, 
2002). The antimicrobial activity of defensins is very broad-spectrum with activity against 
bacteria, fungi and enveloped viruses (Pasupuleti, Schmidtchen and Malmsten, 2012).  
Cathelicidins are the second largest group of CAMPs and are identified by the far N-
terminal region, the central conserved region and the variable C-terminal region (Zanetti 
and Gennaro, 1995). They are synthesised as pro-peptides and undergo cleavage to 
produce the active CAMP. The only currently known human cathelicidin is LL-37 (Zanetti 
and Gennaro, 1995). LL-37 (Figure 1.6A) is a 37 residue peptide which forms an α helix with 
a hydrophobic N-terminus which facilitates binding of LL-37 to the negatively charged 
hydrophobic bacterial membranes. LL-37 is able to bind both the bacterial membrane and 
lipopolysaccharide and has potent and widespread antimicrobial activity (Larrick et al., 
1995).  
Histatins are histidine rich peptides ranging in size from 7 to 38 residues and are 
constitutively expressed in salivary glands of humans (Rijnkels et al., 2003). Histatins cause 
bacterial membrane permeabilisation, and like cathelicidins and defensins, histatins have a 
broad spectrum of antimicrobial activity (Luque-Ortega et al., 2008; Wiesner and Vilcinskas, 
2010; Pasupuleti, Schmidtchen and Malmsten, 2012). 
Melittin from bee venom is a linear 26 residue cytolytic peptide and spontaneously 
integrates into phospholipid bilayers. Melittin is composed of an amphiphilic α helix that 
has a bent rod shape (Figure 1.6B) (Terwilliger and Eisenberg, 1982). Melittin forms 
transmembrane pores in the phospholipid membrane of bacteria (Yang et al., 2001).  
The 32-residue peptide protamine is a small arginine-rich peptide with histone like 
properties. Protamine is synthesised in the late stages of spermatids and binds to DNA 






Figure 1.6. The structure of CAMPs LL-37 and melittin. 
The structure of the CAMP LL-37 is shown in (A) and melittin is shown in (B). N and C refer 
to the N and C-terminus. Both are shown as a purple ribbon, with side chains displayed in 
ball and stick form. Green indicates an uncharged side chain, blue indicates a positively 
charged side chain and red indicates a negatively charged side chain. The bent helix shape 













Protamine, taken from salmon sperm, was used in early CAMP resistance studies as it 
showed preferential killing of Salmonella, unlike other compounds, and was inexpensive 
and easily available (Groisman et al., 1992).  
1.3.1 CAMP mode of action 
The positive charge of CAMPs leads to their accumulation at the negatively charged 
membranes of both Gram-positive and Gram-negative bacteria, although the outer 
surfaces of these two classes of bacteria are substantially different. CAMPs appear to be 
able to pass easily through the porous peptidoglycan outer layer of Gram-positive bacteria 
(Koch, 1996; Malanovic and Lohner, 2016). Likewise, some CAMPs have the ability to cross 
the outer membrane of Gram-negative bacteria, however the mechanism is slightly 
different. To cross the outer membrane these CAMPs seem to use a charge-exchange 
mechanism involving Ca2+ and Mg2+ ions bound to the lipopolysaccharide, possibly aided by 
outer membrane protein binding according to the “self-promoted uptake hypothesis” 
(Anunthawan et al., 2015; Malanovic and Lohner, 2016). This gives CAMPs access to the 
inner bacterial membrane.  
Once CAMPs have crossed the outer barrier, either the outer membrane or the cell wall, 
they are able to exert their bactericidal effect. There are three accepted models for how 
CAMPs disrupt the membrane, barrel-stave, carpet or toroidal-pore. The method used by 
each CAMP can change depending on a variety of factors including membrane structure, 
aggregation, net charge and topology (Malanovic and Lohner, 2016).  
A barrel-stave pore is much like a multi protein ion channel. A defined number of CAMPs 
are able to interact with each other in a specific way to create a pore structure (Figure 1.7). 
However, in the toroidal-pore system those specific CAMP interactions are not present, 
instead the CAMPs accumulate together and non-specifically interact with each other to 
disrupt the membrane curvature to create a toroid of high curvature forms (Figure 1.7). 
The carpeting model (Figure 1.7) is the unorganised association of CAMPs with the 
membrane. At high concentrations of CAMPs, they behave much like detergents forming 
micelles from the membrane (Wimley, 2010).  
Although CAMP integration into the inner membrane of bacteria is a major cause of 
bacterial cell death, CAMPs are also able to stimulate the immune system which is an 
important feature for the hosts defence against invading pathogens. When local cells are 




Figure 1.7. Mechanisms of CAMP action. 
The lipid bilayer of the membrane is shown in grey and CAMPs are shown in blue, the 
different modes of CAMP action can be clearly seen in each diagram. Image adapted from 





recruits leukocytes to the location and can stimulate the production of chemokines and 
cytokines. Production of chemokines and cytokines such as IL-8 and IFN-α recruits immune 
cells like dendritic cells and T cells to the site of microbial invasion. This immune cell 
recruitment helps to clear the infection from the host quickly. CAMPs are also able to 
promote wound healing, helping to prevent further infection of the affected area (Lai and 
Gallo, 2009).  
1.3.2 Polymyxins 
Although polymyxin B and polymyxin E (also known as colistin) are not thought of as 
traditional CAMPs, they have a similar morphology and mode of action as CAMPs. This is a 
result of the large number of amino groups in the molecules giving rise to a net positive 
charge at physiological pH. This net positive charge attracts polymyxin B and colistin to the 
negatively charged bacterial membrane.  Initially both polymyxin B and colistin appear to 
target the outer membrane of Gram-negative bacteria, however at high enough 
concentrations (above 20 µg/ml) it has been shown that polymyxin B has the ability to 
depolarise the inner membrane of Gram-negative bacteria by forming pores in the 
membrane (Hancock, 1997; Daugelavičius, Bakienė and Bamford, 2000). This inner 
membrane pore forming ability of polymyxin B closely resembles the mode of action of 
CAMPs. Polymyxin B was isolated from Bacillus polymyxa and is a lipopeptide antibiotic. Its 
structure (Figure 1.8) consists of a cationic peptide ring and a tripeptide side chain with a 
fatty acid tail (Hancock, 1997). Polymyxin B and colistin differ in a single amino acid (Figure 
1.8) (Li et al., 2006). 
1.3.3 Resistance to CAMPs 
Resistance to CAMPs can be either intrinsic or acquired. Intrinsic resistance can occur via 
passive or inducible mechanisms. Passive intrinsic resistance commonly refers to 
modifications certain bacterial species have to their lipid A which makes it more positively 
charged. The more positively charged lipid A is, the less attractive it is to the positively 
charged CAMPs and therefore the less CAMP binding occurs (Manniello, Heymann and 
Adair, 1978; Viljanen and Vaara, 1984). The transient molecular modifications of bacteria in 
response to CAMPs is called inducible resistance, the reversibility of these modifications 
offsets the energetic burden of the changes. Again, these changes often involve 
components of the membrane, including incorporation of positively charged molecules to 
reduce the interaction of CAMPs with the bacterial cell surface (Andersson, Hughes and 






Figure 1.8. Chemical structure of polymyxin B and polymyxin E (colistin). 
The amino acid residue that differs between the two structures is highlighted by the green 
circle, Phenylalanine for polymyxin B and Leucine for colistin. Image adapted from (Jerke, 







Although membrane modification is the most common defence mechanism against CAMPs, 
there are other defence strategies employed by bacteria, these include efflux of CAMPs 
and CAMP proteolytic degradation. The membrane protein OmpT from E. coli has been 
shown to degrade both LL-37 and the positively charged peptide protamine. Due to the fact 
that the active site of OmpT is extracellular these peptides would be degraded before they 
could integrate into the cell membrane therefore preventing membrane disruption 
(Stumpe et al., 1998; Thomassin et al., 2012). An ATP-binding cassette (ABC) transporter 
dependent efflux pump that acts on CAMPs is encoded by the chromosomal gene vraFG in 
S. aureus (Min et al., 2007).  Efflux pump systems that act on CAMPs have also been 
identified in many other bacterial species including N. gonorrhoeae (Shafer et al., 1998) and 
Yersinia spp. (Bengoechea and Skurnik, 2000).  
Interestingly, there have also been reports of ABC transporters that actively import CAMPs 
into the cytoplasm of bacterial cells. Although this seems counter intuitive, by importing 
the CAMPs into the cytoplasm, these ABC transporters prevent the CAMPs integrating into 
the cell membrane. These importing ABC transporters are named Sap (sensitive to 
antimicrobial peptides) and Yej (Groisman et al., 1992; Parra-Lopez, Baer and Groisman, 
1993; Eswarappa et al., 2008).  
1.4 ATP-binding cassette (ABC) transporters 
Transport of molecules across cell membranes is critical for all organisms as it allows the 
cells to acquire nutrients required for survival and cell growth. In the case of active 
transport, transporters also allow the cells to maintain a concentration gradient across the 
membrane. It is possible for molecules such as oxygen, carbon dioxide and water to simply 
diffuse through the cellular membrane as they are small uncharged molecules. However, 
larger and charged molecules are actively transported across the membrane via primary or 
secondary transport. Primary transporters are defined as transporters that require the 
breakdown of the high-energy molecule ATP to catalyse the transport reaction. Secondary 
transport is driven by the electrochemical potential difference across the cell membrane 
created by pumping ions in/out of the cell. Allowing an ion to move down the 
electrochemical gradient increases entropy and can serve as an energy source for 
transporting a desired molecule. In bacteria hydrogen is the ion commonly used in 
secondary transport. Secondary transporters can be categorised into antiporters, where 
the molecules move in opposite directions across the membrane, or symporters where the 
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molecules move in the same direction across the membrane (Lodish H, Berk A, Zipursky SL, 
2000). 
ABC transporters are primary transporters and use ATP to transport their substrates across 
the membrane. ABC transporters have a very diverse range of substrates including; ions, 
sugars, amino acids, vitamins, drugs, peptides and lipid molecules (Davidson et al., 2008).  
1.4.1 ABC transporter structure 
ABC transporters can be classified as exporters, importers or energy-coupling factors, with 
importers further classified as either type I or type II transporters depending on their 
structure and mechanism (ter Beek, Guskov and Slotboom, 2014; Wilkens, 2015a). A typical 
ABC transporter contains two nucleotide binding domains (NBDs) and two transmembrane 
domains (TMDs) (Figure 1.9). Bacterial ABC importers also have a substrate binding 
domain/protein (SBD/P) which delivers the substrate for transport to the transmembrane 
domains. In Gram-negative bacteria the SBP is free to move around the periplasm, in Gram-
positive bacteria however the SBP is lipid anchored to the membrane. In bacteria it is also 
possible to have fused, homodimeric and heterodimeric NBDs and TMDs (Wilkens, 2015b).  
The NBDs of ABC transporters are cytosolic and contain many highly conserved motifs. 
NBDs comprise two subdomains, one similar to the RecA protein and containing the Walker 
A motif and the other named the helical domain and containing the LSGGQ motif. In the 
transporter the NBDs are arranged so that the ATP binding interfaces are facing each other 
in a head to tail orientation (Figure 1.10). This arrangement allows for the binding and 
hydrolysis of two ATPs. Upon ATP binding the two NBDs move closer via the coupling 
helices, pulling the lower sections of the TMDs together and therefore changing the TMD 
conformation from inward facing to outward facing allowing the transport of a substrate 
molecule to the cytoplasm (Figure 1.11) (Locher, 2009).  
All of the genomes sequenced to date encode ABC exporters. Although for several ABC 
exporters the physiological substrate is unknown many of them are involved in extrusion of 
toxic substances such as drugs. All ABC exporters share a common core architecture of 12 
transmembrane helices which extend below the membrane and into the cytoplasm of the 
cell, often the TMDs are fused to the NBDs (Figure 1.9) (Locher, 2009). 
Type I ABC importers typically take up small molecules such as ions, sugars and amino acids 




Figure 1.9. Structure of ABC Transporters. 
(A) A typical ABC importer structure which includes a substrate binding protein (SBP), and 
(B) a typical ABC exporter which does not. TMD = transmembrane domain, NBD = 









Figure 1.10. NBDs of ABC transporters have a head to tail dimer orientation. 
Top down view of NBDs. The two nucleotide binding domains of ABC transporters are 
orientated in a head to tail orientation, as the helical domain contains the LSGGQ motif and 








Figure 1.11. Upon ATP binding, NBDs change the orientation of TMDs of ABC 
transporters. 
The coupling helices of the transmembrane domains (TMDs) interact with the nucleotide 
binding domains (NBDs), so that when the NBDs change conformation upon ATP binding 
the TMDs change from the inward facing to the outward facing conformation. The second 





However the type II importers which transport larger molecules including haem and 
vitamins typically have 20 transmembrane helices (Locher, Lee and Rees, 2002). It should 
be noted at this point that type I importers appear to have a transient binding pocket in the 
TMDs. This binding pocket encourages substrate release from the SBP when it binds to the 
TMD and the lobes of the SBP are opened, it also helps prevent the substrate diffusing out 
of the TMDs before transport is affected. Upon ATP binding in the NBDs and the swivelling 
of the TMDs from the outward facing to the inward facing conformation the transient 
binding pocket is occluded and the substrate is pushed into the cytoplasm (Oldham et al., 
2007). In type II importers the TMDs seem to be inert with little or no affinity for their 
substrates (Locher, 2009).  
Although type I importers have a transient binding site in the TMDs, the SBPs of both type I 
and type II importers have very high specificity for their substrates. Although there is 
considerable variation in the size of SBPs (25-70 kDa) with little shared sequence similarity, 
the overall fold of SBPs is well conserved. SBPs consist of two domains with the binding 
pocket for the substrate lying at the interface of the domains. Binding occurs in a Venus fly 
trap like manner accompanied by large conformational changes. Upon binding, the 
substrate is completely buried in a cavity between the two domains of the SBP (Locher, 
2009). Berntsson et al., 2010 classified SBPs into 6 structural categories (Cluster A-F) (Figure 
1.12).  
Cluster C SBPs bind a range of substrates including di and oligopeptides, nickel and 
polysaccharides such as cellobiose. One of the defining features of this group is their larger 
size and possession of an extra domain which is thought to extend the binding pocket to 
allow room for larger substrates (Berntsson et al., 2010). This larger binding cavity, extra 
domain, and for some members of the cluster their preference for oligopeptides, may have 
significance for how they bind and transport CAMPs.    
Energy-coupling factors (ECF) are a type of ABC transporter widely used by prokaryotes to 
take up micronutrients and can be either importers or exporters. Every ECF transporter 
contains two cytosolic NBDs, a membrane embedded substrate binding domain (EcfS) and 
a transmembrane energy coupling protein (EcfT) that links the NBDs and EcfS (Figure 1.13). 
The EcfS protein is the substrate-binding component of the transporter and determines the 
specificity of the transporter. These proteins are able to bind a wide range of small 
molecules such as vitamins, amino acids and metals. From information gathered from 




Figure 1.12. Structural classifications of SBPs. 
Substrate binding proteins (SBPs) have been classified in Clusters A-F, as indicated by the 
lettering in the figure, based on structure. The structural differences which define a cluster 
are shown in orange. Cluster C SBPs have a clearly defined extra domain. Image taken from 




Figure 1.13. Schematic diagram of an energy-coupling factor (ECF) transporter. 
ECF transporters consist of two nucleotide binding domains, a membrane-embedded 









are transported across the membrane via ECFs. In this hypothesis upon substrate binding, 
the EcfS protein topples over in the membrane to transport the substrate across the 
membrane. This process is fuelled by ATP binding and hydrolysis. EcfS is horizontally 
orientated in the membrane when the NBDs are in the open conformation, upon ATP 
binding the NBDs come together and push the EcfS into a conformation where the 
substrate binding site is accessible to substrates. ATP hydrolysis allows the NBDs to move 
apart and the EcfS to topple back over in the membrane and release the substrate to the 
opposite side of the membrane (Figure 1.14) (Zhang, 2013).  
1.5 ABC transporters and CAMP resistance 
1.5.1 ABC transporters and two-component regulatory systems in peptide antibiotic 
resistance 
Transporters can act as co-sensors for signal transduction pathways in bacteria. These 
transporters can interfere with signal transduction pathways by transporting effector 
molecules into the cytoplasm or interacting directly with sensory components. Direct 
interaction with sensory components involves interaction between a membrane bound 
sensor domain, which binds specific substrates, and the signalling domain, which transfers 
the signal information into the cytoplasm of the cell. Commonly in signal transduction 
pathways the transporters act as inhibitors of the respective pathways, however in the case 
of antimicrobial peptide resistance systems the transporter is required for activation of 
signalling and the system remains inactive without the transporter. These antimicrobial 
resistance systems are widespread in Gram-positive bacteria and consist of a two-
component regulatory system (TCS), where the histidine kinase lacks an obvious input 
domain, and an ABC transporter with an unusual 10 transmembrane helical structure and 
large extracellular domain. All examples of this kind of system characterised to date involve 
resistance to peptide antibiotics and the ABC transporter is a key component of the system 
(Dintner et al., 2014). 
An example of such a TCS and ABC transporter antimicrobial peptide resistance system is 
the BceRS-BceAB system in B. subtilis which confers resistance to the peptide antibiotic 
bacitracin, an inhibitor of cell wall synthesis. Bacitracin is very similar to polymyxins in that 
it is a nonribosomally synthesised cyclic peptide antibiotic. BceS, the histidine kinase, is 
unable to detect bacitracin in the absence of the ABC transporter BceAB. This led to the 
assumption that the BceAB transporter is the sensory domain, however the mechanism by 




Figure 1.14. Schematic of the mechanism of transport of ECF transporters. 
EcfS is horizontal in the membrane when the nucleotide binding domains (NBDs) are in the 
open conformation, upon ATP binding the NBDs come together and push the EcfS into a 
conformation where the substrate binding site is accessible to substrates. Upon ATP 
hydrolysis the EcfS topples back over in the membrane and releases the substrate to the 








evidence indicates that resistance to bacitracin is via translocation of the antibiotic through 
the BceAB transporter to prevent contact with the cell wall synthesis machinery (Dintner et 
al., 2014).  
From the experimental evidence gathered a working hypothesis of the system has been 
produced in which bacitracin is bound directly by the transporter BceAB (Figure 1.15). A 
sensory complex is then formed in the membrane via the interaction between BceAB and 
BceS. When ATP is hydrolysed by the BceAB transporter, the activation of BceS is triggered, 
this then leads to phosphorylation of BceR. The target promoter, PbceA, is activated by BceR 
which induces increased production of BceAB to ensure resistance. It is not known whether 
BceR interacts with the complex of BceAB and BceS (Dintner et al., 2014).  
1.5.2 Sap ABC transporter  
The Sap transporter was originally discovered in S. Typhimurium via transposon 
mutagenesis along with a number of other genes which conferred resistance to protamine, 
however the sap operon gave the strongest phenotype and so was studied further 
(Groisman et al., 1992). The sapABCDF operon encodes the Sap (sensitive to antimicrobial 
peptides) transporter which consists of an SBP (SapA), two TMDs (SapB and SapC) and two 
NBDs (SapD and SapF) (Figure 1.16) (Parra-Lopez, Baer and Groisman, 1993). The regulation 
of the sap operon is not currently understood.  
1.5.3 The Sap transporter and CAMP resistance 
Salmonella enterica serovar Typhimurium is a Gram-negative bacterium that causes a 
systemic disease in mice similar to typhoid in humans. S. Typhimurium is a key causative 
agent of food poisoning in humans and is a facultative intracellular pathogen that can resist 
CAMP attack in macrophages (Parra-Lopez, Baer and Groisman, 1993). 
To identify genes involved in CAMP resistance, a MudJ transposon library was created in S. 
Typhimurium and screened for sensitivity to protamine, a cationic peptide. A number of 
transposon mutants were isolated that were more susceptible to protamine, including 
some which mapped to the sap operon (Groisman et al., 1992). 
The components of the Sap transporter were tested to determine their role in resistance to 
protamine. All components of the Sap transporter were required for resistance to 
protamine with the exception of SapA. A ΔsapA deletion mutant was more susceptible to 




Figure 1.15. BceRS-BceAB system from Bacillus subtilis confers resistance against the 
antibiotic bacitracin. 
Double headed arrows indicate interactions between proteins, dotted arrows indicate 
transcription events, a question mark indicates the possible interaction of BceR with the 
sensory complex of BceAB and BceS. Bacitracin is bound by the ABC transporter BceAB. A 
sensory complex is formed between BceAB and BceS. ATP hydrolysis by BceAB activates 
BceS which phosphorylates BceR. BceR activates the promoter PbceA which increases 





Figure 1.16. Schematic diagram of the Sap transporter. 
SapA is the substrate binding protein, SapB and SapC are the transmembrane domains and 









protamine that prevented growth of the ΔsapC and ΔsapD mutant strains (Parra-Lopez, 
Baer and Groisman, 1993).  
It has also been shown that the sap operon is upregulated in a chinchilla model of non-
typeable Haemophilus influenzae-induced otitis media. A non-typeable Haemophilus 
influenzae (NTHI) reporter strain was created with a bioluminescent reporter that was 
driven by the sap promoter. This allowed the expression of the sap operon to be localised 
during NTHI infection of the chinchilla. The data showed that the sap operon was 
transiently expressed in the middle ear, eustachian tube, nasopharynx, and the oropharynx 
of the chinchilla. A non-polar DsapA mutant of NTHI was then created and tested against 
chinchilla b-defensin 1, a CAMP. The DsapA mutant was eight-fold more sensitive to 
chinchilla b-defensin 1 than the wild-type. This mutation also significantly impaired the 
strain’s ability to colonise and survive in the middle ear and nasopharynx of the chinchilla. 
In competition with the wild type strain in the middle ear, the loss of the SapA protein 
allowed the wild type strain to outcompete the mutant (Mason, Munson and Bakaletz, 
2005). Further work demonstrated that sap promoter activity was specifically upregulated 
in the presence of chinchilla b-defensin 1. This led to the hypothesis that SapA, the SBP of 
the Sap transporter, was involved in the recognition of, and defence against, chinchilla b-
defensin 1. To test this hypothesis western immunoblot analysis and immunoprecipitation 
were used and showed a specific association of NTHI SapA with chinchilla b-defensin 1. This 
was the first demonstration of a direct interaction between a CAMP and SapA (Mason et 
al., 2006).  
 
A ΔsapD mutant was also created and inoculated into the nares and middle ears of 
chinchillas. Colonisation of the nasopharynx was impaired in the ΔsapD mutant as 
compared to the wild type. Complementation of the ΔsapD mutation restored colonisation 
to wild type levels. Competitive fitness was monitored for the ΔsapD mutant and wild type 
strains in the nasopharynx. The ΔsapD mutant strain was unable to compete with the wild 
type and was significantly reduced 2 days post inoculation and completely cleared 4 days 
after inoculation. Complementation of the ΔsapD mutation restored competitive 
colonisation to levels similar to the wild type. As with the nasopharynx, the ΔsapD mutant 
was unable to survive in the middle of ear of the chinchilla. The ΔsapD mutant was then 
tested for sensitivity to CAMPs and found to be more sensitive to chinchilla b-defensin 1, 
human b-defensin 3 and LL-37 than the wild type strain. These data clearly show a role for 
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SapD in protection against CAMPs and a requirement for SapD in the survival of NTHI in the 
chinchilla middle ear and nasopharynx (Mason et al., 2006).  
 
A NTHI DsapBCDF mutant caused periplasmic accumulation of CAMPs implying that 
SapBCDF is required for transport of CAMPs to the cytoplasm. Due to CAMPs being 
susceptible to cytoplasmic peptidase activity, it is hypothesised that when SapA binds 
CAMPs the SapBCDF transporter transports the CAMPs to the cytoplasm where peptidases 
degrade them to prevent their periplasmic accumulation. This leads to protection against 
membrane disruption caused by CAMPs (Shelton et al., 2011).  
 
Other studies have indicated that there may be a role for SapD in other cellular functions 
unrelated to the transport of substrates. For example studies with Pasteurella show that 
sapD expression is upregulated in the presence of different iron sources (Paustian et al., 
2002). SapD has been shown to mediate potassium uptake in E. coli by energising the 
TrkG/TrkH potassium uptake system (Harms et al., 2001). The NTHI ΔsapD mutant was 
analysed for potassium uptake in different media, a 1000-fold increase in extracellular 
potassium was required to support minimal growth when compared with either the wild 
type or complemented sapD mutant strain (Mason et al., 2006). SapD has also been 
implicated in polymyxin B resistance in Proteus species via LPS modifications. A transposon 
mutagenesis library was created and polymyxin B hypersensitive mutants were identified. 
sapD was one of those genes and LPS defects were found in the sapD mutant. It is possible 
that SapD indirectly affects the biosynthesis or modification of LPS in the inner membrane 
(McCoy et al., 2001).  
 
1.5.4 The Sap transporter and putrescine export 
Polyamines, such as putrescine, contain two or more amino groups and have an important 
role as growth factors in animals, plants and bacteria. In the intestinal tract polyamines can 
impact the health of the animals either positively or negatively depending on their 
concentration. The polyamine concentration is regulated by the uptake and export systems 
of the intestinal tract bacteria. However, the mechanism of export of putrescine by these 
intestinal tract bacteria was unknown (Sugiyama, Nakamura and Matsumoto, 2016).  
Keio collection E. coli strains with gene deletions in annotated transport systems were 
screened for lower concentrations of putrescine in the supernatant as compared to the 
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wild type. Strains with lower concentrations of putrescine in the supernatant than the wild 
type were hypothesised to contain a mutation in the genes responsible for putrescine 
export. Strains with the gene deletions of sapF and sapD had the lowest concentrations of 
putrescine in the supernatant. The other genes in the sap operon were tested and sapB 
and sapC mutants were also shown to be associated with slightly decreased putrescine 
supernatant concentrations, however a sapA mutation was shown to have no effect on the 
concentration of putrescine in the supernatant. This implicates the Sap transporter in 
putrescine export although SapA is not required (Sugiyama, Nakamura and Matsumoto, 
2016).  
Isotopically labelled arginine was used to demonstrate putrescine export by SapBCDF. The 
labelled arginine is internalised by an arginine transporter and then converted to isotope 
labelled putrescine. The concentration of labelled putrescine can then be measured in the 
supernatant from strains in which the SapBCDF transporter is present or absent. In the 
sapBCDF deleted strain there was a 62% decrease in putrescine in the supernatant as 
compared to the parent strain. When sapBCDF was complemented back into the strain the 
putrescine concentration in the supernatant was restored to 77% of the parental strain 
(Sugiyama, Nakamura and Matsumoto, 2016).  
sapBCDF was also tested for resistance to LL-37. E. coli MG1655 and the mutant strain 
ΔsapBCDF were exposed to LL-37. Susceptibility to LL-37 was not significantly different in 
either strain. This result indicates that SapBCDF is not involved in resistance to LL-37 
(Sugiyama, Nakamura and Matsumoto, 2016).  
1.5.5 Yej ABC transporter  
The Yej transporter, encoded by the yejABEF operon, consists of an SBP (YejA), two 
transmembrane domains (YejB and YejE) and a single NBD protein (YejF) (Figure 1.17). 
Unusually, YejF does not form a homodimer to create the NBDs of the Yej transporter, 
instead it appears that a single polypeptide chain contains both of the NBDs required to 
power the transporter (Eswarappa et al., 2008). The yejABEF operon is regulated by a small 
non-coding RNA, RydC. RydC forms a complex with the RNA-binding protein Hfq and then 
interacts with the yejABEF mRNA. Impairing the expression of RydC reduces the amount of 
yejABEF mRNA, therefore endogenous expression of RydC in cells increases the amount of 
yejABEF mRNA. However, overexpression of rydC results in the degradation of the yejABEF 




Figure 1.17. Schematic diagram of the Yej Transporter. 
YejA is the substrate binding protein, YejB and YejE are the transmembrane domains and a 









expression in bacteria and mediates the interaction of small regulatory RNAs with mRNA 
(Sobrero and Valverde, 2012).  
1.5.6 The Yej transporter and CAMP resistance  
The role of the yejABEF operon in virulence was investigated in Salmonella. A macrophage 
cell line, J774A.1, and an epithelial cell line, Intestine 407, were infected with bacteria. 
After 12 hours the bacteria were recovered, the RNA extracted and reverse transcription 
carried out. The results showed that the yejABEF operon was upregulated seven-fold in 
both J774A.1 and Intestine 407 cells. This highlights the importance of the yej operon in the 
immune and epithelial cells that Salmonella first encounters on its course of infection 
(Eswarappa et al., 2008).  
YejF, the NBD of the Yej transporter, was deleted via the Lambda Red recombinase system. 
The resulting S. Typhimurium ΔyejF mutant was tested for susceptibility to different CAMPs 
(protamine, polymyxin B and melittin). It was found that the ΔyejF mutant was more 
susceptible to protamine, polymyxin B and melittin than the wild type strain (S. 
Typhimurium). sap mutants in S. Typhimuirum have also been shown to be sensitive to 
protamine (Parra-Lopez, Baer and Groisman, 1993). Therefore, the sensitivity of ΔyejF, 
Δsap and ΔyejFΔsap S. Typhimurium mutants were tested with protamine and compared. 
The ΔyejF, Δsap and ΔyejFΔsap strains were equally sensitive to 40 µg/ml protamine. 
Unusually the ΔyejFΔsap double mutant was not more susceptible to protamine than the 
other mutants. This may be due to other genes playing a role in counteracting CAMPs when 
both Sap and Yej are non-functional. ΔyejB and ΔyejE strains were also tested with 
polymyxin B and protamine, and both showed susceptibility. However, when the ΔyejA 
mutant was tested, the strain was not more susceptible to polymyxin B, protamine or 
melittin, suggesting that YejA is not required for defence against CAMPs (Eswarappa et al., 
2008).  
The morphology of the different S. Typhimuirum strains was investigated. It is clear from 
the scanning electron micrographs that the ΔyejF strain has several membrane 
irregularities. Many of the bacteria show membrane damage, extruded cytoplasms and 
other features associated with cell lysis (Figure 1.18) (Eswarappa et al., 2008).  
Like Salmonella, Brucella are intracellular pathogens. The bacteria cause severe febrile 
illness in humans and have evolved to exist in host macrophages in the presence of a series 




Figure 1.18. Scanning electron microscopic images of wild-type (WT) and ΔyejF, the Yej 
transporter NBD, treated with polymyxin B. 
Insets are zoomed in images of single bacterial cells from the main images. When the DyejF 
mutant is exposed to polymyxin B membrane disruption and cell lysis occurs as shown in 
the above image. When cells are not treated with polymyxin B or the WT is treated with 
polymyxin B the same membrane disruption and lysis does not occur. Image taken from 





particular study, contains five genes within its yej operon. yejA1 and yejA2 which are the 
SBPs, yejB and yejE which are the TMD domains and yejF the NBD (Wang et al., 2016).  
A ΔyejAABEF mutant strain of B. melitensis NI was created, this strain was more susceptible 
to polymyxin B than the wild type. The ΔyejE strain was also more susceptible to polymyxin 
B than the wild type. When yejE was complemented back into the mutant strain resistance 
to polymyxin B increased to the same level as the wild type strain. However, ΔyejA1, 
ΔyejA2, ΔyejB and ΔyejF mutant strains showed no difference in susceptibility to polymyxin 
B as compared to the wild type (Wang et al., 2016).  
Again, scanning electron microscopy was conducted on the different strains. The 
ΔyejAABEF and ΔyejE mutant strains showed membrane irregularities, extruded cytoplasm 
and other signs of cell lysis and membrane disruption (Figure 1.19) (Wang et al., 2016). 
The relative gene expression level of the yej operon was investigated in the presence of 
polymyxin B. Polymyxin B was able to induce the expression of yejA1, yejA2, yejB, yejE and 
yejF in B. melitensis NI. The gene expression levels of yejA1, yejB and yejE increased by 3-4 
fold in the presence of polymyxin B as compared to the untreated control (Wang et al., 
2016).  
Together these experimental data strongly suggest a role for the Yej transporter in the 
defence against CAMPs. Although in different studies different components of the 
transporter gave the strongest/weakest CAMP resistance phenotypes, it is important to 
note that in most cases a transporter needs all of its components to function in 
transmembrane substrate translocation.  
1.5.7 The Yej transporter and Microcin C  
Microcin C is a bacterially produced peptide-nucleotide antibiotic and a potent inhibitor of 
aspartyl-tRNA synthetase. Microcin C, which is not a CAMP, is a heptapeptide with a 
modified AMP covalently attached to its C-terminus (Figure 1.20). Microcin C sensitive cells 
process Microcin C in the cytoplasm into its active form, a non-hydrolysable aspartyl-
adenylate, which inhibits translation and leads to bacterial cell death (Figure 1.20). 
Unprocessed Microcin C has no effect on translation and processed Microcin C has no 
effect on Microcin C sensitive cells. This means Microcin C must be transported to the 
cytoplasm in its unprocessed form where it is degraded to the processed active form, a so-




Figure 1.19. Scanning electron microscopic images of B. melitensis NI, ΔyejAABEF and 
ΔyejE mutants treated with polymyxin B. 
Boxes highlight areas of membrane disruption. B. melitensis NI is shown in A and B, DyejE 
mutants in C and D and DyejAABEF mutant in E and F. All untreated samples show no cell 
disruption but DyejE and DyejAABEF mutants when treated with polymyxin B show signs of 
cell disruption and lysis whereas the wildtype has the same morphology as the untreated 





Figure 1.20. Structure of Microcin C in the unprocessed and processed forms. 
(A) shows Microcin C in the unprocessed form, the form in which YejA binds Microcin 
C. R1 is either CHO or H. (B) shows Microcin C in the processed form. (C) Shows 
aspartyl-adenylate, the molecule processed Microcin C mimics to inhibit aspartyl-tRNA 







To investigate how Microcin C enters the cytoplasm, a random transposon insertion library 
was created with the mariner-based transposon TNSC189. Microcin C resistant colonies of 
E. coli SG289 cells were then selected and the transposon insertion sites mapped. Three 
different insertions were found in yejA and yejB and a single further insertion was found in 
yejF. Cells were created carrying deletions of each of the yejABEF genes and tested for their 
ability to grow in the presence of Microcin C. The results showed that deletion of any one 
of the yejABEF genes led to complete resistance to Microcin C. Therefore the Yej 
transporter was identified as the only transporter required for Mcirocin C uptake (Novikova 
et al., 2007).  
In later work, a series of Microcin C analogues were created to test the specificity of the Yej 
transporter. Aminoacyl-sulfamoyl adenosines were used to try to mimic natural Microcin C 
and a series of compounds were created where the heptapeptide part of Microcin C was 
truncated from the C-terminus, although aspartate was always maintained as the C-
terminal residue. These compounds were then tested on Microcin C sensitive cells whilst 
the inhibition of the aspartyl-tRNA aminoacylation reaction was monitored. It was shown 
that Microcin C analogues required a minimum peptide chain length of 6 residues and an 
N-terminal formyl-methionyl-arginyl sequence to allow transport, indicating possible 
requirements of YejA substrates (Gaston et al., 2011).  
The Yej transport system therefore confers susceptibility to Microcin C, so why would a 
bacterium maintain a system that makes it vulnerable to Microcin C? Possibly the 
evolutionary advantage of maintaining the Yej transporter is to provide resistance to 
CAMPs.  
1.6 Aims of the project 
This thesis aims to biochemically characterise specific peptide SBPs which are thought to 
recognise CAMPs. A structural approach is used to examine how specific peptides are 
coordinated by the SBPs whilst a biochemical approach is used to investigate the specificity 
of binding. This research is conducted with a view to developing new drugs to help tackle 
the spread of antibiotic resistance.  
SapA and YejA are the receptor components of their respective ABC-type antimicrobial 
peptide transporters. These proteins are therefore expected to capture the extracellular 
substrate and define the specificity of the transporter. Determining the structure of SapA 
and YejA will help to understand how they are able to transport different, and possibly 
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folded, CAMPs. Solving the structure of a SapA-CAMP or YejA-CAMP complex would give 
great insight into the binding mechanism of the SBPs. The technique used to determine the 
structure of SapA, YejA and associated CAMPs will be X-ray crystallography. For the latter 
studies, either Isothermal Titration Calorimetry and/or thermal shift assays will be used to 
study the binding of CAMPs to SapA and YejA using facilities in the Technology Facility (TF) 
at the University of York. This work will indicate a method of binding and highlight key 
residues in CAMPs, SapA and YejA which are important in binding. These residues could 

















2. Materials and Methods 
2.1 Media and Antibiotics 
2.1.1 Luria-Bertani broth and agar 
Luria-Bertani broth (LB) was made using 10 g/L tryptone, 10 g/L NaCl, 5 g/L yeast extract 
and made up to 1 L with distilled water. LB agar was made up in smaller volumes of 200 ml 
with 4 g tryptone, 4 g NaCl, 2 g yeast extract, 3 g agar and made up to volume with distilled 
water. Once made up all media were sterilised via autoclave at 121 °C for 15-20 minutes.  
2.1.2 Antibiotics  
Where appropriate antibiotic selection was used at a working concentration of 100 µg/ml 
ampicillin and 30 µg/ml kanamycin, both of which were 0.22 µm filter sterilised and stored 
at 4 °C.  
2.1.3 IPTG 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Melford Biolaboratories) was made up as a 1 
M stock in distilled water, 0.22 µm filter sterilised and stored in 1 ml aliquots at -20 °C. 
When added to cells the final concentration of IPTG was 1 mM or the concentration is 
otherwise indicated.  
2.1.4 Overnight bacterial cultures 
5 ml of LB with appropriate antibiotic was added to a Sterilin tube along with a single 
bacterial colony or a scraping from a glycerol stock. The bacterial culture was grown 
overnight at 37 °C with shaking at 220 rpm.  
2.1.5 Glycerol stocks 
800 µl of overnight culture was added to 400 µl of 50% glycerol and vortexed to create 
glycerol stocks. These were stored at -80 °C until further use.  
2.1.6 Bacterial strains and proteins used 
Table 2.1 details all of the bacterial strains, genomes and protein identifiers used 
















































BsAppA B. subtilis 168 U20909.1 2732-4363 P42061 1XOC 






Table 2.1. Table of bacterial strains, genome and protein identifiers. 
Information on bacterial strains used in this work along with the genome identifiers. 
Protein identifiers as well as PDB codes have also been added where appropriate. These 
proteins have been used throughout this work.   
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2.2 Gene Cloning 
2.2.1 Agarose gel electrophoresis 
A 1% (w/v) agarose gel in TBE buffer (16.2 g/L Tris, 2.75 g/L boric acid, 0.95 g/L EDTA) was 
used to separate DNA fragments of varying sizes. Molten agarose was mixed with either 10 
µl/100 ml ethidium bromide or 1 µl/100 ml SYBR safe and poured into a gel container. A 
plastic comb was inserted to create a number of wells, and the gel allowed to solidify. After 
the gel had set the comb was removed and the gel covered with a solution of TBE buffer. 5 
µl of ladder, either HyperLadder 1 kb plus (Bioline) or 2-Log ladder (NEB), was loaded into 
one of the wells. 5 µl of sample was mixed with 1 µl of sample loading buffer (Bioline) and 5 
µl loaded into a well. The gel was run at 70 V for 50 mins and imaged using a 
transilluminator (Syngene Imaging System).  
2.2.2 Polymerase Chain Reaction (PCR)  
The high fidelity DNA polymerase Phusion was used in PCR reactions to amplify target DNA 
fragments. A standard PCR reaction mixture consisted of 32.5 µl water, 10 µl 5x Phusion HF 
buffer (Thermo Scientific), 1 µl 10 mM dNTPs (Thermo Scientific), 0.5 µl Phusion (Thermo 
Scientific 2U/pL), 2.5 µl genomic DNA template, 2.5 µl each of forward and reverse primers 
(at 10 µM). Primers were supplied by IDT and designed using the online NEBuilder 
Assembly Tool (Table 2.2). The mixture was stored on ice until placed in the thermocycler. 
An initial denaturing step at 98 °C for 2 mins was performed. After this, 35 cycles of 98 °C 
for 20 seconds, 60 °C for 30 seconds and 72 °C for 1.5 mins was used to amplify the DNA. A 
final extension at 72 °C for 5 mins was then performed. The sample was then held in the 
thermocycler at 10 °C until it was frozen or run on an agarose gel.  
2.2.3 Restriction digest of DNA 
All PCR amplified inserts were cloned into the pETFPP_30 vector for future expression. The 
pETFPP_30 vector is based on the pET22b+ vector and contains an optional N-terminal PelB 
leader sequence and a cleavable C-terminal hexahistidine tag (Figure 2.1). Both pETFPP_30 
and PCR insert DNA were treated with restriction endonucleases to digest the DNA ready 
for assembly. Each 50 µl reaction contained 5 µl cutsmart buffer (NEB), 1 µl Nde1 (NEB), 1 
µl Xho1 (NEB) and 1 µg DNA with the reaction made up to 50 µl with sterile milliQ water. 
The mixture was incubated at 37 °C for 1 hour and then immediately put through a PCR 




Primer Name Primer Sequence 
EcYejA-F 5’-CTTTAAGAAGGAGATATACATATGCAGGCTATCAAGGAAAGCTATG-3’ 
















Table 2.2. Primers used to amplify DNA. 
Primers were used to either amplify genomic DNA via PCR or for sequencing of inserts once 









Figure 2.1. pETFPP_30 and pET22b+ vectors. 
(A) Shows the open reading frame of the pETFPP_30 vector with an optional N-terminal 
PelB leader sequence and cleavable C-terminal hexahistidine tag. (B) shows the pET22b+ 
vector, the block black arrow indicates the region which changes have been made to 






2.2.4 HiFi DNA Assembly 
This method is used to assemble DNA fragments, in this case PCR amplified genes of 
interest, with overlaps matching the target vector, in this case pETFPP_30. An exonuclease 
creates further single-stranded 3’ overhangs on both the restriction digested vector and 
insert which allows them to anneal. A DNA polymerase fills in any gaps between the 
assembled DNA and is followed by a DNA ligase which seals the nicks. The gene of interest 
and pETFPP_30 vector were assembled via the NEB HiFi DNA assembly protocol for 2-3 
fragment assembly. The mixture was incubated at 50 °C for 15 mins and then used 
immediately in a transformation into Solopack Gold DH5a competent cells (Agilent) or 
stored at -20 °C until further use.   
2.2.5 Transformation of competent cells via heat shock  
An aliquot of the appropriate competent cells was thawed on ice whilst an aliquot of Super 
Optimal broth with Catabolite repressor (SOC) media was heated to 42 °C. SOC media is a 
variant of LB with added glucose which results in higher transformation efficiencies. Once 
the cell aliquots had defrosted they were swirled gently to mix and 0.1-50 ng of appropriate 
plasmid DNA or a volume of ligation mixture was added to each tube which was incubated 
on ice for 30 mins. The cells were then heat pulsed at 42 °C for 1 min and incubated on ice 
for 2 mins before 175 µl of 42 °C SOC media was added, the tubes were then incubated at 
37 °C for an hour with shaking at 220 rpm. Afterwards 200 µl of the cells were plated onto 
LB agar plates with the appropriate antibiotics and incubated overnight at 37 °C.  
2.2.6 Colony PCR 
Colony PCR was used to screen colonies arising from transformation experiments for the 
desired clones. Template DNA for the colony PCR reaction was the DNA extracted from 
each colony during the initial heat step at 95 °C. Each standard colony PCR mix contained 
2.5 µl of (10 mM) reverse primer, 2.5 µl of (10 mM) forwards primer, 0.5 µl of 10 mM 
dNTPs (Thermo Scientific), 5 µl 5x green GoTaq reaction buffer (Promega), 0.2 µl GoTaq G2 
DNA polymerase (Promega) and 14.3 µl of water. The mixture was stored on ice until 
transferred to the thermocycler. An initial step of 95 °C for 5 mins was performed and then 
35 cycles of 95 °C for 30 seconds, 60 °C for 30 seconds, 68 °C for 1 minute 45 seconds. A 
final extension of 72 °C for 5 mins was performed, after which the mixture was held at 12 
°C until frozen or run on an agarose gel. 
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 2.2.7 Miniprep and sequencing of DNA 
Plasmids were isolated from overnight cultures of bacteria using a Qiagen miniprep kit, 
following the manufacturer’s instructions. All plasmids were checked for accuracy and 
confirmed via DNA sequencing using T7-F and T7-R primers. The sequencing was carried 
out by GATC and analysed using Ugene software.  
2.3 Expression of recombinant protein 
Following DNA sequencing, correctly cloned constructs were transformed into BL21-
Gold(DE3) competent cells (Agilent) for protein overexpression using the protocol detailed 
in 2.2.5.  
2.3.1 Small scale whole cell expression trials 
50 ml of LB, supplemented with appropriate antibiotic, was inoculated to an OD600 between 
0.01-0.2 with overnight cultures. The cells were grown at a variety of different 
temperatures, induced with a variety of different concentrations of IPTG and grown for 
varying lengths of time to determine which conditions gave the highest yield of soluble 
protein. An initial “uninduced” 1 ml culture sample was taken immediately before addition 
of IPTG and additional 1 ml samples were taken every hour until the 4 hour time point. The 
following morning an additional 1 ml culture sample was taken. All 1 ml culture samples 
were centrifuged at 23897 x g for 5 mins to pellet cells immediately after harvesting. The 
supernatant was discarded and the pellets were stored at -20 °C.  
2.3.2 Lysing cells using Bugbuster 
Bugbuster disrupts the cell wall of bacterial cells to release soluble protein as an alternative 
to mechanical methods such as sonication. Pelleted cells from 2.3.1 were re-suspended in 
50 µl Bugbuster (Novagen) and PMSF (Alpha Diagnostic International Inc.) protease 
inhibitor. The mixture was incubated at room temperature for 10-20 mins with 
shaking/rocking before centrifugation at 16000 x g for 20 mins at 4 °C. Soluble and 
insoluble fractions were then separated and samples were analysed via SDS-PAGE.  
2.3.3 Lysing cells using sonication 
Pelleted cells from 2.3.1 were re-suspended in 200 µl Buffer A (50 mM Tris pH 8.0, 150 mM 
NaCl, 20 mM imidazole) with PMSF protease inhibitor and sonicated for 30 secs. The 
mixture was then centrifuged at 18787 x g for 20 mins. Soluble and insoluble fractions were 
then separated and samples were analysed via SDS-PAGE. 
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2.3.4 Large scale expression of EcYejA 
1 L of LB, supplemented with 100 µg/ml ampicillin, was inoculated to an OD600 of 0.02 with 
overnight cultures of the EcYejA strain. They were grown at 37 °C with shaking at 150 rpm 
until they reached an OD600 between 0.4 – 0.6. At this point expression was induced with 
the addition of 1 mM IPTG. If EcYejA was to be treated with 2 M guanidine hydrochloride 
during the purification step the flasks were moved to 30 °C with shaking at 180 rpm and 
allowed to grow overnight. If the 2 M guanidine hydrochloride step was to be omitted 
during purification, cells were allowed to grow for a further 3 hours at 37 °C.  Cells were 
harvested by centrifugation at 5000 rpm, 4 °C for 20 mins using an F10S rotor.  
2.4 Preparation of bacterial extracts 
2.4.1 Tris-sucrose solution supplemented with EDTA extraction of periplasm 
The TSE periplasmic fraction extraction method was developed as a variation on the 
osmotic shock method of periplasmic fraction extraction. Osmotic shock can often 
contaminate the periplasmic fraction with cytoplasmic content, the TSE method has been 
shown to produce cleaner periplasmic fractions and so was used in this work (Quan et al., 
2013). Induced cells were harvested by centrifugation at 3000 x g for 20 mins at 4 °C. 
Supernatant was discarded and the pellet carefully resuspended in 1 ml/100 ml of culture 
TSE buffer (200 mM Tris pH 8.0, 500 mM sucrose, 1 mM EDTA) with a wire loop. Cells were 
incubated in TSE buffer on ice for 30 mins then centrifuged at 15000 x g for 30 mins at 4 °C. 
The supernatant and cell pellet were stored separately at -20 °C until further analysis. 
2.4.2 Periplasmic fraction extraction with lysozyme 
Lysozyme is a glycoside hydrolase which breaks down peptidoglycan. Induced cells were 
harvested by centrifugation at 3000 x g for 20 mins at 4 °C. The cell pellet was then 
weighed and resuspended in 4 ml/g of cells ICOS buffer (20 mM Tris pH 8.0, 25% (w/v) 
sucrose, 5 mM EDTA) and incubated on ice for 15 mins. The mixture was then centrifuged 
at 8500 x g for 20 mins, supernatant was removed and stored at -20 °C (sucrose fraction). 
Pellet was dissolved in 4-5 ml/g of cells of 5 mM MgCl2 with protease inhibitor, 40 µl of 15 
mg/ml lysozyme per gram of cells was added and mixture was incubated on ice for 30 mins. 
Mixture was then centrifuged at 8500 x g for 20 mins at 4 °C, the supernatant and cell 
pellet were stored separately at -20 °C until further analysis.  
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2.4.3 Cytoplasmic EcYejA protein recovery 
Induced cells were harvested by centrifugation at 5000 rpm, 4 °C for 20 mins using an F10S 
rotor. If EcYejA was to be treated with 2 M guanidine hydrochloride during the purification 
step cell pellets were resuspended in 35 ml (for 1 L of culture) buffer A (50 mM Tris pH 8.0, 
150 mM NaCl, 20 mM imidazole) with PMSF protease inhibitor. If the 2 M guanidine 
hydrochloride step was to be omitted during purification, cell pellets were resuspended in 
35 ml (for 1 L of culture) resuspension buffer (50 mM KPi pH 7.8, 200 mM NaCl, 20% 
glycerol, 10 mM imidazole) with PMSF protease inhibitor. All cells were then lysed via 
sonication (6 mins on time, 3 secs on, 7 secs off) and centrifuged to remove cell debris at 
15,000 rpm, 4 °C for 25 mins, using an SS34 rotor. The soluble fraction containing EcYejA 
was then purified. 
2.5 Protein purification 
2.5.1 Guanidine hydrochloride denaturation to unfold-refold EcYejA followed by nickel-
affinity chromatography using HisTrap HP columns 
Two 5 ml HisTrap HP columns (GE Healthcare) were attached in series effectively to create 
a 10 ml HisTrap column and equilibrated via a peristaltic pump with buffer A (50 mM Tris 
pH 8.0, 150 mM NaCl, 20 mM imidazole). The 2 M guanidine hydrochloride treated soluble 
fraction from 2.4.3 was flowed over the column, again using the peristaltic pump. The 
column was then washed with ~3 column volumes (CV) of buffer A to elute any weakly 
bound protein contaminants. The column was then connected to an Akta purifier and a 
prepared method run automatically, using the Unicorn software package, where the 
column was washed with 3.5 CVs of buffer A and then 2 CVs of 100% buffer B1 (50 mM Tris 
pH 8.0, 150 mM NaCl, 20 mM imidazole, 2 M guanidine hydrochloride) followed by 2 CVs of 
75% buffer B1, 2 CVs of 50% buffer B1, 2 CVs of 25% buffer B1 and 2 CVs 0% buffer B1 
(therefore 100% buffer A). Purification was monitored by detecting the absorbance of 
column eluent at a wavelength of 280 nm and fractions collected using an automated 
fraction collector. Following this, the column was developed with a 0-100 % imidazole 
gradient in buffer A over 10 CV. Purification was monitored by detecting the absorbance of 
column eluent at a wavelength of 280 nm and fractions collected using an automated 
fraction collector.  
2.5.2 Nickel-affinity chromatography using HisTrap HP columns of EcYejA 
The soluble protein sample from 2.4.3 that was not treated with 2 M guanidine 
hydrochloride was purified using an Akta start and the Unicorn software package. A 5 ml 
71 
 
HisTrap HP column (GE Healthcare) was equilibrated with 5 CVs wash buffer (50mM KPi pH 
7.8, 200mM NaCl, 20% glycerol, 40mM imidazole). The protein sample was added to a 
single 5 ml HisTrap HP column via the sample line and the column washed to remove any 
unbound protein with 10 CVs of wash buffer. Protein bound to the HisTrap column was 
eluted in a single step by washing the column with 5 CVs of elution buffer (50mM KPi pH 
7.8, 200mM NaCl, 20% glycerol, 500mM imidazole).  
2.5.3 Cleavage of Histidine tag 
The hexahistidine tag of EcYejA was cleaved with human rhinovirus 3C (HRV 3C) protease in 
a ratio of 1:200 HRV 3C protease:EcYejA before further purification via size exclusion 
chromatography. Both EcYejA and HRV 3C protease were added to dialysis tubing with a 
molecular weight cut off of 12-14 kDa and incubated in SEC (size exclusion 
chromatography) buffer (50 mM Tris pH 8.0 and 150 mM NaCl) overnight at 4 °C with 
stirring in preparation for the size exclusion chromatography the following day.  
2.5.4 Size exclusion chromatography 
A superdex 200 SEC column (GE Healthcare) was equilibrated with SEC buffer overnight. 
Protein from the overnight cleavage of the hexahistidine tag was concentrated to less than 
2 ml using a 30 kDa molecular weight Vivaspin column. Concentrated protein was then 
pushed straight onto the SEC column via a syringe. The column was washed with one CV of 
SEC buffer (120 ml) and EcYejA protein eluted. Purification was monitored by detecting the 
absorbance of column eluent at a wavelength of 280 nm and fractions collected using an 
automated fraction collector. 
2.6 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
2.6.1 Buffers and gel 
Polyacrylamide gels were either Mini-PROTEAN TGX stain-free 12% 15 well gels (Bio-Rad) or 
made using the following protocol. Resolving polyacrylamide gel was cast using 375 mM 
Tris-HCl pH 8.8, 12% acrylamide, 0.1% sodium dodecyl sulphate (SDS), 0.08% 
tetramethylethylenediamine (TEMED) and 0.05% ammonium persulfate (APS). The stacking 
gel was cast from 130 mM Tris-HCl pH 6.8, 4% acrylamide, 0.1% SDS, 0.1% bromophenol 
blue, 0.16% TEMED and 0.05% APS. Running buffer (14.4 g/L glycine, 3 g/L Tris, 0.1% SDS) 
was added to the gels in the gel tank.    
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2.6.2 Sample preparation 
3 µl of 2x sample buffer (60 mM Tris pH 6.8, 10% glycerol, 5% β-mercaptoethanol, 2% SDS, 
0.05% bromophenol blue) was added to 10 µl of soluble protein. Insoluble protein was 
resuspended in 50 x n µl 2x sample buffer (n µl is OD600 of cells when sample was taken). 
Sample mixtures were heated to 95 °C for 5 minutes before 10 µl of sample mixture was 
added to each well, 5 µl of broad range blue protein standard (NEB) was used as a marker. 
The method for naming SDS-PAGE gel samples is shown in Figure 2.2.  
2.6.3 Running and staining/de-staining of SDS-PAGE gels 
SDS-PAGE gels were run using a Mini-PROTEAN® Tetra Vertical Electrophoresis Cell (Bio-
Rad) assembled via the manufacturer’s instructions. After submerging the gel in running 
buffer, samples were loaded and the gel was run at 200 V for 50 mins. The gels were then 
rinsed with distilled water. SDS-PAGE gels were then boiled in ~200 ml deionised water in a 
microwave and then placed on a rocker for ~5 mins before the distilled water was drained 
off and ~50 ml magic dye (60 mg/L Coomassie Brilliant Blue G-250, 35mM HCl) added. The 
gels were then boiled again and placed back on the rocker until bands were visible and the 
gels imaged. To further de-stain the gels they were incubated in deionised water on the 
rocker.  
2.7 Protein concentration determination  
The Bioteck epoch 2 microplate reader with Gen5 3.00 software was used to measure the 
absorbance at a wavelength of 280 nm. The extinction coefficient and molecular weight of 
purified protein were calculated using Protparam from the Swiss Institute of Bioinformatics 
(https://web.expasy.org/protparam/). The Beer-lambert law was used to determine 
protein concentration.  
2.8 Storage of protein 
Protein was stored at 4 °C in SEC buffer (50 mM Tris pH 8.0 and 150 mM NaCl) and used for 
up to a month before being discarded and a fresh batch of protein prepared.  
2.9 Peptide synthesis 
Peptides were synthesised from C to N-terminus. A cartridge was prepared by adding a 
filter and a tap. 300 mg of both Fmoc-Gly-Rink Amide-MBHA resin (Cambridge Bioscience) 
and Fmoc-Asp(OtBu)-Rink Amide-MBHA resin (Cambridge Bioscience) were weighed out 




Figure 2.2. Protein sample preparation for SDS-PAGE gels. 
Schematic diagram showing the three different methods of extracting, preparing and 




(DMF) and left to swell for 30 mins with rotation. The DMF was then drained into a 
manifold and the resin washed with 20% piperidine (PIP) in DMF five times followed by five 
washes with DMF. PIP washes consisted of half-filling the cartridge with 20% PIP, sealing 
and inverting the cartridge before allowing the cartridge to rotate for 2 mins and then 
draining in the manifold. DMF washes were carried out in identical fashion.  
To couple amino acids to the peptide chain the following quantities (Table 2.3), chosen to 
give a yield of ~100 mg of synthesised peptide, were weighed out for the synthesis of 
MRTGNAD and fMRTGNAD peptides. For the synthesis of ~100 mg of fMRTGNAD(dansyl 
K)G, the quantities of amino acids listed in Table 2.4 were weighed out.  
The residues were added to a sample vial along with O-(1H-6-Chlorobenzotriazole-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) at 1.02 equivalents (for 
MRTGNAD and fMRTGNAD 274 mg at 0.662mM and for fMRTGNAD(dansyl K)G 207 mg at 
0.5 mM). The residues and HCTU were dissolved in DMF and, for MRTGNAD and 
fMRTGNAD 249 µl of N,N-Diisopropylethylamine (DIPEA) and for fMRTGNAD(dansyl K)G 
188 µl DIPEA was added. The mixture was quickly transferred to the cartridge, which was 
sealed and inverted to mix and then rotated for 60 mins.  
After each amino acid coupling, the resin was washed by draining the contents into a 
manifold and half-filling the cartridge with DMF, sealing and inverting the cartridge and 
leaving it to rotate for 2 mins. This was repeated three times. Fmoc cleavage was carried 
out by five PIP washes followed by five DMF washes. The cartridge was then either stored 
overnight or another amino acid coupled. At the point of addition of the final residue (fMet 
or Met), the MRTGNAD peptide was weighed and split in half and half added to a new 
cartridge. To one cartridge –Met-OH was added and to the other –fMet-OH added to 
create both MRTGNAD and fMRTGNAD.  
Once the peptides were complete, resin shrinkage was carried out by washing the 
cartridge, in the same manner as the PIP and DMF washes, with dichloromethane (DCM) 
three times followed by three washes with methanol. The cartridge was then left overnight 
on a high vacuum line with the tap off and the lid on in an inverted position.  
For resin cleavage 5 ml of 88:5:5:2 trifluoroacetic 




Residue mg mM 
Fmoc-Ala-OH (Sigma) 210 0.675 
Fmoc-Asn(Trt)-OH (Sigma) 403 0.675 
Fmoc-Gly-OH (Sigma) 201 0.675 
Fmoc-Thr(tBu)-OH (Sigma) 268 0.675 
Fmoc-Arg(Pbf)-OH (Sigma) 438 0.675 
--Met-OH/--fMet-OH (Sigma) 101/120 0.675 
Table 2.3. Information on amino acids coupled to MRTGNAD and fMRTGNAD peptides. 
Concentrations and respective weights of the amino acids coupled to synthesise ~100 mg 
of peptides MRTGNAD and fMRTGNAD.  
 
Residue mg mM 
Fmoc-L-Lys(Dansyl)-OH (Santa Cruz Biotechnology) 245 0.510 
Fmoc-Asp(tBu)-OH (Sigma) 210 0.510 
Fmoc-Ala-OH 159 0.510 
Fmoc-Asn(Trt)-OH 304 0.510 
Fmoc-Gly-OH 152 0.510 
Fmoc-Thr(tBu)-OH 203 0.510 
Fmoc-Arg(Pbf)-OH 331 0.510 
--fMet-OH 90 0.510 
Table 2.4. Information on amino acids coupled to fMRTGNAD(dansyl K)G. 
Concentrations and respective weights of the amino acids coupled to synthesise ~100 mg 




cartridges half filled with the solution. The cartridges were then sealed and inverted and 
left rotating for 60 mins.  
30 ml of diethylether per cartridge was prepared and chilled to -80 °C and stored in a falcon 
tube. After resin cleavage, cartridge contents were drained into the diethylether to 
precipitate the peptide. The solvent and peptide were then centrifuged at 4000 x g for 5 
mins at 4 °C to form a pellet, the ether was decanted off and the pellet left to evaporate off 
any remaining ether. The pellet was then resuspended in 30 ml of ice cold ether and the 
process repeated three times. 
The peptide was then dissolved in 10% (v/v) aqueous glacial acetic acid and flash frozen in 
liquid nitrogen with rolling to maximise surface area. The sample was then lyophilised for 
~24 hours to afford a fully white solid. Peptide purity was then checked using LC-MS and 
the yield of each peptide was ~100 mg. 
2.10 General biochemical and biophysical techniques 
2.10.1 Electrospray mass spectrometry  
Electrospray Mass Spectrometry was conducted on a Waters LCT Premier XE system with 
MassLynx 4.1 software. The system was calibrated with sodium formate solution and 
calibration verified with horse heart myoglobin (16951.5 ± 1.5 Da). EcYejA was run at a 
concentration of 10 mg/ml in 2 mM Tris-HCl pH 8.0. Samples were prepared in 1:1 
acetonitrile-water containing 0.1% formic acid.  
2.10.2 Native electrospray ionisation (ESI) mass spectrometry and matrix-assisted laser 
desorption/ionisation mass spectrometry mass spectrometry (MALDI-MS/MS) 
All native ESI and MALDI-MS/MS experiments were carried out with Dr. Adam Dowle in the 
University of York Technology Facility. For all acquisitions, protein in aqueous 1 M 
ammonium acetate was infused at 3 mL/min into a Bruker maXis qTOF mass spectrometer 
via an electrospray ionisation source.  All presented spectra were summed over 1 min 
acquisitions at 0.1 Hz spectral acquisition rate.  Ion funnel voltages were adjusted as 
detailed in the results to aid the preservation (100 eV) or separation (200 eV) of gas-phase 
complexes. Subsequently all data from section 5.2.1 have been baseline subtracted (0.8 
flatness) and smoothed (0.19, Gauss, 1 cycle) before maximum entropy deconvolution to 
average mass. All data from section 5.2.2 have been smoothed (0.5 Da, 1 cycle, Gauss) and 
baseline subtracted (flatness 0.8) before maximum entropy deconvolution to average 
masses. Concentrations of EcYejA and GEP are noted in the results sections 5.2.1 and 5.2.2.  
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For MALDI-MS/MS a 100 µl aliquot of sample was acidified with the addition of 10 µl 
aqueous 1% trifluoroacetic acid (TFA) before extracting and desalting peptides using 
Promega C18 ZipTips.  Desalted peptides were spotted out onto a MALDI target plate and 
overlaid with 5 mg/ml 4-hydroxy-a-cyano-cinnamic acid matrix.  Peptides were analysed by 
MALDI-MS/MS using a Bruker ultraflex III mass spectrometer with the 30 strongest 
precursors, with a S/N greater than 30, selected for MS/MS fragmentation. Spectra were 
baseline-subtracted and smoothed (Savitsky-Golay, width 0.15 m/z, cycles 4); monoisotopic 
peak detection used a SNAP averaging algorithm C4.9384, N1.3577, O1.4773, S0.0417, H7.7583) with a 
minimum S/N of 5.  MS2 spectra were searched against the expected sequence of EcYejA 
using the Mascot search program with enzyme cleavage set at wild. 
2.10.3 Size Exclusion Chromatography with Multi-Angle Laser Light Scattering (SEC-
MALLS) 
EcYejA samples at either 1 mg/ml or 3 mg/ml in buffer (20 mM Tris-HCl pH 8.0, 50 mM 
NaCl) were resolved on a Superdex 200 SEC column (GE Healthcare) at 0.5 ml/min with an 
HPLC system (Shimadzu). Light scattering data was collected continuously on material 
eluting from the column using an in-line Wyatt Dawn Heleos LS detector with an inline 
Wyatt Optilab rEX refractive index detector and SPD-20A UV detector. Molecular weights 
were calculated by analysing data with the Wyatt program ASTRA version 5.3.4.14.  
2.10.4 Circular Dichroism (CD) spectroscopy 
CD spectra of protein were collected using a J-810 spectropolarimeter (Jasco) along with 
the supplied software SpectraManager version 1.53.00 (Jasco). 0.2 mg/ml (2.92 µM) 
protein was analysed in 20 mM Tris pH 8.0 and 50 mM NaCl buffer. Spectra were recorded 
at 20 °C in a 1 mm pathlength quartz cuvette (Starna) between 190 – 260 nm at 200 
nm/minute with 0.5 nm pitch.  
2.10.5 Thermal shift assay 
To initially set the parameters for the assay, a series of dilutions of EcYejA and the assay 
dye, SYPRO orange (Sigma), were carried out. A protein concentration of 0.5 mg/ml (7.3 
µM) EcYejA and 5 x SYPRO orange was found to give good curves without using a large 
quantity of protein or dye. A total volume of 25 µl per well was used throughout the 
thermal shift assays and each combination of EcYejA + ligand was carried out in triplicate 
on the same plate. For each assay 71 cycles were carried out starting at 25 °C and 
increasing by 1 °C every 30 secs, taking a fluorescence measurement every 1 °C.  
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2.10.6 Crystallisation and structure determination of protein  
Purified protein was dialysed into crystallisation buffer (20 mM Tris pH 8.0, 50 mM NaCl) 
and concentrated to 20 mg/ml. Initial crystallisation screens were created using the 
HYDRA96 (Robbins Scientific) to dispense commercial screens to 96-well plates and the 
Mosquito Nanolitre Pipetting robot (TTP Labtech) to create the sitting drops of protein and 
reservoir solution using the sitting-drop vapour diffusion method where 150 nl of protein 
was mixed with 150 nl of reservoir solution. Two drops were set up per well. The protein 
concentration in the upper drop of the 96-well plate was 20 mg/ml and concentration in 
the lower drop was 10 mg/ml. A series of commercially available screens were used: JCSG+, 
PDB Min and PEG/ION. Plates were then sealed and stored at 18 °C and checked at regular 
intervals for crystal growth.  
If crystals had grown, crystal optimisation was carried out in 24-well plates using the 
hanging-drop vapour diffusion method with the same or similar reservoir conditions and 
the same concentration of protein. A reservoir volume of 1 ml was used and a 1 µl:1 µl and 
2 µl:2 µl protein:reservoir solution ratio was used. Again the plate was sealed and stored at 
18 °C and checked regularly for crystal growth.  
Crystals were harvested using nylon loops of varying sizes. 1 µl of a cryoprotectant solution 
(30% glycerol, 14 µl mother liquor to a total of 20 µl) was added to the drop containing the 
crystal and immediately after fishing, the crystal was cryocooled in liquid nitrogen.  
The most promising crystals, EcYejA grown in 0.1 M MES pH 6.5, 12% w/v polyethylene 
glycol 20,000 in sitting nanodrops, were stored in liquid nitrogen and transported to the 
DIAMOND light source, Didcot for X-ray diffraction data collection on beamline i04-1. Data 
collection was performed remotely by Dr. Johan Turkenburg. 
Data were processed using Xia2 followed by Aimless (Evans and Murshudov, 2013), a data 
reduction pipeline in CCP4i2 (Potterton et al., 2018). The PDB structure 4ONY for an 
uncharacterised substrate binding protein from Brucella melitensis (Uniprot ID C0RL96) was 
used for molecular replacement. Searches with the complete 4ONY molecule did not give a 
satisfactory solution. Therefore, the 4ONY structure was separated into two domains and 
molecular replacement calculations were performed firstly using residues 1-261 and 545-
580. This gave a convincing solution which was refined using REFMAC5 (Murshudov, Vagin 
and Dodson, 1997). This solution was fixed while a second molecular replacement 
calculation was performed using residues 262-544. This gave a solution which was later 
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refined in REFMAC5 (Murshudov, Vagin and Dodson, 1997) and gaps in the model filled in 
using BUCCANEER (Cowtan, 2006). Iterative rounds of model building using COOT (Emsley 
and Cowtan, 2004) and refinement in REFMAC5 (Murshudov, Vagin and Dodson, 1997) 
were carried out. Figures were made using the CCP4mg software program.  
2.11 In vivo sensitivity assays 
2.11.1 Disc diffusion assays 
1% LB agar plates were prepared along with a bottle of 0.7% LB agar, called top agar. Small 
discs of filter paper were created with a hole punch and autoclaved. Just before use the 
poured LB agar plates were warmed to 37 °C and the top agar was melted and cooled to 
~55 °C. 3.5 ml aliquots of top agar were transferred to sterile 15 ml falcon tubes and kept at 
55 °C until use. Bacterial culture from overnights was added to the aliquot of top agar to a 
final OD600 of 0.05 and mixed thoroughly by pipetting. The inoculated top agar was then 
immediately poured onto the pre-warmed 1% agar plates. The plates were then allowed to 
cool and dry on the bench. Once dry, up to 4 filter paper discs were placed evenly spaced 
on the top agar using sterile tweezers. A total volume of 5 µl of antibiotic at various 
concentrations was added to the filter paper discs before the plates were incubated at 37 
°C overnight and imaged the next day.  
2.11.2 Determination of Minimum Inhibitory Concentrations (MICs) of CAMPs and 
antibiotics with E. coli BW25113 in liquid culture 
5 ml of LB with various concentrations of antibiotics and CAMPs were inoculated to a final 
OD600 of 0.05 with overnight cultures of E. coli BW25113. Bacterial cultures were grown 
overnight at 37 °C with shaking at 220 rpm. The following day the OD600 of the cultures was 
taken and the MICs of the CAMPs and antibiotics was calculated as an approximate 
decrease in OD600 of 40-50% in the stationary phase between cultures with and without 
CAMPs and antibiotics.  
2.11.3 Plate reader sensitivity assays 
1.7 ml of sterile MilliQ water was added to the reservoirs on the outer most edge of the 96-
well plate (Thermo Scientific Nunclon Delta surface) and 200 µl of sterile MilliQ water was 
added to outer wells (column 1, column 12, row A, row H). 195 µl of LB and 
CAMPs/antibiotics at different concentrations were added to the wells and 200 µl of LB 
only was added to wells to generate blanks.  Overnight bacterial cultures were diluted in LB 
to create a final OD600 of 0.4, 5µl of this was added to the 195 µl of media and 
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CAMPs/antibiotics in the wells giving a final OD600 in the wells of 0.01. The plate was then 
incubated in the plate reader (Bioteck epoch 2 microplate reader, Gen5 3.00 software) at 
37 °C for 48 hours with double orbital constant shaking (282 cpm, 3mm) whilst taking OD600 
readings every 30 minutes.  
2.11.4 Shake flask sensitivity assays 
20 ml of LB with CAMPs/antibiotics at different concentrations was added to a 100 ml 
conical flask. The flasks were inoculated to an OD600 of 0.01 (exact OD600 stated) with 
overnight bacterial cultures and grown at 37 °C with shaking at 150 rpm for 48 hours, or 
the length of time is otherwise stated. OD600 readings of the cultures were taken at regular 






















3. Expression of Putative CAMP Binding Proteins  
3.1 Phylogenetic analysis of Cluster C substrate binding proteins (SBPs) 
SapA and YejA are SBPs of ABC transporters and each is hypothesised to bind CAMPs, 
however the mechanism of binding is not yet known (Parra-Lopez, Baer and Groisman, 
1993; Mason et al., 2006; Eswarappa et al., 2008; Rinker et al., 2012; Wang et al., 2016). In 
keeping with the accepted structure based classification of SBPs, both SapA and YejA fall 
into the Cluster C SBPs as they contain an extra domain compared to other SBPs (Berntsson 
et al., 2010). To better understand how the proteins relate to other Cluster C SBPs, a 
limited phylogenetic analysis was undertaken. This type of analysis can give insights into 
the possible ligands of the SBPs SapA and YejA that are both hypothesised to bind CAMPs. 
Depending on where SapA and YejA fall within the phylogenetic tree could either lend 
weight to this hypothesis or provide suggestions on a more fitting hypothesis.  
To create the phylogenetic tree the protein sequences of a number of Cluster C SBPs were 
collected. The initial focus was on Cluster C SBPs (i) whose structures had been solved (ii) 
had been referred to in previous literature (iii) all the Cluster C SBPs from the organisms (E. 
coli K12, S. Typhimurium LT2, L. lactis MG1363, H. influenzae Rd, B. subtilis strain 168, B. 
melitensis biotype 1 strain 16M) where Sap or Yej had been functionally studied or the 
structure of the SBP had been solved. Cluster C SBPs have been shown to bind a range of 
different substrates e.g. DppA is known to bind dipeptides, L. lactis OppA has been shown 
to bind peptides up to 35 residues long and NikA is known to bind both Nickel and haem 
(Manson et al., 1986; Detmers et al., 2000; Heddle et al., 2003; Shepherd, Heath and Poole, 
2007). The collated SBPs were then aligned in Jalview using the Muscle alignment algorithm 
and then an unrooted Maximum Likelihood phylogenetic tree was created from the 
alignment using Ugene.  
3.1.1 SapA is DppA-like 
The phylogenetic tree (Figure 3.1) shows the SapA proteins positioned very close to the 
DppA proteins (36% identity between E. coli SapA and E. coli DppA) and the H. influenzae 
haem binding protein HbpA (37% identity between E. coli SapA and H. inflenzae HbpA), 
DppA has been shown to bind dipeptides (Manson et al., 1986). A sequence alignment of 
some of the Cluster C SBPs from the phylogenetic tree indicated that there were four 
conserved cysteine residues between E. coli SapA and E. coli DppA (Figure 3.2). When a 





Figure 3.1. Phylogenetic analysis of Cluster C SBPs shows novel clade for YejA 
proteins. 
Unrooted maximum likelihood phylogenetic tree populated with a series of Cluster 
C SBPs. E. coli = E. coli K12, S. typhimurium = S. Typhimurium LT2, L. lactis = L. lactis 
MG1363, H. influenzae = H. influenzae Rd, B. subtilis = B. subtilis strain 168, B. 
melitensis = B. melitensis biotype 1 strain 16M. Green circles indicate the SapA and 
YejA proteins. Red circles on the tree indicate bootstrapping. The larger the red 










Figure 3.2. Alignment of a select few of the Cluster C SBPs in the phylogenetic 
tree. 
EcDppA = E. coli DppA, EcSapA = E. coli SapA, EcOppA = E. coli OppA, EcYejA = E. coli 
YejA, LlOppA = L. lactis OppA, BsAppA = B. subtilis AppA, further strain information 
listed in Table 2.1. EcDppA secondary structure is shown along the top of the 
alignment. Blue arrows below alignment show conserved cysteine residues 
between EcDppA and EcSapA. Green arrow below alignment shows the aspartate 






Figure 3.3. PHYRE model predicts two disulphide bonds in EcSapA and crystal structure of 
E. coli DppA shows two disulphide bonds. 
PHYRE model of EcSapA (A) is shown in blue ribbon form, the four cysteine residues 
forming the two disulphide bonds are shown in red spheres. Crystal structure (coordinates 
1DPE) of E. coli DppA (B) is shown in lilac ribbon, the four cysteine residues forming the two 






conserved cysteines created two disulphide bonds in the predicted structure, similar to the 
disulphide bonds in known structures of DppA (Figure 3.3B) (Nickitenko, Trakhanov and 
Quiocho, 1995; Tame et al., 1995; Levdikov et al., 2005). The phylogenetic data and the 
similarities between SapA and DppA suggest that SapA is a dipeptide binding protein, 
however recent literature gives many examples of how this may not be the case. Via 
genetic and biochemical analysis SapA has been shown to be involved in resistance to 
CAMPs in various different bacterial species (Parra-Lopez, Baer and Groisman, 1993; Mason 
et al., 2006; Rinker et al., 2012). As CAMPs are much longer than dipeptides, commonly 20-
30 residues, this literature indicates that SapA may be more than just a dipeptide binding 
protein.  
3.1.2 YejA is part of a novel clade 
Unlike the SapA proteins, the YejA proteins are not positioned close to the DppA family, nor 
the OppA/MppA families of oligopeptide SBPs, on the phylogenetic tree. YejA forms a novel 
clade on the phylogenetic tree with the clade positioned closer to, but distinct from, B. 
subtilis AppA which has been shown to bind longer peptides (Levdikov et al., 2005). The 
evidence demonstrated here seems to correlate more closely with the hypothesis that YejA 
is able to bind CAMPs rather than the hypothesis that SapA is able to bind CAMPs.  
Structures of some Cluster C SBPs have shown the presence of an aspartate residue in the 
binding pocket which appears to “cap” the end of the binding pocket and serve as an 
anchor for the amino terminus of peptide ligands. This aspartate forms a salt bridge with 
the alpha amino group of the peptide ligand and therefore prevents a longer peptide 
binding, “capping” the binding site. In the sequence alignment (Figure 3.2) this aspartate 
can be seen in EcDppA, EcSapA and EcOppA. However, in Cluster C SBPs which have been 
shown to bind longer peptides, such as BsAppA and LlOppA, this aspartate residue is not 
conserved. This presence or omission of the capping aspartate residue can therefore be 
used to predict whether a Cluster C SBP binds longer or shorter peptides. Using this 
prediction tool it is possible to hypthesise that EcYejA has the ability to bind longer 
peptides as it is predicted to not contain the capping aspartate residue. Likewise, it is 
possible to predict that due to the predicted presence of the capping aspartate residue in 
EcSapA, it only binds shorter peptides, i.e. not full length CAMPs as initially hypothesised.  
From the phylogenetic analysis, initially E. coli SapA (EcSapA) and E. coli YejA (EcYejA) were 
chosen as targets as they are represented in the phylogenetic tree and they appear to be 
good representatives of all the SapA and YejA proteins.  
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3.2 Cloning and expression of SapA 
Commonly genes encoding SBPs are cloned into vectors which produce the desired protein 
fused to short in-frame tags to aid in the purification process, for example hexahistidine 
tags (PORATH et al., 1975). In this study the gene sapA (Table 2.1, Chapter 2), encoding a 
putative CAMP SBP, was cloned into the pETFPP_30 vector for expression and further 
purification.  
The pETFPP_30 vector is based on the pET22b vector (Figure 2.1, Chapter 2) and contains 
an optional PelB leader sequence (Table 3.1), which targets the protein to the periplasm, 
and a cleavable C-terminal hexahistidine tag (Figure 3.4A). The hexahistidine tag is 
cleavable by human rhinovirus (HRV) 3C protease. sapA was PCR amplified from E. coli K12 
genomic DNA and the resulting fragments were cut using restriction endonucleases then 
assembled into the pETFPP_30 vector via HiFi DNA assembly. Different restriction 
endonucleases were used to create different constructs, for constructs with a PelB leader 
sequence NcoI and XhoI were used, for constructs with a native leader sequence or no 
leader sequence NdeI and XhoI were used. All constructed plasmids were verified firstly by 
colony PCR to establish the presence of an insert of expected length in the plasmid (Figure 
3.5). Plasmids containing the desired insert size were then sent for DNA sequencing of the 
open reading frame. The resulting sequence was checked to ensure the gene was in-frame 
and that no mutations had been introduced.  
Initial small scale overexpression trials were carried out on SapA constructs to determine 
whether recombinant protein was being produced. Small scale overexpression trials 
consisted of inoculating 50 ml of LB in a conical flask with the bacterial cells harbouring the 
various DNA constructs. The flasks were inoculated to different starting OD600 between 
0.01-0.2, incubated at different temperatures and for different lengths of time. The cells 
were induced with different concentrations of IPTG to try and find the conditions which 
produced the highest yield of soluble protein. Sample preparations for SDS-PAGE gels were 
as depicted in Figure 2.2, Chapter 2.  
The cytoplasmic EcSapA protein construct was received from Dr. Tim Rasmussen 
(University of Aberdeen) and its solubility was assessed in small scale overexpression trials. 
The small scale overexpression trials were carried out at 30 °C and 37 °C and induced with 1 
mM IPTG. Unfortunately, SapA was not soluble under these conditions, however an 
accumulation of protein at the expected molecular weight for SapA can be seen overnight   
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Table 3.1. PelB and Native leader sequences for EcSapA, StSapA and HiSapA. 
Further strain and protein information is listed in Table 2.1. The PelB leader sequence is 
derived from the vector, pETFPP_30, whereas the native signal sequences are unique to 
each protein from the different species. Both signal sequences target the proteins to the 






Figure 3.4. Schematic of SapA constructs used. 
PelB and Native refer to the leader sequences used, HRV is the HRV 3C cleavage point and 
6His is the hexahistidine tag used. Residue number of bordering amino acids are noted 





















Figure 3.5. Colony PCR showing the expected size insert for cytoplasmic ecYejA. 
M = Marker; 1, 2, 3 = Number of picked colony from cytoplasmic ecYejA transformation 
plate. A band is shown in lane 3 at the expected size (1804 bp) for cytoplasmic ecYejA, 
indicating this colony has been transformed correctly and contains plasmid DNA with the 
correct insert. Lanes 1 and 2 contain other colonies with DNA inserts of much lower size, 





in the insoluble fraction (Figure 3.6). Cytoplasmic expression of SapA yielded very low 
quantities of soluble protein, which may be due to the predicted disulphide bonds in SapA. 
Disulphide bonds, which form in oxidising conditions, are commonly important for the 
structure of proteins. The cytoplasm of E. coli is a reducing environment where disulphide 
bonds are not expected to form, however the periplasm has an oxidising environment 
allowing the formation of disulphide bonds.  
Due to the insolubility of EcSapA when cytoplasmic overexpression was trialled, expression 
of the SapA protein in the periplasm was tested using various leader sequences (Table 3.1). 
The range of sapA genes was also broadened to include sapA from S. Typhimurium LT2 
(StSapA) and H. influenzae (HiSapA), in attempts to increase the chances of producing a 
soluble version of the SapA protein. Initially sapA from all three species were cloned into 
the pETFPP_30 vector to create constructs that included both the PelB leader sequence for 
transport to the periplasm and the cleavable C-terminal hexahistidine tag (Figure 3.4A, 
3.4C, 3.4D). The primers used to create the constructs were EcPSapA-F and EcPSapA-R for 
EcSapA; StPSapA-F and StPSapA-R for StSapA and HiPSapA-F and HiPSapA-R for HiSapA.  
As with the cytoplasmic expression of EcSapA, SapA from all three organisms when 
expression cells were grown at 37 °C and induced with 1 mM IPTG produced little to no 
soluble protein (Figure 3.7). Although the amounts of protein loaded in the soluble lanes of 
Figure 3.7 were very low, as indicated by the lack of many protein bands in those lanes, 
when the soluble fractions were run through a Nickel affinity column a very small peak was 
eluted. This indicated that there was very little soluble SapA being produced and therefore 
it was not practical to continue with these constructs.  
A variety of approaches were employed to overcome the insolubility of SapA. First different 
growth temperatures of the cultures were tested. Often lowering the temperature of 
bacterial cultures reduces the speed at which they replicate and therefore the speed and 
quantity of protein they produce (Schein and Noteborn, 1988). This can help with the 
solubility of proteins by reducing the workload of the cell and therefore avoiding protein 
aggregation. Temperatures were tested between 20 °C and 37 °C, none showed any 
improvement in solubility across all three SapA proteins (Figure 3.8). Protein bands on the 
SDS-PAGE gels at the expected molecular weight for SapA are not seen in any of the soluble 
fractions but large bands are seen at the expected molecular weight in the insoluble 




Figure 3.6. EcSapA is not soluble in the cytoplasm at 30 °C or 37 °C. 
12% polyacrylamide SDS-PAGE gels stained with Coomassie blue dye. Cells were incubated 
at either 30 °C or 37 °C and recombinant protein production was induced with 1 mM IPTG. 
Gel A shows the soluble fractions at both 30 °C and 37 °C, B shows the insoluble fractions at 
37 °C and C shows the insoluble fractions at 30 °C. M = Marker; U = Uninduced sample; 1, 2, 
3, 4hr = Number of hours after induction that a soluble/insoluble sample was taken; O/N = 
Overnight soluble/insoluble sample. No accumulating band of protein at the expected 
molecular weight for SapA (59.4 kDa) can be seen in the soluble samples gel. There is a 
band at the expected molecular weight for SapA in Gel B, the band appears to increase in 





Figure 3.7. EcSapA, StSapA and HiSapA with a PelB leader sequence are insoluble at 37 °C 
when induced with 1 mM IPTG. 
12% polyacrylamide SDS-PAGE gels stained with Coomassie blue dye. M = Marker; 0, 2, 4S = 
Number of hours after induction that a TSE periplasmic sample was taken; 0, 2, 4I = 
Number of hours after induction that a TSE post-periplasmic extraction insoluble sample 
was taken; NS = Overnight soluble sample; NI = Overnight insoluble sample. A = EcSapA, B = 
StSapA, C = HiSapA. All protein bands of the expected molecular weight for SapA (EcSapA = 
59.4 kDa, StSapA = 59.5 kDa, HiSapA = 61.8 kDa) are in the insoluble fractions of the 




Figure 3.8. SapA with a PelB leader sequence is insoluble at different temperatures. 
12% polyacrylamide SDS-PAGE gels stained with Coomassie blue dye. Images A and B are of 
EcSapA, C and D are of StSapA and E and F are of HiSapA. Overexpression trials show in 
images A, C and E were carried out at 25 °C and trials shown in images B, D and F were 
carried out at 37 °C. M = Marker; 1 = Uninduced sample; 2 = Pre-harvest sample; 3 = 
Soluble sucrose fraction; 4 = Soluble periplasmic fraction; 5 =Post-periplasmic extraction 
soluble sample; 6 = Blank; 7 = Post-periplasmic extraction insoluble sample. All of the gels 
show an increase in protein at the expected molecular weight for SapA (EcSapA = 59.4 kDa, 
StSapA = 59.5 kDa, HiSapA = 61.8 kDa) in the Pre-harvest whole cell sample as compared to 
the uninduced whole cell sample. This indicates that the process of inducing expression of 




Secondly a range of different IPTG concentrations were tested in small scale 
overexpression trials. IPTG induces the production of the target gene cloned into a pET 
vector by binding to the Lac repressor and causing its dissociation from the Lac operator 
site adjacent to the pT7 promoter, allowing transcription of the encoded gene. By titrating 
the concentration of IPTG it is possible to control the rate of protein production. Much like 
the control of temperature, lowering the rate of protein produced lowers the burden on 
the cell and therefore helps ensure that the protein that is produced is processed properly 
(Donovan, Robinson and Click, 1996). IPTG concentrations were tested in the range 0.1 mM 
– 1 mM, unfortunately changing the concentration of IPTG did not have an impact on the 
solubility of any of the three SapA proteins (Figure 3.9). In each case protein was being 
made, but it was insoluble. There are no bands in the soluble periplasmic fraction to 
suggest soluble expression, however there are bands in the pre-harvest whole cell sample 
at the predicted molecular weight for SapA suggesting overexpression of insoluble protein. 
This shows that the lower concentration of IPTG is not aiding the solubilisation of SapA in 
the periplasm.  
Following on from the unsuccessful expression of SapA with a PelB leader sequence, the 
next strategy employed was to try and express EcSapA solubly in the periplasm using the 
protein’s native signal sequence (Table 3.1, Figure 3.4B). The construct was cloned into 
pETFPP_30 using primers EcNSapA-F and EcNSapA-R and contained the EcSapA native 
signal sequence and an HRV 3C cleavable hexahistidine tag. The native signal sequence of 
SapA works in the same way as the PelB leader sequence, it targets the protein for 
secretion to the periplasm via the Sec translocase.  
Again, different growth temperatures and IPTG concentrations were trialled, none of these 
produced soluble SapA (Figure 3.10). The uninduced samples in Figure 3.10A have a small 
band of protein at the predicted molecular weight for SapA, this may be due to leaky 
expression in the cells. However this band is not seen in the subsequent soluble samples 
after induction, indicating that the protein band seen in the pre-induction sample is 
insoluble. In Figure 3.10 gels B and C a large band of protein is shown at the predicted 
molecular weight for SapA and increases in size as the timepoints increase, indicating 
accumulation of protein. The protein that is accumulated seems to be insoluble due to it 
appearing in the insoluble fractions and it not being seen in the soluble fractions.   
As a control, Shewana3-2073 protein was expressed. It has been previously shown that it is 




Figure 3.9. SapA with a PelB leader sequence is insoluble when induced with 0.8 mM 
IPTG. 
12% polyacrylamide SDS-PAGE gel stained with Coomassie blue dye. M = Marker; U = 
Uninduced sample; WC = Pre-harvest sample; P = Post-periplasmic extraction soluble 
fraction. Cells were grown at 25 °C and recombinant protein production was induced 
overnight with 0.8 mM IPTG.  In the pre-harvest samples there is an increase in protein in 
one of the bands, this is slightly lower than the expected molecular weight of SapA (EcSapA 





Figure 3.10. EcSapA with native leader sequence is insoluble. 
12% polyacrylamide SDS-PAGE gels stained with Coomassie blue dye. A) depicts soluble 
protein when cells are grown at 30 °C and 37 °C, B) shows insoluble protein when cells are 
grown at 30 °C and C) shows insoluble protein when cells are grown at 37 °C. M = Marker; 
U = Uninduced sample; 1, 2, 3, 4hr = Number of hours after induction that a 




coli cells using the ICOS method (Drousiotis, 2017). Shewana3-2073 is an SBP for an ABC 
transporter from Shewanella ANA-3, Shewana3-2073 has a molecular weight of ~32.5 kDa 
and a single disulphide bond. Shewana3-2073 was used as a positive control for periplasmic 
expression and extraction of protein alongside SapA (Figure 3.11). The band of protein 
shown slightly higher than that of Shewana3-2073 in lanes 1, 5 and 7 could possibly be 
Shewana3-2073 with an uncleaved signal sequence as these samples are taken from the 
whole cell and the signal sequence is only cleaved upon transport to the periplasm. This gel 
displays that it is possible to extract soluble Shewana3-2073 from the periplasm via the 
ICOS method, as indicated by the large bands of protein in lanes 3 and 4. However it was 
not possible to do the same with SapA, leading to the conclusion that the problem lies with 
the solubility of SapA, not the methodology employed to extract the protein.  
This work shows SapA from different bacterial species is insoluble when expressed in the 
cytoplasm, with a PelB leader sequence or with a native leader sequence at different 
temperatures and IPTG concentrations.  
Work was carried out on the SapA protein for almost a year when it was learned (8/8/2016) 
that the research group of Dr. Martin Walsh had experienced similar problems with the 
solubility and expression of SapA over a longer time period. They had overcome their 
problems and moreover had solved the structure of SapA (personal communication). Due 
to this new information and in the interests of time it was decided to continue on solely 
with EcYejA. 
3.3 Cloning and expression of EcYejA 
As with the SapA constructs EcYejA was cloned into the pETFPP_30 vector (Table 2.1 
Chapter 2). Two different EcYejA constructs were created with the pETFPP_30 vector. One 
with an N-terminal PelB leader sequence and a C-terminal histidine tag, targeting EcYejA 
for expression in the periplasm, using primers EcPYejA-F and EcPYejA-R. The second 
construct, created using primers EcYejA-F and EcYejA-R, directed the synthesis of the 
protein without a leader sequence but with a C-terminal histidine tag and so targeted 
EcYejA for expression in the cytoplasm.  
After DNA cloning and verification, small scale overexpression trials were carried out. 
Expression of the EcYejA construct lacking a leader sequence produced a large quantity of 
soluble protein, particularly after growth overnight at 30 °C (Figure 3.12). As this construct 




Figure 3.11. Overexpression and retrieval of soluble Shewana3-2073 from the periplasm 
of E. coli. 
12% polyacrylamide SDS-PAGE gel stained with Coomassie blue dye. M = Marker; 1 = 
Uninduced sample; 2 = Pre-harvest sample; 3 = soluble sucrose fraction; 4 = soluble 
periplasmic fraction; 5 = Post-periplasmic extraction soluble sample; 6 = blank lane; 7 = 
Post-periplasmic extraction insoluble sample. Shewana3-2073 was expressed in BL21 (DE3) 
star cells at 37 °C and recombinant protein production was induced with 1 mM IPTG 





Figure 3.12. EcYejA can be produced as a soluble protein. 
12% polyacrylamide SDS-PAGE gel stained with Coomassie blue dye. Cells were grown at 30 
°C and recombinant protein production was induced with 1 mM IPTG, all samples were 
boiled at 95 °C in SDS for 5 mins before loading on the gel. M = Marker; U = Uninduced 
whole cell sample; 1, 2, 3, 4hr = Number of hours after induction that a soluble sample was 
taken; O/N = Overnight soluble sample. A band showing an increasing amount of protein at 
each sample time point can be seen, detailed by the arrow, at the expected molecular 





is accumulating in the cytoplasm. As with the cytoplasmic expression of EcYejA the 
expression of EcYejA with the PelB leader sequence was soluble and a large enough 
quantity was produced to carry out further data analysis (Figure 3.13). Due to the ease of 
purifying EcYejA from the cytoplasm, as opposed to the additional steps needed to purify 
from the periplasm, it was decided to remain with cytoplasmic expression and purification 
of EcYejA for future work. The verified plasmid encoding cytoplasmic EcYejA encodes a 
protein consisting of residues 2-586 of mature E. coli YejA fused N-terminally to a 
methionine residue and C-terminally to an HRV 3C cleavable hexahistidine tag. 
Having established the success of the small scale overexpression trials with EcYejA, large 
scale overexpression and purification was carried out using the EcYejA construct lacking the 
leader sequence (cytoplasmic accumulation of EcYejA). SBPs can be subjected to a 2 M 
guanidinium-HCl treatment whilst bound to a Nickel affinity column (Lanfermeijer et al., 
1999). This treatment allows the release of any pre-bound ligand that might have purified 
with the protein from the cell extract.  
3.4 Purification of EcYejA 
EcYejA protein was eluted from the Nickel affinity column (Figure 3.14) and dialysed 
overnight into SEC buffer with HRV 3C protease (1:200 HRV 3C:protein ratio) to remove the 
cleavable C-terminal hexahistidine tag. Removal of the tag can aid in crystallisation as the 
hexahistidine tag is expected to be flexible and can therefore hinder the crystallisation 
process. The following day the dialysed EcYejA was subjected to size exclusion 
chromatography to further purify EcYejA (Figure 3.15). Another very faint band can be seen 
on the SDS-PAGE gel (Figure 3.15) running at approximately 46 kDa, this could be EcYejA 
degradation or other impurity. Due to the faintness of the band, therefore indicating low 
concentration compared to EcYejA, it was decided that this probably would not interfere 
with downstream experimentation. The resulting protein (~90 mg/L of LB liquid culture) 





Figure 3.13. EcYejA fused to a PelB leader sequence is soluble. 
12% polyacrylamide SDS-PAGE gel stained with Coomassie blue dye. M = Marker; P = Pre-
harvest whole cell sample; 1, 2, 3, 4hr = Number of hours after induction that a soluble 
sample was taken; O/N = Overnight soluble sample. There is a band at the same molecular 
weight across the time points indicating that soluble EcYejA with a PelB leader sequence is 
being produced. The pre-harvest sample also shows a protein band at the expected 







Figure 3.14. EcYejA can be purified by Nickel affinity chromatography. 
12% polyacrylamide SDS-PAGE gels stained with Coomassie blue dye. Top shows the 
chromatogram of Nickel affinity purification of EcYejA, bottom shows the SDS-PAGE from 
the same purification. M = Marker; U = Uninduced sample; L = Load (1 in 100 dilution); F = 
Flow through (1 in 100 dilution); W = Wash through; Peak Fractions indicates fractions from 
the peak in the above chromatogram. There is no band on the gel in the flow through at 
the expected molecular weight for EcYejA (68.4 kDa) but there is a band at the expected 
molecular weight for EcYejA in the peak fractions, indicating EcYejA is binding to the Nickel 
column and eluting when imidazole is added to the column. The fraction samples are much 




Figure 3.15. EcYejA can be further purified by Size Exclusion Chromatography. 
12% polyacrylamide SDS-PAGE gels stained with Coomassie blue dye. Top shows the 
chromatogram of Size Exclusion purification of EcYejA, bottom shows the SDS-PAGE from 
the same purification. M = Marker; L = Load (1 in 100 dilution); Peak indicates fractions 
from the peak in the above chromatogram. The gel shows that the peak samples are purer 
than the load sample and are at the expected molecular weight for EcYejA. The 1st peak 















4. Biochemical Analysis and Structure Determination of EcYejA  
4.1 Biochemical analysis of EcYejA 
After cytoplasmic expression and purification of EcYejA via a Nickel affinity column 
followed by an S200 SEC column EcYejA consisted of an N-terminal Methionine, residues 2-
586 of the protein and a remaining LEVLFQ sequence at the C-terminus produced by HRV 
3C protease cleavage. EcYejA was then subjected to further biochemical analysis and 
crystallisation to understand the properties of the protein in more detail.  
Initially EcYejA was analysed by denaturing electrospray mass spectrometry, carried out by 
Dr. Andrew Leech, to establish that authentic and intact protein had been purified. The 
mass spectrometry equipment was calibrated using horse heart myoglobin and has an 
error of ± 1.5 Da. A clearly defined peak at 68375.6 Da can be seen (Figure 4.1), this peak 
was corrected using the horse heart myoglobin as a standard and gave a corrected value of 
68383.6 Da. The expected molecular weight of EcYejA is 68382.42 Da, which is within the ± 
1.5 Da error range of the instrument away from the corrected mass value. This indicates 
that the EcYejA protein has been purified and no alterations have been made during the 
expression or purification process.  
To determine whether EcYejA was monomeric, dimeric or otherwise SEC-MALLS was 
carried out, under the supervision of Dr. Andrew Leech, on EcYejA using two different 
concentrations of EcYejA, 1 mg/ml and 3 mg/ml (Figure 4.2). The data indicate that the 
majority of EcYejA is monomeric. The majority of substrate binding proteins are monomeric 
and there was nothing to indicate that EcYejA would be any different to this. There is a 
small proportion of the protein that is dimeric.  
During purification EcYejA was treated with 2 M guanidinium-HCl whilst bound to the 
Nickel affinity column, to determine whether EcYejA was folded following the treatment 
Circular Dichroism (CD) was used under the supervision of Dr. Andrew Leech. Proteins with 
α-helices produce CD spectra with negative troughs at 208nm and 222nm and a positive 
peak at 193nm. Proteins containing β-sheets have a positive peak at 195nm and a negative 
trough at 218nm. Disordered proteins however have a negative trough at 195nm and very 
low ellipticity above 210nm (Greenfield, 2006). A sample of untreated EcYejA was used as a 
control, as the spectra shows (Figure 4.3) both the treated and untreated EcYejA are within 
the range of α-helices and β-sheets and neither show any indication of random disordered 




Figure 4.1. Denaturing electrospray mass spec shows EcYejA has been purified 
successfully. 
The mass of the largest peak shown in the figure when corrected using horse heart 
myoglobin as a standard is 68383.6 Da, very close to the predicted molecular weight for 
EcYejA at 68382.42 Da and within the error range of the instrument. 
  
mass














Figure 4.2. SEC-MALLS data shows EcYejA is mainly monomeric. 





Figure 4.3. EcYejA treated with 2 M guanidinium-HCl is the same as untreated EcYejA. 
EcYejA treated with 2 M guanidinium-HCl is shown by a blue line and EcYejA not treated 




concentrations of the two samples. This indicates that the 2 M guanidinium-HCl treatment 
has not had an effect on the structure of EcYejA. 
4.2 Crystallisation of EcYejA 
To allow X-ray diffraction and structure determination of EcYejA the protein first had to be 
crystallised. Purified EcYejA protein was put into crystallisation trials using a 96-well plate 
sitting drop format. The crystallisation screens used were JCSG+, PDB Min and PEG/ION 
with 10 mg/ml and 20 mg/ml EcYejA. Crystals appeared (Figure 4.4) from 0.2 M ammonium 
formate and 20% w/v polyethylene glycol 3350 at both 10 mg/ml and 20 mg/ml EcYejA. 
Before crystals were captured for X-ray diffraction and data collection they were preserved 
using a cryo protectant (30% glycerol, 14 µl mother liquor to a total of 20 µl). 1 µl of cryo 
protectant was added to each drop before fishing crystals from the drop using a nylon loop. 
The crystals were rapidly submerged in liquid Nitrogen for storage. 
The crystals grown in 0.2 M ammonium formate and 20% w/v polyethylene glycol 3350 did 
not diffract well when sent to DIAMOND and gave two different crystal lattices, this is 
possibly due to the crystals growing in an overlapping way, which are very difficult to 
separate when fishing the crystals.  
Several variations of the crystallisation conditions were tested in 24 well hanging drop 
plates with a reservoir volume of 1 ml. All of the resulting crystals had a very similar 
morphology (Figure 4.5), long thin overlapping rod like shapes. These crystals were very 
difficult to separate and mount for X-ray diffraction. A variety of different strategies were 
tested to try and slow the growth of the crystals and to improve their quality, these 
included adding DMSO and ethylene glycol to the reservoirs.  
Approximately 1 month after setting up the 96-well sitting drop crystallisation plate of 
EcYejA, crystals were observed (Figure 4.6) in 12% w/v Polyethylene glycol 20,000 and 0.1 
MES pH 6.5 at both 10 mg/ml and 20 mg/ml EcYejA. These crystals were usually single and 
of “chunkier” morphology. They were easy to mount and send to the DIAMOND Light 
Source for X-ray diffraction.  
4.3 Structure determination of EcYejA 
Data was collected remotely by Dr. Johan Turkenburg and Sam Hart on the i04-1 beamline 




Figure 4.4. Crystals of EcYejA in 0.2 M ammonium formate and 20% w/v polyethylene 
glycol 3350. 







Figure 4.5. Crystals of EcYejA in 0.2 M ammonium formate, 1% DMSO and 25% PEG 3350. 






Figure 4.6. Crystals of EcYejA in 12% w/v Polyethylene glycol 20,000 and 0.1 M Mes 6.5. 






and 0.1 M Mes 6.5. Data processing was carried out via Xia2 and the space group was 
found to be I222 (Table 4.1). 
The initial aim was to solve the structure of EcYejA by molecular replacement using the 
coordinate set with the PDB entry 4ONY. 4ONY was found by using BLAST and searching 
with the protein sequence of EcYejA whilst setting the results to search for only things 
deposited in the PDB, therefore meaning their structure is known. 4ONY was the top hit 
from this search meaning it had the most sequence similarity (32% identity) with EcYejA 
and therefore was a good choice for molecular replacement. In the PDB 4ONY is annotated 
as an SBP from B. melitensis and is in the apo form, again meaning it was a good choice for 
EcYejA as EcYejA was also expected to be in the apo form.  SBPs go through large 
conformational changes upon ligand binding therefore meaning the difference between 
the apo/open and ligand bound/closed forms can be large so having a molecular 
replacement model in the same conformation can aid molecular replacement. As later 
discovered EcYejA was actually in the closed form and therefore molecular replacement 
was carried out in a slightly different way. As SBPs have two clear domains with the binding 
cleft residing in the interface between the two domains it was relatively simple to separate 
the two domains of 4ONY and use the two domains separately in molecular replacement 
calculations. Domain one of 4ONY was defined as residues 1-261 and 545-580, domain two 
was residues 262-544. Using Molrep (Vagin and Teplyakov, 2010), a molecular replacement 
tool in CCP4i2, it was possible to carry out molecular replacement with one domain of 
4ONY, fix that domain in place and then carry out molecular replacement on the second 
domain. This approach was successful and following molecular replacement BUCCANEER 
(Cowtan, 2006) was used to build peptide chains between the two domains of the protein 
that were cut to carry out the molecular replacement. Following on from this step iterative 
rounds of REFMAC (Murshudov, Vagin and Dodson, 1997) and model building in COOT 
(Emsley and Cowtan, 2004) were carried out. The structure was judged to be solved when 
the R value was 0.16 and the Rfree was 0.19 (Table 4.1), at this point it was clear that 
EcYejA was in the closed conformation (Figure 4.7). The structure shows EcYejA has two 
clear domains with a binding cleft in the middle, as expected and is common with all 
Cluster C SBPs. It also has the extra domain which is characteristic of Cluster C SBPs. The 
only thing initially noticed as being slightly different from other Cluster C SBPs was the 





X-ray source DLS beamline i04-1 
Wavelength (Å) 0.92819 
Resolution range (Å) 29.91-1.60 
Space group I222 
Unit-cell parameters (Å/°) 91.44, 105.27, 145.34/ 90.0, 90.0, 90.0 
Matthews coefficient (Å3/Da) /solvent content (%) 2.56/ 51.95% 
Number of observations overall/outer shella 754721/38115 
Number of unique observations overall/outer shella 91935/4473 
Completeness (%), overall/outer shella 99.6/99.1 
I /σ(I), overall/outer shella 17.4/3.4 
Rmergeb, overall/outer shella 0.064/0.550 
CC ½ c 0.999/0.930 
Refinement and model statistics 
R-factord/R-freee 0.160/0.191 
Reflections (working/free) 91932/4545 
Molecules/asymmetric unit 1 
No. of atoms: Protein 4736 
No. of atoms: Ligand 91 
No. of atoms: Water 592 
No. of atoms: Glycerol 18 
R.m.s deviationsf: Bonds (Å); Angles (°) 0.0262; 2.158 
Average B-factor (Å2): Protein 21.89 
Average B-factor (Å2): Ligand 27.6 
Average B-factor (Å2): Water 34.77 
Average B-factor (Å2): Glycerol 31.93 
Ramachandran plot: preferred regions/ allowed regions/ 
outliers (%) 97.09/2.05/0.85 
Table 4.1. X-ray data collection and refinement statistics obtained for EcYejA. 
aThe outer shell corresponds to 1.63-1.60 Å. bRmerge = ∑hkl∑i|Ii-<I>|/∑hkl∑i <I> where Ii is 
the intensity of the ith measurement of a reflection with indexes hkl and <I> is the 
statistically weighted average reflection intensity. cCC1/2 is the correlation coefficient 
between two randomly selected half data sets as described in Karplus & Diederichs (2012). 
dR-factor = ∑||Fo|-|Fc||/∑|Fo| where Fo and Fc are the observed and calculated structure 
factor amplitudes, respectively. eR-free is the R-factor calculated with 5% of the reflections 
chosen at random and omitted from the refinement. fRoot-mean-square deviation of bond 




Figure 4.7. Structure of EcYejA.  
EcYejA is shown in ribbon form coloured from N to C terminus in blue to red. The surface of 
EcYejA is shown in grey. The dark blue disordered section of EcYejA between the two red 
arrows is the disordered loop in the N-terminal region, as described in the text, which is 






4.4 Ligand determination 
In the course of refining the structure of EcYejA, extended electron density was discovered 
in the protein interior which could not be accounted for by the protein sequence of EcYejA. 
Once the modelling of EcYejA chain had been completed, it was possible to determine 
specific features of the density. The density strongly resembled a peptide chain with very 
clear density for some of the side chains of the peptide chain (Figure 4.8) however, some of 
the side chains were difficult to pick out (Figure 4.9). As these Cluster C SBPs are often 
peptide binding proteins this peptide chain was assumed to be a ligand of EcYejA. Due to 
the density for the peptide ligand being so clear it was possible to build the peptide ligand 
backbone and add in certain side chains. A BLAST search using the inferred peptide 
sequence was carried out using the identified ligand sequence XXPRYXFXFX, the results 
came back showing the disordered loop in the N-terminal region of EcYejA as the source of 
the ligand and identified the ligand as LGEPRYAFNFN (GEP). When the unknown residues of 
GEP were fitted into the density they fitted the density well and therefore confirmed the 
ligand sequence as LGEPRYAFNFN (Figure 4.10). EcYejA having a ligand bound was highly 
unexpected as it was assumed that the 2 M guanidinium-HCl treatment of EcYejA whilst 
bound to the Nickel affinity column would release any pre-bound ligand and EcYejA would 
be in the apo form. This combined with the highly unusual source of the ligand led to much 
consideration of how the ligand could have been produced and available for EcYejA 
binding. It is possible that during the month it took for the crystals to grow that a 
proportion of the EcYejA was proteolytically cleaved in the mother liquor and was bound by 
full length EcYejA. It is also important to note at this point that 100% occupancy was seen 
for the full length EcYejA and additional 100% occupancy density for the ligand (Figure 
4.11), meaning a single molecule of EcYejA was not binding its own N-terminal region. 
To ensure that EcYejA was in a truly closed conformation, as opposed to a partially closed 
conformation, the software rdock and rbcavity were used to create a binding pocket mesh. 
If this mesh was visible when a surface view was used on the EcYejA structure then EcYejA 
was in a partially closed conformation, but if the mesh was not visible then it shows EcYejA 
is in the truly closed conformation (Figure 4.12). As Figure 4.12 shows only a small amount 







Figure 4.8. Electron density shows the presence of side chains in the crystal ligand. 
EcYejA is shown in grey ribbon form and electron density is shown in blue mesh. The red 
circle highlights the side chains. (A) Shows a Proline at position 4 in the ligand, contour level 
1.0, (B) shows an Arginine residue at position 5 in the ligand, contour level 1.0, (C) shows a 
Tyrosine residue at position 6 in the ligand, contour level 1.5, (D) shows a phenylalanine 
residue at position 8 in the ligand, contour level 1.5 and (E) shows a phenylalanine residue 







Figure 4.9. Example of electron density where it was not possible to determine the side 
chain. 
EcYejA is shown in grey ribbon form and electron density is shown in blue mesh at a 
contour level of 1.0. The red circle highlights the side chain that could not be determined 





Figure 4.10. GEP ligand fully built with final density after refinement. 
EcYejA is shown in grey ribbon form, GEP ligand is shown in cylinder form with carbon 
atoms shown in green, nitrogen atoms shown in blue and oxygen atoms shown in red. 






Figure 4.11. GEP ligand and corresponding section of EcYejA highlighted in structure. 
(A) EcYejA is shown in grey ribbon form with N and C termini labelled. GEP ligand in the 
binding pocket is shown in green bond format and corresponding GEP peptide section of 







Figure 4.12. EcYejA with binding pocket mesh shown in different views. 
EcYejA is shown in grey ribbon form or electrostatic surface view, N and C refer to EcYejA N 







4.4.1 Analysis of the interactions between LGEPRYAFNFN and EcYejA 
Leucine-1 makes two backbone hydrogen bonds to surrounding water molecules, one from 
the alpha amino group nitrogen and one from the backbone oxygen (Figure 4.13). 
Interestingly there appears to be more space on the N-terminus of GEP to build further into 
binding pocket, indicating that EcYejA may be able to bind longer peptides. As calculated by 
PDBePISA, 80% of the accessible surface area of Leu1 from GEP is buried upon binding. 
PDBePISA is an online tool from EMBL-EBI which determines the interface interactions 
between proteins and the properties of specific residues, this tool was used to further 
understand GEP binding. The solvation energy effects, in kcal/mol, of each GEP residue was 
also calculated using PDBePISA. A positive solvation energy of a residue makes a negative 
contribution to the solvation energy of the interface and therefore corresponds to 
hydrophobic effects. All solvation energy effects calculations made in PDBePISA do not 
include the effects of Hydrogen bonds (-0.44 kcal/mol per bond) or salt bridges (-0.15 
kcal/mol per salt bridge). PDBePISA calculates the solvation energy effect of Leucine from 
GEP as +1.93 kcal/mol.  
Glycine-2 again contributes two hydrogen bonds from the peptide backbone, one from the 
nitrogen to the carboxylate side chain of Asp477 (Figure 4.14A). The other one is 
interestingly between the backbone oxygen and the backbone nitrogen of Arg5 from GEP, 
this interaction is helping to hold GEP in a twisted almost α-helical form. 100% of the 
accessible surface area of Gly2 is buried upon EcYejA binding of GEP and the solvation 
energy effect is calculated as +0.1 kcal/mol.  
Glutamate-3 which makes a single hydrogen bond with water molecule 292 via an oxygen 
on the side chain (Figure 4.14B). PDBePISA predicts that a salt bridge is also formed 
between a side chain oxygen and Arg51 in EcYejA. Unlike Leu1 and Gly2 beforehand there 
are no backbone interactions with EcYejA. PDBePISA calculated that 40% of the accessible 
surface area is buried upon EcYejA binding of GEP and the solvation energy effect is -0.45 
kcal/mol.  
Proline-4 forms a single hydrogen bond between the backbone oxygen and Gln132 from 
EcYejA (Figure 4.14C). 80% of Pro4 accessible surface area is buried upon EcYejA binding of 






Figure 4.13. Neighbourhood and interactions of the first residue of GEP, Leucine, with 
EcYejA. 
GEP is depicted in green and EcYejA in grey, water molecules are shown as red spheres and 
bonds are shown as black dashed lines. Hydrogen bonds can be seen between GEP Leu1 












Figure 4.14. Neighbourhood and interactions of GEP residues with EcYejA. 
GEP is depicted in green and EcYejA in grey, water molecules are shown as red spheres and 
bonds are shown as black dashed lines. (A) is a view of Gly2 from GEP. Hydrogen bonds can 
be seen between Gly2 and Asp477 from EcYejA and Arg5 from GEP. (B) is a view of Glu3 
from GEP. A single Hydrogen bond is formed between a side chain oxygen on Glu3 and 
water molecule 292. A salt bridge is also formed between Glu3 and Arg51. (C) is a view of 
Pro4 of GEP, a hydrogen bond is formed between the oxygen from the peptide backbone 





The arginine-5 side chain in GEP makes two hydrogen bonds with surrounding residues, 
one with Ser476 and one with Tyr137 (Figure 4.15A). PDBePISA predicts Arg5 to make 4 salt 
bridges with EcYejA, two to Asp477 and another two to Asp161. As well as the side chain 
interactions there is also a hydrogen bond formed between the backbone nitrogen of Arg5 
and the backbone oxygen of Gly2, as mentioned previously. Upon EcYejA binding of GEP 
100% of Arg5 is buried and the solvation energy effect is -0.81 kcal/mol.  
Tyrosine-6 makes a single hydrogen bond from the backbone oxygen to a water molecule 
(60) (Figure 4.15B). There are possible stacking interactions between the Tyr6 side chain 
and the rest of the GEP peptide. 90% of accessible surface area of Tyr6 is buried upon 
EcYejA binding of GEP and the solvation energy effect is +1.13 kcal/mol. 
The seventh residue in GEP, Alanine-7, again makes a single hydrogen bond from the 
backbone oxygen to Tyr491 in EcYejA (Figure 4.15C). 100% of Ala7 is buried upon EcYejA 
binding of GEP and the solvation energy effect is +0.66 kcal/mol.  
Phenylalanine-8 from GEP makes three hydrogen bonds, two of which are from the 
backbone oxygen to Arg51 and the other is from the backbone nitrogen to water molecule 
34 (Figure 4.16A). 100% of Phe8 is buried upon EcYejA binding of GEP and the solvation 
energy effect is +2.44 kcal/mol. 
Asparagine-9 makes a total of 6 hydrogen bonds to EcYejA, three from the side chain and 
three from the backbone (Figure 4.16B). Two are made from the side chain oxygen to water 
molecules 288 and 385, whilst one is made from the sidechain nitrogen to Met456. 
Interestingly this hydrogen bond is only formed when Met456 is in one of two 
conformations. The backbone oxygen makes two Hydrogen bonds to Arg457 and the 
backbone nitrogen makes one Hydrogen bond to Thr490. Upon EcYejA binding of the GEP 
ligand 80% of Asn9 is buried and the solvation energy effect is -0.27 kcal/mol.  
There are two hydrogen bonds from the backbone of Phe10 to water molecule 288, one 
from the nitrogen and one from the oxygen (Figure 4.16C). There also seems to be stacking 
interactions between the side chain of Phe10 and Pro58 from EcYejA. 70% of Phe10 is 
buried upon EcYejA binding of GEP and the solvation energy effect is +2.05 kcal/mol. 
Although the sidechain of asparagine-11 cannot be seen in the density it is possible to 
identify a hydrogen bond between the backbone nitrogen and water molecule 541 (Figure 





Figure 4.15. Neighbourhood and interactions of GEP residues with EcYejA. 
GEP is depicted in green and EcYejA in grey, water molecules are shown as red spheres and 
bonds are shown as black dashed lines. (A) shows Arg5 of GEP. Hydrogen bonds are made 
between Arg5 and Ser476 and Arg5 and Tyr137. Four salt bridges are also made, two with 
Asp477 and two with Asp161. (B) is a view of Tyr6 of GEP. There is single hydrogen bond 
between the oxygen from the back bone of Tyr6 and water molecule 60. (C) shows Ala7 of 










Figure 4.16. Neighbourhood and interactions of GEP residues with EcYejA. 
GEP is depicted in green and EcYejA in grey, water molecules are shown as red spheres and 
bonds are shown as black dashed lines. (A) shows Phe8 of GEP. Two hydrogen bonds are 
made between the backbone oxygen and Arg51 and one is made between the backbone 
nitrogen and water molecule 34. (B) is a view of Asn9 of GEP. The side chain of Asparagine 
makes three hydrogen bonds, one to water molecule 288, one to water molecule 385 and 
one to Met456. The main chain backbone makes two from the backbone oxygen to Arg457 
and one from the backbone nitrogen to Thr490. (C) shows Phe10 of GEP. Two hydrogen 
bonds are formed between the backbone and water molecule 288, one from the backbone 
oxygen and one from the backbone nitrogen. (D) is a view of Asn11 of GEP. A single 








effect is +0.26 kcal/mol. This may be due to the side chain of Asn11 not being built into the 
structure. 
Between GEP and either EcYejA or water molecules there are a total of 24 hydrogen bonds, 
15 of which are from the backbone of the GEP peptide and 9 are from the side chains of 
GEP. 13 of hydrogen bonds formed are between GEP and EcYejA and 11 are between GEP 
and surrounding water molecules. Asn9 from the GEP peptide makes the most hydrogen 
bonds, 6 in total, of any of the GEP residues, however Arg5 makes the most side chain 
hydrogen bonds.  
There are a total of 5 salt bridges between EcYejA and GEP, 4 of which are formed from the 
Arginine residue to various EcYejA residues. The other is between Glu3 from GEP and Arg51 
of EcYejA.  
When all the hydrogen bonds and salt bridges formed between GEP and EcYejA, i.e. not 
including those between GEP and water molecules, are taken into account the solvation 
energy effects of each of the GEP residues are as shown in Table 4.2. From this analysis it is 
possible to see that Arg5 is the residue with the best solvation energy effects, closely 
followed by Asn9, both of these residues also made the most hydrogen bonds with EcYejA, 
indicating that these residues are important for EcYejA binding of GEP. It can also be seen 
that Phe10 and Leu1 are the residues with the worst solvation energy effects and therefore 
are the residues that are contributing the least to EcYejA binding of GEP. These results 
indicate that EcYejA is binding the central portion of GEP and the ends of the peptide are 
not as important for binding as the middle region of the peptide. This means it could be 
possible for EcYejA to bind peptides that are longer than 11 residues so long as the central 
portion of the peptides remain the same as or similar to the central portion of GEP.  
Due to the Guanidinium-HCl treatment step during the purification process, the only source 
of ligands available in the crystallisation tray was the crystal screen components or EcYejA. 
Therefore, it isn’t surprising that the ligand is from EcYejA as these proteins are peptide 
transporters and the only source of peptides was EcYejA itself.  
GEP is located 12 residues from the N-terminus of EcYejA (Figure 4.17), which begs the 
questions, where is the rest of the N-terminus of EcYejA? Why doesn’t EcYejA bind that 12 
residue peptide as well as the GEP? To what extent is EcYejA broken down? Is EcYejA 








Leu1 80 +1.93 
Gly2 100 -0.34 
Glu3 40 -1.04 
Pro4 80 +0.42 
Arg5 100 -3.61 
Tyr6 90 +0.69 
Ala7 100 -0.22 
Phe8 100 +1.56 
Asn9 80 -2.47 
Phe10 70 +2.05 
Asn11 20 +0.26 
Table 4.2. Buried surface area and solvation energy effects of residues of GEP. 
The numbers were calculated using PDBePISA, a web based tool which analyses the 
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Figure 4.17. GEP ligand is located 12 residues from the N-terminus of EcYejA. 




Once the ligand had been identified as a portion of the N-terminus of EcYejA, it was 
decided that truncating EcYejA at various points to remove the N-terminal region 
containing the ligand would be a good course of action. It was decided that truncating the 
N-terminus of EcYejA would help to prevent the GEP ligand from binding to EcYejA in future 
ligand binding experiments and therefore prevent skewing of future data. Three different 
truncations were made in EcYejA to remove GEP from the protein but limit the removal of 
any secondary structure features of EcYejA (Figure 4.18). The constructs were cloned into 
pETFPP_30 and created using the primers STEcYejA-F and EcYejA-R; MTEcYejA-F and 
EcYejA-R; and LTEcYejA-F and EcYejA-R for the truncations at positions 1, 2 and 3 in Figure 
4.18 respectively. It was thought that this would prevent truncations in EcYejA from 
drastically altering the structure or function of EcYejA. However, when all three truncated 
EcYejA proteins were expressed following the same protocols as the expression of full 
length EcYejA, none were expressed (Figure 4.19). In the interests of time it was decided 
that pursuing the truncated versions of EcYejA would not be beneficial, instead fresh 
preparations of full length EcYejA were made regularly and stored at 4 °C for up to a month 
whilst being used in experiments.  It was thought that the crystallisation solution was 
causing the breakdown of EcYejA, therefore storing it at 4 °C for short periods of time 
wouldn’t cause the breakdown of EcYejA and release of the ligand seen in the crystal 
structure.  
4.5 Comparisons between EcYejA structure and other Cluster C SBP 
structures 
4.5.1 Overall structure of EcYejA as compared to other Cluster C SBPs 
A number of other Cluster C SBPs, whose structures have been solved or are relevant to 
this work, were chosen to make comparisons with the structure of EcYejA, they included; E. 
coli MppA (EcMppA) which binds murein tripeptide (PDB:3O9P); S. Typhimurium OppA 
(StOppA) which binds peptides 2-5 residues in length, but in this structure is complexed 
with KLK (PDB:1B9J); B. subtilis AppA (BsAppA) that binds a nonapeptide (PDB:1XOC); L. 
lactis OppA (LlOppA) which binds a 35 residue peptide, but in this structure is complexed 
with a nonapeptide (PDB:3DRG) and E. coli SapA (EcSapA) where the ligand and structure 
are unknown. Further protein information is detailed in Table 2.1 Chapter 2.  
A noticeable thing with the EcYejA structure when overlaid with other Cluster C SBPs is that 
EcYejA is a longer protein, there are extra elements of secondary structure and disordered 





Figure 4.18. Truncations of EcYejA. 
EcYejA is shown in grey ribbon form. The N and C refer to the N and C termini of EcYejA. 
The section of EcYejA which corresponds to the GEP ligand is shown in turquoise cylinder 
form. The residues at which truncations were made are shown in red cylinder form and 







Figure 4.19. Truncations of the N-terminus of EcYejA are not expressed. 
12% polyacrylamide SDS-PAGE gel stained with Coomassie blue dye. Cells were grown at 30 
°C and recombinant protein production was induced with 1 mM IPTG, all samples were 
boiled at 95 °C in SDS for 5 mins before loading on the gel. M = Marker; U = Uninduced 
sample; 1, 2, 3, 4hr = Number of hours after induction that a sample was taken; O/N = 





Figure 4.20. EcYejA superposed with BsAppA and StOppA.  
EcYejA is shown in grey, BsAppA (PDB:1XOC) is shown in pink and LlOppA (PDB:3DRG) is 
shown in coral. The N and C refer to the N and C termini of EcYejA. The red circle indicates 






EcYejA without its signal sequence is 585 residues, LlOppA is 570, BsAppA is 520, StOppA is 
517 and EcMppA is 515. We hypothesise that EcYejA and LlOppA are longer proteins to 
allow them to create a larger binding pocket and therefore the ability to bind longer and 
bulkier substrates.  
Interestingly GEP is not present in other Cluster C substrate binding proteins (Figure 4.21). 
Sequence and structural alignments of this family of substrate binding proteins show 
omissions in the protein sequences where GEP is present in EcYejA. This suggests the 
release of this specific GEP might have a role in EcYejA function such as autoregulation. 
PDBePISA was used to better analyse and understand the structure of EcYejA as compared 
to other Cluster C SBPs. Residues in Cluster C SBP structures that were interacting with the 
bound ligands were identified using PDBePISA. 52 residues from BsAppA interact with the 
ligand, 50 from LlOppA, 42 from EcYejA, 31 from EcMppA and 30 from StOppA. Naturally 
the larger a ligand is the more residues there are that will interact with that ligand, 
however this is not the case with BsAppA, LlOppA and EcYejA. EcYejA has been shown to 
bind an 11 residue peptide whereas BsAppA and LlOppA, in these structures, are only 
complexed with 9 residue peptides. This gives an indication that there could be some 
differences in the binding pockets of EcYejA as compared to these proteins.  
4.5.2 Binding pocket comparisons of EcYejA with other Cluster C SBPs 
As mentioned in 3.1.2, some Cluster C SBPs have an aspartate residue in the binding pocket 
which “caps” the end of the binding pocket and serve as an anchor for the amino terminus 
of peptide ligands by forming a salt bridge with the alpha amino group of the peptide 
ligand. This prevents a longer peptide binding therefore “capping” the binding site. In 
sequence alignments (Figure 4.22) this aspartate can be seen in EcMppA, StOppA and is 
predicted to be present in the binding site of EcSapA. However, in Cluster C SBPs which 
have been shown to bind longer peptides, such as BsAppA, LlOppA and EcYejA, this 
aspartate residue is not conserved and is not present in the binding site. Therefore, the 
presence or absence of this capping aspartate can be used as a method to predict whether 
Cluster C SBPs bind longer or shorter peptides. Using this method it is possible to predict 
that even if GEP is not the natural ligand for EcYejA and is possibly only a crystal artefact, 
EcYejA has the ability to bind longer peptides. Again, the indication is that EcSapA is only 






Figure 4.21. GEP ligand is not present in other Cluster C SBPs. 
Top, the GEP peptide is underlined in red, EcYejA secondary structure is shown along the 
top of the alignment and the residue numbers shown in the alignment are detailed next to 
the sequence name. The majority of the GEP peptide is only present in the EcYejA protein 
sequence. Bottom, EcYejA is shown in grey, BsAppA (PDB:1XOC) is shown in pink and 
LlOppA (PDB:3DRG) is shown in coral. The N and C refer to the N and C termini of EcYejA. 
The section of EcYejA which corresponds to the GEP ligand is shown in turquoise cylinder 
form. The red circle indicates an area of EcYejA that is not present in either BsAppA or 
LlOppA which contains the GEP ligand. 
                                              TT       TT  TEcYejA/1-604
            1       10        20        30        40        
EcYejA/1-604               V I    IAL                                    ............MI R LLLF   FTFGVQAQAIKESYAFAVLGEPRYAFNFNHFDYVNP
LlOppA/1-600               A      AA    A                                ....MNKLKVTLL. SSVV.L  TLLS CG.SNQSSSTSTKKLKA............GNF
BsAppA/1-543               L V    LAI   A                                ....MKRRKTALMM S LM.V   FLS CSGSKSSNSSAKKSAGK...............
EcSapA/1-547                 L     LV   A                                ..MRQV......LSSL .VIAG  SGQ IAAPE.......SPPHA...............
StOppA/1-543               L A    L A   A                                MSNITKKS...... I AG.I T LIA SA.....ATAADVPAGV...............
EcMppA/1-537               V V    ALL   I                                ....MKHS...... S TC.C   VSS SL.....SYAAEVPSGT...............
T                   TT                                      EcYejA/1-604
50        60        70          80        90       100      
EcYejA/1-604  A           G          L                     D             A PKGGQITLSAL TFDNFNRYA. R.GNPGARTEQLYDTLFTTSD EPGSYYPLIAESA
LlOppA/1-600  V           G                                              D A.YQNPDKAIK GNLKVAYQSDSPMKAQWLSGLSND.ATFATMSGPGGGQDGLFFTDS
BsAppA/1-543              G          L                     D             ..P..QQGGDLVV SIGEPTLFNS YSTDDASTDIENMLYSFLTKT EKLNVKL..SLAE
EcSapA/1-547  I           G          A                     D             D RDSGFVYCVS. QV.NTFNPSK SSG.......LIVDTLAAQFY RLLDVDP......
StOppA/1-543  L           G          I                     E             Q ADKQTLVRNN. SEVQSLDPHK E.G.......VPESNVSRDLF GLLISD......V
EcMppA/1-537  L                      A                     E             V AEKQELVRHIKDEP.ASLDPAK V.G.......LPEIQVIRDLF GLVNQN......E
   TT         TT   T............T                       ....EcYejA/1-604
 110       120                   130       140       150    
EcYejA/1-604         V                       DG  ITA D  FTF   M          RYADDYSW EVAINPRARFH............  SP   R VE   QKF TEGVPQ....
LlOppA/1-600         A                       DG  VTA D  FTY   A          GFKFIKGG ADVALDKESKTATITLRKDLKWS  SE   K YE   ETI NPAYG..SDR
BsAppA/1-543         L                       DG  LTA D  FTY   L          SIKELDGG AYDVKIKKGVKFH..........  KE   D VV   SVP SKDYK..GER
EcSapA/1-547                                                  V          .YTYRLMPELAESWEVLDNGATYRFHLRRDVPFQKTDWFTPTRKMNADD VFTFQRIFDR
StOppA/1-543         A                       DG  VTA D  YSW   A          EGHPSPGV EKWENKDF.KVWTFHLRENAKWS  TP   H FV   QRL DPNTA.....
EcMppA/1-537         A                       DG  VTA D  YSW   V          KGEIVPGV TQWKSNDN.RIWTFTLRDNAKWA  TP   Q FV   QRL DPKTL.....
...   ..                      ........  TT                  EcYejA/1-604
                         160               170       180    
EcYejA/1-604    F                                                        ... RL..VYKG.............TTVKA........IAPLTVRIELAKPGKEDMLSL.
LlOppA/1-600  T                                                          W DS.....LANIVGLSDYHTGKAKT.ISGITFPDGENGKVIKVQFKEMKPGMTQSGNGY
BsAppA/1-543  S Y                                                        G T EM...LKSVE...................KKGDYEVLFKLKYKDG....NFYNNAL
EcSapA/1-547  N W                                                        N P HNVNGSNFPYFDSLQFA............DNVKSVRKLD...NHTVE..FRLAQPD
StOppA/1-543  S Y                                                        . P ASYLQYGHIANIDDIIAGKKPATDLGVKALD...DHTFE..VTLSEPVPYFYKLL.
EcMppA/1-537  S F                                                        . P AWFAALAGINNAQAIIDGKATPDQLGVTAVD...AHTLK..IQLDKPLPWFVNLT.
                       TT                             TT    EcYejA/1-604
    190               200       210       220       230     
EcYejA/1-604       P                         L SG Y          I       YW  FSLPVF EKYWKDH........KLSDPLATPP A  P RVTSWKMGQN VYSRVKD  AA
LlOppA/1-600       P                         L TG F          I       YW  FLETVA YQYLKDVAPKDLA...SSPKTTTKP V  P KPENVVAGES KYVPNPY  GE
BsAppA/1-543       P                         I SG F          I       YF  DSTAIL KHILGNVPIADLE...ENEFNRKKP G  P KFKEWKQGQY KLEANDD  EG
EcSapA/1-547                                   Q                         ASFLWHLATHYASVM....SAEYARKLEKEDRQE LDRQPVGTGPYQLSEYRAGQFIRLQ
StOppA/1-543       P                         V NG Y          I       YW  VHPSVS ....V..PKSAVEKFGDKWTQPANI T  A KLKNWVVNER VLERNPQ  DN
EcMppA/1-537       P                         I NG Y          L       YW  ANFAFF ....V..QKANV.ESGKEWTKPGNL G  A VLKERVVNEK VVVPNTH  DN
                                                            EcYejA/1-604
  240       250       260       270       280        290    
EcYejA/1-604              I Y        A      G                Y           NLPVNRGRWNFDT R DYYLDDNV FEAFKA AFDLRMENDAKNWATR TG.KNFDKKYI
LlOppA/1-600           L  I Y        V                       Y           KPK....... NS T EVVSTAKS AAL.SSSKYDII.NGMVSS...Q KQVKNLKGYKV
BsAppA/1-543           L  V Y        A      G                Y           RPY....... DT T KVIPDANA VAQLQA DINFF..NVPAT...D KT.AEKFNNLK
EcSapA/1-547           L             L      G                W           RHDDFWRGKP M......PQVVVD G.SGGT RLSKLLTGECDVLA.. PAA...SQLSI
StOppA/1-543           I  V Y               G                F           AKTV...... NQ T LPISSEVTDVNRYRS EIDMTYNNMPIE...L QK.LKKE....
EcMppA/1-537           L  V F        A      G                Y           AKTV...... QK T LPINQESA TKRYLA DIDIT.ESFPKN...M QK.LLKD....
                           TT                               EcYejA/1-604
   300       310               320       330       340      
EcYejA/1-604                                      VR A                   I R D    I A M LKDEQKNESAQDTRWLAFN........IQ PVFS RR E TL FDFEW NKA FYNAW
LlOppA/1-600                                      VR A                   L M K D    I A VGQQAMYISL YYNLGHYDAKNSINVQDR TPLQ QN Q GY RNVAE DNKFSNGLS
BsAppA/1-543                                      VR A                   I L D    L A I VVTDLA.... SYVYIGWN.E.......KNELFK KK Q TT LDRES VSQ LDGDG
EcSapA/1-547                                      VR A                   L L K    L A L IRDD....PR RLTLRPGMNVAYLAFNTA PPLNNPA H AL INNQR MQS YYGTA
StOppA/1-543                                      VR A                   I L K D    L A I VPNEVRVDPY CTYYYEIN........NQ APFN VR T KL LDRDI VNK K.NQG
EcMppA/1-537                                      VR A                   I L K D    L M VPGQVYTPPQ GTYYYAFN........TQ GPTA QR L SMTIDRRL TEK L.GTG
          TT                                             ...EcYejA/1-604
 350       360       370       380       390       400      
EcYejA/1-604                             M                      Y   N    SRTNSYFQNTEYAARNYPDAAELVLLAP KKDLPSEVFTQIYQPPVSKGDG DRD L...
LlOppA/1-600                      A      I                      Y        T.P.................. NSLIPP FKQFT...........SSSVKG EKQDLD..
BsAppA/1-543                      A      L                      F   N    E.V.................. YIPESP SWNYPK..........DIDVPK .EY EK..
EcSapA/1-547                      A      A                          N    ET................... ASILPR SWAYDN..........E...AKITEY PAKS
StOppA/1-543                      A                             W   S    DLP.................. YSYTPPYTDGAKL..........V..EPE FKW QQKR
EcMppA/1-537                      A      V                      F   S    EKP.................. WHFTPD TAGFTP..........E..PSP EQM QEEL
β1 β2 
β3 η1 β4 β5 β6 
β7 α1 
α2 β8 β9 α3 
α4 β10 β11 
η2 β12 α5 β13 α6 α7 
β14 β15 η3 α8 α9 
β16 α10 η4 α11 
                                      TT TT TEcYejA/1-604
            1       10        20      30 40   
EcYejA/1-604               V I    IAL              ............MI R LLLF   FTFGVQAQAIKESYAFAVLGEPRYAFNFNHFDYVNP
LlOppA/1-600               A      AA    A          ....MNKLKVTLL. SSVV.L  TLLS CG.SNQSSSTSTKKLKA...... .....GNF
BsAppA/1-543               L V    LAI   A          ....MKRRKTALMM S LM.V   FLS CSGSKSSNSSAKKSAGK............ ..
EcSapA/1-547                 L     LV   A          ..MRQV......LSSL .VIAG  SGQ IAAPE..... SPPHA ..... ....
StOppA/1-543               L A    L A   A          MSNITKKS...... I AG.I T LIA SA.....ATAADVPAGV. ..... ..
EcMppA/1-537               V V    ALL   I          ....MKHS...... S TC.C   VSS SL.....SYAAEVPSGT. ..... ..
T                   TT                   EcYejA/1-604
50        60        70          80      90   100   
EcYejA/1-604  A           G          L             DA PKGGQITLSAL TFDNFNRYA. R.GNPGARTEQLYDTLFTTSD EPGSYYPLIAESA
LlOppA/1-600  V           G                        D A.YQNPDKAIK GNLKVAYQSDSPMKAQWLSGLSND.ATFATMSGPGGGQDG FFTDS
BsAppA/1-543              G          L             D..P..QQGGDLVV SIGEPTLFNS YSTDDASTDIENMLYSFLTKT EKLNVKL..SLAE
EcSapA/1-547  I           G          A             DD RDSGFVYCVS. QV.NTFNPSK SSG.......LIV TLAAQ Y RLLDVDP .....
StOppA/1-543  L           G          I             EQ ADKQTLVRNN. SEVQSLDPHK E.G.......VPESNVSRDLF GLLISD......V
EcMppA/1-537  L                      A             EV AEKQELVRHIKDEP.ASLDPAK V.G.......LPEIQVIRDLF GLVNQN. ....E
   TT         TT   T............T         ..EcYejA/1-604
 110       120                   130     140    150
EcYejA/1-604         V                       DG  ITA D FTF MRYADDYSW EVAINPRARFH............  SP  R VE QKF TEGVPQ..
LlOppA/1-600         A                       DG  VTA D FTY AGFKFIKGG ADVALDKESKTATITLRKDLKWS  SE  K YE ETI NPAYG..SDR
BsAppA/1-543         L                       DG  LTA D FTY LSIKELDGG AYDVKIKKGVKFH..........  KE  D VV SVP S DY ..GER
EcSapA/1-547                                       V.YTYRLMPELAESWEVLDNGATYRFHLRRDVPFQKTDWFTPT K NADD VFTFQRIFDR
StOppA/1-543         A                       DG  VTA D YSW AEGHPSPGV EKWENKDF.KVWTFHLRENAKWS  TP  H FV QRL DPNTA ....
EcMppA/1-537         A                       DG  VTA D YSW VKGEIVPGV TQWKSNDN.RIWTFTLRDNAKWA  TP  Q F QRL DPKTL ....
...   ..                      ........  TT   EcYejA/1-604
                         160          170 180
EcYejA/1-604    F                                  ... RL..VYKG.............TTVKA........IAPLTVRIELAKPGKEDMLSL
LlOppA/1-600  T                                    W DS.....LANIVGLSDYHTGKAKT.ISGITFPDGENGKVIKVQFKEMKPGMTQSGNGY
BsAppA/1-543  S Y                                  G T EM...LKSVE...................KKGDYEVLFKLKYKDG... NFYNNAL
EcSapA/1-547  N W                                  N P HNVNGSNFPYFDSLQFA............DNVKSVRKLD...NHTVE..FR AQPD
StOppA/1-543  S Y                                  . P ASYLQYGHIANIDDIIAGKKPATDLGVKALD...DHTFE..VTLSEPVPYFYKLL.
EcMppA/1-537  S F                                  . P AWFAALAGINNAQAIIDGKATPDQLGVTAVD...AHTLK..IQ DKPLPWFVNLT.
                       TT             TTEcYejA/1-604
    190               200       210   22 230
EcYejA/1-604       P                         L SG Y I YWFSLPVF EKYWKDH........KLSDPLATPP A  P RVTSWKMGQN VYSRVKD AA
LlOppA/1-600       P                        L TG F I YWFLETVA YQYLKDVAPKDLA...SSPKTTTKP V  P KP N VAGES Y PNPY GE
BsAppA/1-543       P                         I SG F I YFDSTAIL KHILGNVPIADLE...ENEFNRKKP G  P KFKEWKQGQY KLEAND EG
EcSapA/1-547                                   Q   ASFLWHLATHYASVM....SAEYARKLEKEDRQE LDRQPVGTGPYQLSEYRAGQFIRLQ
StOppA/1-543       P                         V NG Y I YWVHPSVS ....V..PKSAVEKFGDKWTQPANI T  A KLKNWVVNER LERNPQ DN
EcMppA/1-537       P                         I NG Y L YWANFAFF ....V..QKANV.ESGKEWTKPGNL G  A VLKERVVNEK VVPNTH DN
                                      EcYejA/1-604
  240       250       260       270     280    290
EcYejA/1-604              I Y        A      G                Y           NLPVNRGRWNFDT R DYYLDDNV FEAFKA AFDLRMENDAKNWATR TG.KNFDKKYI
LlOppA/1-600           L  I Y        V                       Y           KPK....... NS T EVVSTAKS AAL.SSSKYDII.NGMVSS...Q KQVKNLKGYKV
BsAppA/1-543           L  V Y        A      G                Y           RPY....... DT T KVIPDANA VAQLQA DINFF..NVPAT...D KT.AEKFNNLK
EcSapA/1-547           L             L      G                W           RHDDFWRGKP M......PQVVVD G.SGGT RLSKLLTGECDVLA.. PAA...SQLSI
StOppA/1-543           I  V Y               G                F           AKTV...... NQ T LPISSEVTDVNRYRS EIDMTYNNMPIE...L QK.LKKE....
EcMppA/1-537           L  V F        A      G                Y           AKTV...... QK T LPINQESA TKRYLA DIDIT.ESFPKN...M QK.LLKD....
                          TT                               EcYejA/1-604
   300       310               320       330       340      
EcYejA/1-604                                      VR A                   I R D    I A M LKDEQKNESAQDTRWLAFN........IQ PVFS RR E TL FDFEW NKA FYNAW
LlOppA/1-600                                      VR A                   L M K D    I A VGQQAMYISL YYNLGHYDAKNSINVQDR TPLQ QN Q GY RNVAE DNKFSNGLS
BsAppA/1-543                                      VR A                   I L D    L A I VVTDLA.... SYVYIGWN.E.......KNELFK KK Q TT LDRES VSQ LDGDG
EcSapA/1-547                                      VR A                   L L K    L A L IRDD....PR RLTLRPGMNVAYLAFNTA PPLNNPA H AL INNQR MQS YYGTA
StOppA/1-543                                      VR A                   I L K D    L A I VPNEVRVDPY CTYYYEIN........NQ APFN VR T KL LDRDI VNK K.NQG
EcMppA/1-537                                      VR A                   I L K D    L M VPGQVYTPPQ GTYYYAFN........TQ GPTA QR L SMTIDRRL TEK L.GTG
          TT                                             ...EcYejA/1-604
 350       360       370       380       390       400      
EcYejA/1-604                             M                      Y   N    SRTNSYFQNTEYAARNYPDAAELVLLAP KKDLPSEVFTQIYQPPVSKGDG DRD L...
LlOppA/1-600                      A      I                      Y        T.P.................. NSLIPP FKQFT...........SSSVKG EKQDLD..
BsAppA/1-543                      A      L                      F   N    E.V.................. YIPESP SWNYPK..........DIDVPK .EY EK..
EcSapA/1-547                      A      A                          N    ET................... ASILPR SWAYDN..........E...AKITEY PAKS
StOppA/1-543                      A                             W   S    DLP.................. YSYTPPYTDGAKL..........V..EPE FKW QQKR
EcMppA/1-537                      A      V                      F   S    EKP.................. WHFTPD TAGFTP..........E..PSP EQM QEEL
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                                              TT       TT  TEcYejA/1-604
            1       10        20        30        40        
EcYejA/1-604               V I    IAL                                    ............MI R LLLF   FTFGVQAQAIKESYAFAVLGEPRYAFNFNHFDYVNP
LlOppA/1-600               A      AA    A                                ....MNKLKVTLL. SSVV.L  TLLS CG.SNQSSSTSTKKLKA............GNF
BsAppA/1-543               L V    LAI   A                                ....MKRRKTALMM S LM.V   FLS CSGSKSSNSSAKKSAGK...............
EcSapA/1-547                 L     LV   A                                ..MRQV......LSSL .VIAG  SGQ IAAPE.......SPPHA...............
StOppA/1-543               L A    L A   A                                MSNITKKS...... I AG.I T LIA SA.....ATAADVPAGV...............
EcMppA/1-537               V V    ALL   I                                ....MKHS...... S TC.C   VSS SL.....SYAAEVPSGT...............
T                   TT                                      EcYejA/1-604
50        60        70          80        90       100      
EcYejA/1-604  A           G          L                     D             A PKGGQITLSAL TFDNFNRYA. R.GNPGARTEQLYDTLFTTSD EPGSYYPLIAESA
LlOppA/1-600  V           G                                              D A.YQNPDKAIK GNLKVAYQSDSPMKAQWLSGLSND.ATFATMSGPGGGQDGLFFTDS
BsAppA/1-543              G          L                     D             ..P..QQGGDLVV SIGEPTLFNS YSTDDASTDIENMLYSFLTKT EKLNVKL..SLAE
EcSapA/1-547  I           G          A                     D             D RDSGFVYCVS. QV.NTFNPSK SSG.......LIVDTLAAQFY RLLDVDP......
StOppA/1-543  L           G          I                     E             Q ADKQTLVRNN. SEVQSLDPHK E.G.......VPESNVSRDLF GLLISD......V
EcMppA/1-537  L                      A                     E             V AEKQELVRHIKDEP.ASLDPAK V.G.......LPEIQVIRDLF GLVNQN......E
   TT         TT   T............T                       ....EcYejA/1-604
 110       120                   130       140       150    
EcYejA/1-604         V                       DG  ITA D  FTF   M          RYADDYSW EVAINPRARFH............  SP   R VE   QKF TEGVPQ....
LlOppA/1-600         A                       DG  VTA D  FTY   A          GFKFIKGG ADVALDKESKTATITLRKDLKWS  SE   K YE   ETI NPAYG..SDR
BsAppA/1-543         L                       DG  LTA D  FTY   L          SIKELDGG AYDVKIKKGVKFH..........  KE   D VV   SVP SKDYK..GER
EcSapA/1-547                                                  V          .YTYRLMPELAESWEVLDNGATYRFHLRRDVPFQKTDWFTPTRKMNADD VFTFQRIFDR
StOppA/1-543         A                       DG  VTA D  YSW   A          EGHPSPGV EKWENKDF.KVWTFHLRENAKWS  TP   H FV   QRL DPNTA.....
EcMppA/1-537         A                       DG  VTA D  YSW   V          KGEIVPGV TQWKSNDN.RIWTFTLRDNAKWA  TP   Q FV   QRL DPKTL.....
...   ..                      ........  TT                  EcYejA/1-604
                         160               170       180    
EcYejA/1-604    F                                                        ... RL..VYKG.............TTVKA........IAPLTVRIELAKPGKEDMLSL.
LlOppA/1-600  T                                                          W DS.....LANIVGLSDYHTGKAKT.ISGITFPDGENGKVIKVQFKEMKPGMTQSGNGY
BsAppA/1-543  S Y                                                        G T EM...LKSVE...................KKGDYEVLFKLKYKDG....NFYNNAL
EcSapA/1-547  N W                                                        N P HNVNGSNFPYFDSLQFA............DNVKSVRKLD...NHTVE..FRLAQPD
StOppA/1-543  S Y                                                        . P ASYLQYGHIANIDDIIAGKKPATDLGVKALD...DHTFE..VTLSEPVPYFYKLL.
EcMppA/1-537  S F                                                        . P AWFAALAGINNAQAIIDGKATPDQLGVTAVD...AHTLK..IQLDKPLPWFVNLT.
                       TT                             TT    EcYejA/1-604
    190               200       210       220       230     
EcYejA/1-604       P                         L SG Y          I       YW  FSLPVF EKYWKDH........KLSDPLATPP A  P RVTSWKMGQN VYSRVKD  AA
LlOppA/1-600       P                         L TG F          I       YW  FLETVA YQYLKDVAPKDLA...SSPKTTTKP V  P KPENVVAGES KYVPNPY  GE
BsAppA/1-543       P                         I SG F          I       YF  DSTAIL KHILGNVPIADLE...ENEFNRKKP G  P KFKEWKQGQY KLEANDD  EG
EcSapA/1-547                                   Q                         ASFLWHLATHYASVM....SAEYARKLEKEDRQE LDRQPVGTGPYQLSEYRAGQFIRLQ
StOppA/1-543       P                         V NG Y          I       YW  VHPSVS ....V..PKSAVEKFGDKWTQPANI T  A KLKNWVVNER VLERNPQ  DN
EcMppA/1-537       P                         I NG Y          L       YW  ANFAFF ....V..QKANV.ESGKEWTKPGNL G  A VLKERVVNEK VVVPNTH  DN
                                                            EcYejA/1-604
  240       250       260       270       280        290    
EcYejA/1-604              I Y        A      G                Y           NLPVNRGRWNFDT R DYYLDDNV FEAFKA AFDLRMENDAKNWATR TG.KNFDKKYI
LlOppA/1-600           L  I Y        V                       Y           KPK....... NS T EVVSTAKS AAL.SSSKYDII.NGMVSS...Q KQVKNLKGYKV
BsAppA/1-543           L  V Y        A      G                Y           RPY....... DT T KVIPDANA VAQLQA DINFF..NVPAT...D KT.AEKFNNLK
EcSapA/1-547           L             L      G                W           RHDDFWRGKP M......PQVVVD G.SGGT RLSKLLTGECDVLA.. PAA...SQLSI
StOppA/1-543           I  V Y               G                F           AKTV...... NQ T LPISSEVTDVNRYRS EIDMTYNNMPIE...L QK.LKKE....
EcMppA/1-537           L  V F        A      G                Y           AKTV...... QK T LPINQESA TKRYLA DIDIT.ESFPKN...M QK.LLKD....
                           TT                               EcYejA/1-604
   300       310               320       330       340      
EcYejA/1-604                                      VR A                   I R D    I A M LKDEQKNESAQDTRWLAFN........IQ PVFS RR E TL FDFEW NKA FYNAW
LlOppA/1-600                                      VR A                   L M K D    I A VGQQAMYISL YYNLGHYDAKNSINVQDR TPLQ QN Q GY RNVAE DNKFSNGLS
BsAppA/1-543                                      VR A                   I L D    L A I VVTDLA.... SYVYIGWN.E.......KNELFK KK Q TT LDRES VSQ LDGDG
EcSapA/1-547                                      VR A                   L L K    L A L IRDD....PR RLTLRPGMNVAYLAFNTA PPLNNPA H AL INNQR MQS YYGTA
StOppA/1-543                                      VR A                   I L K D    L A I VPNEVRVDPY CTYYYEIN........NQ APFN VR T KL LDRDI VNK K.NQG
EcMppA/1-537                                      VR A                   I L K D    L M VPGQVYTPPQ GTYYYAFN........TQ GPTA QR L SMTIDRRL TEK L.GTG
          TT                                             ...EcYejA/1-604
 350       360       370       380       390       400      
EcYejA/1-604                             M                      Y   N    SRTNSYFQNTEYAARNYPDAAELVLLAP KKDLPSEVFTQIYQPPVSKGDG DRD L...
LlOppA/1-600                      A      I                      Y        T.P.................. NSLIPP FKQFT...........SSSVKG EKQDLD..
BsAppA/1-543                      A      L                      F   N    E.V.................. YIPESP SWNYPK..........DIDVPK .EY EK..
EcSapA/1-547                      A      A                          N    ET................... ASILPR SWAYDN..........E...AKITEY PAKS
StOppA/1-543                      A                             W   S    DLP.................. YSYTPPYTDGAKL..........V..EPE FKW QQKR
EcMppA/1-537                      A      V                      F   S    EKP.................. WHFTPD TAGFTP..........E..PSP EQM QEEL
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Figure 4.22. Alignment showing capping aspartate in the binding pocket of some Cluster C 
SBPs. 
The capping aspartate residue (residue 489) is indicated by the red arrow below the 
alignment, EcYejA secondary structure is shown along the top of the alignment and the 
residue numbers shown in the alignment are detailed next to the sequence name. An 
aspartate residue, which caps the end of the binding pocket and limits peptide ligand size, 
can be seen in the binding pocket of StOppA and EcMppA, it has also been predicted to be 
in the binding site of EcSapA. No aspartate capping residue can be seen in the binding 




It is clear to see from the structure of EcYejA that there is a large internal binding pocket 
that is negatively charged (red on an electrostatic surface image) (Figure 4.23). As CAMPs 
are positively charged this large negatively charged binding pocket fits with the hypothesis 
that EcYejA binds CAMPs. It is also interesting to note that GEP does not actually sit in the 
large negatively charged region of the binding pocket, it sits further down on the edge of 
the binding pocket, taking up very little space in the cavity (Figure 4.24).  
By superposing some of the known Cluster C SBP structures onto that of EcYejA it is 
possible to view the binding pockets and whether the ligands are located in a similar place 
in the proteins. From Figure 4.25 it is clear to see that the GEP peptide is not located in a 
similar position in EcYejA as the ligands in other Cluster C SBPs. The other ligands 
superpose onto each other well even though the ligands are a range of different lengths 
and some of the binding pockets contain the capping aspartate residue. This indicates that 
there is something different about the binding pocket of EcYejA as compared to other 
Cluster C SBPs binding pockets.   
It is also interesting to note that the binding pockets of EcMppA, StOppA and BsAppA are 
more enclosed than those of LlOppA and EcYejA (Figure 4.26 and 4.27). One side of the GEP 
peptide in EcYejA is being coordinated by water molecules as there is a vast space available 
in the binding cavity of EcYejA that is filled by water molecules. This seems to indicate that 
there can be some variability in length and sequence in the Cluster C SBPs that bind longer 
peptides as the binding pocket does not seem as enclosed and specific.  
Using rbcavty within rdock it was possible to calculate the volume of the binding pockets, 
with water molecules removed, of some Cluster C SBPs (Table 4.3). From these results it is 
clear that as the size of the ligand increases the size of the binding pocket increases 
accordingly, as can be expected. However, currently EcYejA has only been shown to bind an 
11 residue peptide but it has the largest binding pocket volume by a large margin. This 
suggests that EcYejA’s natural ligand is much larger than 11 residues, possibly even larger 





Figure 4.23. EcYejA has a large negatively charged binding pocket. 
EcYejA is shown as an electrostatic surface, red indicates negative charge and blue 








Figure 4.24. GEP does not sit in the centre of the EcYejA binding pocket. 
EcYejA is shown as an electrostatic surface, red indicates negative charge and blue 








Figure 4.25. GEP ligand is not located in the same position in the binding pocket as other 
Cluster C SBP ligands. 
EcYejA is shown in grey ribbon form, the GEP peptide is shown in blue, the BsAppA 
nonapeptide (PDB:1XOC) is shown in pink, the LlOppA bradykinin ligand (PDB:3DRG) is 
shown in red, the EcMppA murein tripeptide ligand (PDB:3O9P) is shown in purple and the 
StOppA KLK tripeptide (PDB:1B9J) is shown in coral. Cluster C SBPs were superposed onto 





Figure 4.26. The binding pockets of EcMppA, StOppA and BsAppA are enclosed. 
EcMppA, StOppA and BsAppA are shown in beige sphere form with transparency set to 
25%. (A) BsAppA nonapeptide ligand is shown in pink cylinder form, (B) EcMppA murein 
tripeptide ligand is shown in purple cylinder form and (C) StOppA KLK ligand is shown in 







Figure 4.27. The binding pockets of LlOppA and EcYejA are more open than EcMppA, 
StOppA and BsAppA. 
LlOppA and EcYejA are shown in beige sphere form with transparency set to 25%. 
(A)LlOppA nonapeptide ligand is shown in red cylinder form and (B) EcYejA GEP ligand is 






Known Length Ranges of 
Ligands 
Binding Cavity Size (Å3) 
EcDppA 2 residues 1434 
StOppA 2-5 residues 1874 
BsAppA 9 residues 3773 
LlOppA Up to 35 residues 5955 
EcYejA 11 residues 8253 
Table 4.3. Binding cavity sizes of various Cluster C SBPs. 
EcDppA is E. coli DppA, an SBP which binds dipeptides. The size of the binding pocket 
increases as the length of the peptide bound increases, as expected. This indicates that 
EcYejA is able to bind much larger peptides than other Cluster C SBPs as it has the largest 
























5. Ligand Determination of EcYejA 
The crystal structure of EcYejA revealed the protein to be in the closed conformation with a 
ligand bound. From the electron density maps this ligand was identified as the peptide 
LGEPRYAFNFN (GEP), and identical in sequence to a segment of the EcYejA polypeptide 
close to the amino terminus. There is no evidence to suggest that GEP is a natural ligand of 
EcYejA, and our initial interpretation is that its presence is the result of a crystallisation 
artefact. To better understand the specificity of EcYejA a series of binding experiments 
were conducted with various CAMPs and peptides.  
5.1 Screening peptides for EcYejA ligands 
Thermal shift assays are a screening method for protein ligands based on the melting 
temperature of the protein. As the protein is heated and denatures a fluorescent dye binds 
to the hydrophobic surfaces exposed as the protein unfolds and the melting temperature 
of the protein can be determined. The melting temperature of a protein is defined as the 
midpoint of the unfolding transition and can be read from the thermal shift assay graphs as 
the temperature at which the fluorescence value is half of the total fluorescence observed. 
In theory, if the protein is bound to a ligand the protein will be stabilised and the melting 
temperature will increase, and this can be measured. A number of different potential 
ligands were screened for EcYejA binding using thermal shift assays, some of which were 
carried out by project student Rebecca Lees under the direct supervision of the author. For 
the thermal shift binding experiments the concentration of EcYejA was kept constant at 0.5 
mg/ml (7.3 µM). This value was reached by carrying out a series of thermal shift assay 
optimisations with different concentrations of EcYejA, 0.5 mg/ml EcYejA gave a clear 
fluorescence reading and did not use excessive amounts of protein per run. Potential 
peptide ligands were tested at as high a concentration as possible, with the aim of having a 
one molar excess over EcYejA, however solubility issues meant some peptides were tested 
at lower concentrations. 
All EcYejA protein used in this chapter was purified without the 2 M guanidine 
hydrochloride step as this step was deemed unnecessary due to EcYejA crystallising with a 
ligand bound even after 2 M guanidine hydrochloride treatment. A thermal shift assay was 
carried out with a sample of EcYejA which had undergone 2 M guanidine hydrochloride 
treatment and a sample of EcYejA which had not undergone 2 M guanidine hydrochloride 
treatment, both samples were tested with and without GEP. The melting temperature 
increase of both EcYejA samples with GEP was the same, indicating that omission of the 2 
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M guanidine hydrochloride treatment step during purification was not compromising ligand 
binding studies.  
CAMPs were the obvious target for initial screening of EcYejA to identify potential ligands. 
Previous literature has identified a number of CAMPs, in particular polymyxin B, melittin 
and LL-37 as being involved with the Yej transporter and possibly bound by YejA 
(Eswarappa et al., 2008; Wang et al., 2016). The CAMPs LL-37, as well as shorter fragments 
of LL-37, and polymyxin B were tested here using thermal shift assays.  
Another potential EcYejA ligand is the antibiotic Microcin C, a heptapeptide attached to a 
nucleoside ring that the Yej transporter has been shown to transport into the cytoplasm 
(Novikova et al., 2007). The heptapeptide section of Mircocin C, MRTGNAD, was 
synthesised and tested as a ligand for EcYejA. N-terminally formylated Microcin C has also 
been shown to be transported via the Yej transporter at a higher rate than the 
deformylated version of Microcin C. Therefore fMRTGNAD was also synthesised via solid 
phase peptide synthesis to be tested as a ligand for EcYejA. fMRTGNAD(Dansyl-K)G was 
also synthesised as a mimic of the whole structure of Microcin C, not just the heptapeptide 
section. All of these potential ligands were screened via thermal shift assays.  
GEP and commercially available random peptides of varied sequence and chain length were 
bought in and also screened via thermal shift assays to try and identify any kind of “binding 
motif”. 
P. aeruginosa PhnD, a binding protein for 2-AEP, was used as a control for the thermal shift 
assays (Sophie Rugg). The GEP ligand was also used as a positive control for the assays. A 
thermal shift in melting temperature of anything equal to or more than +3 °C was deemed 
as binding to EcYejA. This value was chosen arbitrarily as variations in melting temperature 
of up to ±1/2 °C were seen across different thermal shift runs, probably due to different 
plates being used in different runs and slight differences in protein and dye concentrations. 
Via thermal shift assays GEP was shown to bind EcYejA (Figure 5.1), however of all the 
ligands tested GEP was the only one whose presence led to a marked increase in the 
melting temperature of EcYejA (Table 5.1), indicating that GEP alone is binding to EcYejA.  
Unfortunately, GEP was insoluble at the concentrations required (>0.56 mM) for binding 
affinity testing using Isothermal Titration Calorimetry (ITC), which is the preferred method 





Figure 5.1. Thermal shift assays confirm EcYejA binding of LGEPRYAFNFN. 
Both graphs show normalised data with 0.5mg/ml (7.3 µM) EcYejA. (A) shows EcYejA in the 
absence of added peptide (red, orange, green) Tm=60.8 oC; 0.05mg/ml LGEPRYAFNFN (pink, 
grey, brown) Tm=67.5 oC; 0.005mg/ml LGEPRYAFNFN (blue, light blue, lime green) Tm= 62.6 
oC. (B) shows EcYejA with no ligand (blue, light blue, orange) Tm=60.8 oC; 0.75mg/ml 





EcYejA + 0.05 mg/ml 
GEP 
EcYejA + 0.005 mg/ml 
GEP 
EcYejA 




of estimating the binding affinity of EcYejA to GEP. However, GEP was not soluble at high 
enough concentrations to saturate EcYejA, determined as the stabilisation of the shift in 
melting temperature, meaning an accurate estimate of the binding affinity could not be 
made.  
5.2 Ligand binding in EcYejA examined by Mass Spectrometry  
Identification of ligands bound to EcYejA was carried out using native electrospray 
ionisation mass spectrometry (native ESI-MS) and matrix-assisted laser 
desorption/ionisation mass spectrometry mass spectrometry (MALDI-MS/MS) in 
collaboration with Dr. Adam Dowle who collected and analysed the data. Native ESI-MS is a 
technique where the biological samples are sprayed from a nondenaturing solvent, in this 
case 1 M ammonium acetate, to allow the transfer of intact proteins and biomolecular 
complexes from solution to the gas phase. It is possible to see a difference in mass between 
a sample of liganded protein and a sample of unliganded protein, the difference in mass 
between these two samples is the mass of the ligand. The liganded protein sample after 
native ESI-MS can then be taken and analysed via MALDI-MS/MS. MALDI-MS/MS strips the 
proteins of ligands and identifies peptide ligands within the range 800-4000 Da, as the mass 
of the ligand bound to the peptide is known from native ESI-MS that particular peptide 
ligand mass can be selected. The selected peptide ligand is then fragmented into different 
smaller pieces which can be searched against a database, in this case the Mascot database, 
to identify the sequence of the ligand (Figure 5.2). It is important to note that the MALDI-
MS/MS data alone shows that the ligands are present in the sample, it does not prove that 
they are bound to EcYejA. Only the positive mass change in the native ESI-MS signifies 
binding of that specific ligand. All samples of EcYejA in these experiments had not 
undergone the 2 M Guanidinium-HCl treatment step during purification.  
5.2.1 Confirmation of EcYejA binding of GEP ligand 
To confirm binding of EcYejA to GEP an initial native ESI-MS experiment was carried out on 
a sample of EcYejA, at a concentration of 1.46 µM. The expected mass of EcYejA is 
68,381.73 Da, a peak can be seen at a mass of 68,381.89 Da (Figure 5.3) which gives a mass 
difference of 0.16 Da. A further native ESI-MS experiment was then conducted on a mixture 
of EcYejA (1.46 µM) and GEP (1.51 µM). The expected mass of an EcYejA-GEP complex is 
69,709.17 Da (GEP mass = 1,326.64Da), a peak can be seen on the spectra at 69,709.31 Da 




Ligand Ligand Concentration Melting Temperature Change (°C) 
Polymyxin B 5 mg/ml (3.8 mM) -1.3 
LL-37 0.75 mg/ml (0.17 mM) -0.8 
LL 13-37 3 mg/ml (0.99 mM) -1.1 
LL 19-29 3 mg/ml (2.1 mM) +0.3 
LL 17-32 1 mg/ml (0.49 mM) -3.6 
RGDSPASSKP 0.75 mg/ml (0.75 mM) +0.2 
KKK 0.75 mg/ml (1.7 mM) -0.2 
RGDS 0.75 mg/ml (1.7 mM) +2 
GRGDSPK 0.75 mg/ml (1.0 mM) -3.17 
DWKDDDK 0.25 mg/ml (0.27 mM) +0.5 
Melittin 0.75 mg/ml (0.26 mM) -5.4 
KGG 3 mg/ml (10.1 mM) -0.7 
AK Hydrochloride 5 mg/ml (19.7 mM) 0 
AQ 5 mg/ml (21.3 mM) -0.2 
AG 3 mg/ml (18.3 mM) -0.1 
GPRP amide 5 mg/ml (11.8 mM) -0.3 
AP Hydrate 3 mg/ml (16.1 mM) 0 
Bradykinin 6 mg/ml (5.7 mM) -1.4 
LGEPRYAFNFN 0.75 mg/ml (0.56 mM) +13 
fMRTGNAD(Dansyl-K)G 1.5 mg/ml (1.2 mM) +0.3 
fMRTGNAD 1.5 mg/ml (1.89 mM) -0.1 
MRTGNAD 1.5 mg/ml (1.96 mM) -0.3 
Table 5.1. Ligands binding to EcYejA monitored by thermal shift assays. 
Potential peptide ligands were tested at as high a concentration as possible, with the aim of 
having a one molar excess over EcYejA, however solubility issues meant some peptides 
were tested at lower concentrations. The EcYejA concentration in all experiments was 0.5 
mg/ml (7.3 µM). A thermal shift in melting temperature of anything equal to or more than 
+3 °C was deemed as binding to EcYejA. This value was chosen arbitrarily as variations in 




Figure 5.2. Schematic diagram of native ESI-MS and MALDI-MS/MS protein analysis. 
Native ESI-MS measures the mass of intact proteins and complexes by spraying the samples 
from a nondenaturing solvent. In MALDI-MS/MS a single mass peak can be selected, 







Figure 5.3. Mass spectra of EcYejA. 
The above spectra were produced by the infusion of EcYejA. (A) shows the convoluted 












Figure 5.4. GEP ligand binds EcYejA. 
Above spectra were acquired from an EcYejA and GEP peptide mix. (A) shows the 









Due to the inability to carry out other techniques such as ITC, native ESI-MS was used as a 
way to try and estimate the binding affinity of EcYejA to the GEP ligand. This was achieved 
by titrating GEP ligand into the EcYejA sample until saturation of EcYejA. EcYejA was used at 
a final concentration of 1.46 µM and the GEP ligand was added from 0-1.51 µM. For this 
experiment a new sample of EcYejA had been produced and purified and from the mass 
spectrometry data appeared to come pre-bound with an endogenous ligand with a mass of 
1424.72 Da (Figure 5.5). On the spectra acquired from the 1.46 µM EcYejA and 0 µM GEP 
infusion a dominant peak can be seen at a mass of 68,381.96 Da, this peak corresponds to 
the unliganded form of EcYejA. However, there is another clear peak on the spectra at a 
higher mass of 69,806.68 Da. Although the intensity of this peak is lower it does indicate a 
ligand bound state of EcYejA with a ligand of mass 1424.72 Da. This ligand could not be 
completely competed off by the addition of 1.51 µM GEP ligand, indicating that it is tightly 
bound to EcYejA (Figure 5.6). When the GEP concentration is 0.755 µM, there is no free 
EcYejA. At this point all EcYejA is either in complex with the GEP peptide or in complex with 
the 1424.72 Da ligand. From the addition of 0.755 µM to 1.51 µM of GEP peptide, 42.3 % of 
the 1424.72 Da ligand was competed off EcYejA and replaced with GEP peptide. 
Approximately 30 % of the initial EcYejA sample from this preparation was in complex with 
the endogenous 1424.72 Da ligand. An attempt was made to estimate the binding affinity 
of EcYejA to GEP but it was deemed too unreliable to make any real estimate. This was 
because approximately 70% of EcYejA (1.02 µM) was unliganded before any GEP titration 
and was completely saturated by 0.755 µM GEP, which is less than a 1:1 ratio. It is possible 
that liganded EcYejA flies better in the mass spectrometer than unliganded EcYejA and 
therefore a higher percentage of the liganded EcYejA is detected, which could give the data 
the appearance that EcYejA was saturated at a less than 1:1 ratio.   
To identify the 1424.72 Da ligand MALDI-MS/MS was used in tandem with the Mascot 
database to identify the ligand as VLGEPRYAFNFN. This ligand is GEP with an additional 
valine residue on the N-terminus of the peptide, VLGEPRYAFNFN is again located in the N-
terminus of EcYejA. In the crystal structure of EcYejA, there is volume within the binding 
pocket of EcYejA to add the valine residue onto the GEP ligand. It is possible that the actual 
ligand in the crystal structure is VLGEPRYAFNFN, and that the electron density for the 





Figure 5.5. EcYejA is co-purified with an unknown ligand. 
Mass spectra shows peaks of 68,381.96 Da and 69,806.68 Da, which corresponds to un-
liganded EcYejA and EcYejA in complex with a ligand of 1424.72 Da respectively. 
 
Figure 5.6. GEP ligand has a high binding affinity for EcYejA. 
EcYejA was used at a final concentration of 1.46 µM and the GEP ligand was added from 0-
1.51 µM. The relative intensities of the peaks corresponding to the free EcYejA, EcYejA + 
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Figure 5.7. There is space in the binding pocket of EcYejA for VLGEPRYAFNFN. 
EcYejA is shown in grey ribbon form, electron density is shown in blue, LGEPRYAFNFN with 
an additional valine on the N-terminus is shown in green, red and blue cylinder form. The 
red circle shows an additional valine residue on the N-terminus of GEP in the binding 
pocket of EcYejA. The additional valine residue is in space in the binding pocket of EcYejA 




5.2.2 Identification of ligands co-purifying with EcYejA 
With the aim of identifying any endogenous ligands bound to EcYejA a fresh sample of 
EcYejA was prepared and native ESI-MS and MALDI-MS/MS was carried out on the sample. 
It was thought that due to the lack of the 2 M guanidinium-HCl treatment step during 
purification that any endogenous ligand acquired from either the LB growth media or the E. 
coli BL21(DE3) expression cells would remain bound to EcYejA throughout the purification 
process and should be seen in the data obtained. This sample of EcYejA was purified and 
then immediately subjected to native ESI-MS and MALDI-MS/MS. The MALDI-MS/MS 
identified species with a range of molecular masses as potential EcYejA ligands. As may be 
seen from Table 5.2, all are overlapping peptides derived from the N-terminus of EcYejA.  
The native ESI-MS data were collected at ion cone voltages of 100 eV and 200 eV. A higher 
cone voltage delivers more energy to the protein complex and this is expected to increase 
the level of ligand dissociation from the complex during the experiment. Spectra collected 
at 100 eV are therefore more likely to represent the solution state, while spectra from 
samples collected at 200 eV will inform on the unliganded protein. The difference in mass 
then informs on the presence and nature of the ligand. At 200 eV the mass of the 
uncomplexed EcYejA is 1,427 Da lower than that recorded at 100 eV indicating the 
presence of bound VLGEPRYAFNFN (Figure 5.8). Two other peaks were also observed with 
masses 1,824 Da and 1,989 Da greater than uncomplexed EcYejA, consistent with the 
presence of EcYejA complexes with the peptides VLGEPRYAFNFNHFD and 
VLGEPRYAFNFNHFDY respectively. These species are present even in 200 eV spectra, 
suggesting these peptides are tightly bound.  
At the lower ion cone voltage of 100 eV, little or no uncomplexed EcYejA protein is 
observed (Figure 5.9). The dominant species present was identified as EcYejA in complex 
with VLGEPRYAFNFN. The other peaks in this spectrum correspond to EcYejA in complex 
with: VLGEPRYAFNFNHFD; VLGEPRYAFNFNHFDY; AVLGEPRYAFNFNHFDY and 
AFAVLGEPRYAFNFNHFDY.  
A further sample of EcYejA was also analysed by native ESI-MS and MALDI MS/MS. This 
sample was exposed overnight to a periplasmic extract from E. coli BW25113. Although 
EcYejA is a periplasmic protein when it is natively expressed and produced, during this work 


















Table 5.2. MALDI-MS/MS identified several peptides from the N-terminus of EcYejA as 
potential EcYejA ligands. 
This data was generated from a sample EcYejA that had been purified and then 




Figure 5.8. Native ESI-MS at 200 eV shows EcYejA in complex with several ligands. 
The peak at 68,382.58 Da indicates the un-complexed form of EcYejA. Peaks can also be 
seen at 1,426 Da, 1,824 Da and 1,989 Da greater than un-complexed EcYejA, these 








Figure 5.9. Native ESI-MS at 100 eV shows EcYejA in complex with several ligands. 
Little to none of the un-complexed form of EcYejA can be seen in the spectra. The peak at 
69,807.59 Da is the dominant peak in the spectra and corresponds to EcYejA complexed 
with VLGEPRYAFNFN. Other peaks with lower intensities can also be seen in the spectra, 
they correspond to EcYejA in complex with the flowing ligands: VLGEPRYAFNFNHFD; 








Therefore, EcYejA may not be coming into contact with its natural ligand as EcYejA has little 
interaction with the periplasmic fraction during production and purification. Exposing 
EcYejA to periplasmic extract from E. coli BW25113 might enable EcYejA to bind its natural 
ligand. E. coli BW25113 was chosen as the strain for the periplasmic preparation as it is a 
wild type strain with no gene deletions. E. coli BL21(DE3) cells, which EcYejA is usually 
produced in, contains gene deletions for the Lon and OmpT proteases. OmpT is a protease 
which is located in the outer membrane of bacteria and therefore influences the peptide 
makeup of the periplasm, which could affect the natural ligand of EcYejA. By exposing 
EcYejA to a periplasmic prep in this way it is hoped that any other EcYejA ligands will be 
picked up. Again, MALDI-MS/MS identified a number of different peptides as potential 
EcYejA ligands, all of which were from the N-terminus of EcYejA (Table 5.3). 
At 200 eV in this sample a large peak can be seen which corresponds to the ligand free 
EcYejA (Figure 5.10). The only other peak seen in the spectra at this ion cone voltage is 
1,426 Da greater than the mass of the free EcYejA, again this indicates that VLGEPRYAFNFN 
is bound at this higher ion cone voltage.  
At the lower ion cone voltage of 100 eV, again very little of the ligand free EcYejA is 
observed (Figure 5.11). Once again the dominant ligand bound form of EcYejA is in complex 
with VLGEPRYAFNFN. The other two ligand bound states of EcYejA indicate binding of 
peptides that are slightly shorter than those seen in the fresh sample of EcYejA: 
VLGEPRYAFNF and FAVLGEPRYAFN.  
A selection of ligands identified as being in complex with EcYejA, and GEP variants, were 
tested for binding via thermal shift assays to gain more information on the specificity of 
EcYejA (Table 5.4). The data shows a general trend of an increase in the melting 
temperature of EcYejA as the length of the ligand increases. The longest ligand shown to 
bind EcYejA via thermal shift assays is the 15 residue peptide VLGEPRYAFNFNHFD with an 
increase in melting temperature of 26.4 °C. The thermal shift data indicates that LGEPR and 
YAFNFN do not bind EcYejA, this implies that the necessary components for GEP 
(LGEPRYAFNFN) binding are contained across the middle of the peptide, not at either end.  
These results clearly identify the N-terminus of EcYejA as the only source of ligands for 
EcYejA prepared in this way. All peptides shown to bind EcYejA contained a core motif of 
EPRYAFN, demonstrating some specificity for EcYejA. When exposed to a periplasmic 
sample from E. coli BW25113, EcYejA did not bind any ligands other than those from the N- 
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Table 5.3. In the periplasm mixed EcYejA sample MALDI-MS/MS identified several 
peptides from the N-terminus of EcYejA as potential EcYejA ligands. 
This data was generated from a sample EcYejA that was exposed overnight to a periplasmic 





Figure 5.10. Native ESI-MS at 200 eV shows EcYejA exposed to periplasm in complex with 
a dominant ligand. 
A peak at 68,382.25 Da can be seen which corresponds to the un-complexed form of 
EcYejA, this is the dominant peak. The only other peak that can be seen is a peak at 









Figure 5.11. Native ESI-MS at 100 eV shows EcYejA exposed to periplasm in complex with 
several ligands. 
A small peak can be seen at 68,380.88 Da, the un-complexed version of EcYejA. Again the 
dominant peak at 69,806.67 Da corresponds to EcYejA in complex with VLGEPRYAFNFN. 











Ligand Ligand Concentration Melting Temperature Change (°C) 
LGEPR 5 mg/ml (8.76 mM) 0 
YAFNFN 2.5 mg/ml (3.23 mM) +2.7 
EPRYAFNFN 2.5 mg/ml (2.16 mM) +7.9 
GEPRYAFNFN 2.5 mg/ml (2.06 mM) +14.4 
LGEPRWAFNFN 2.5 mg/ml (1.85 mM) +22 
LGEPAYAFNFN 2.5 mg/ml (2.01 mM) +6.9 
LGEPRYAFN 1.25 mg/ml (1.17 mM) +17.3 
LGEPRYAFNF 2.5 mg/ml (2.06 mM) +19.9 
VLGEPRYAFNF 2.5 mg/ml (1.9 mM) +22.1 
VLGEPRYAFNFN 2.5 mg/ml (1.75 mM) +20.7 
FAVLGEPRYAFN 5 mg/ml (3.61 mM) +19.1 
VLGEPRYAFNFNHFD 2.5 mg/ml (1.37 mM) +26.4 
Table 5.4. GEP variants tested via thermal shift assays. 
The EcYejA concentration in all experiments was 0.5 mg/ml (7.3 µM). A thermal shift in 
melting temperature of anything equal to or more than +3 °C was deemed as binding to 
EcYejA. This value was chosen arbitrarily as variations in melting temperature of up to ±1/2 




terminus of EcYejA. This implies that there is a biological role for the binding of these N-
terminal peptides by EcYejA, although further investigation is needed before that role can 
be elucidated. Longer peptides are observed in the freshly prepared sample of EcYejA as 
opposed to the EcYejA sample that was exposed to the periplasmic extract. This may be 
due to the longer storage time of the periplasmic extract sample of EcYejA, which may have 
resulted in the break-down of some of the peptide ligands to shorter peptides.  
5.3 In vivo CAMP resistance assays 
Previous literature implicated both the S. Typhimurium and the B. melitensis Yej 
transporters in resistance to CAMPs, including polymyxin B, melittin and LL-37, via genetic 
studies (Eswarappa et al., 2008; Wang et al., 2016). The binding experiments detailed in 
this chapter give no indication that the E. coli Yej transporter can bind, transport or provide 
resistance to CAMPs. Therefore, genetic studies were carried out to determine whether the 
Yej transporter phenotypes seen previously could be replicated in E. coli in the presence of 
CAMPs.   
E. coli BW25113 is the parent strain for the Keio collection, a library of knockouts of the 
non-essential genes in E. coli (Baba et al., 2006). The E. coli ΔyejA, ΔyejB, ΔyejE, ΔyejF and 
ΔtolC mutants referred to in this section were taken from the Keio collection and E. coli 
BW25113 was used as the wild type in experiments.  
Initially disc diffusion assays were carried out with Yej transporter knockout mutants to test 
susceptibility of the different mutants to the CAMP polymyxin B. However, this method 
was not practical to continue with due to the zones of inhibition being very similar in size 
regardless of the concentration of polymyxin B. This indicated that polymyxin B was not 
diffusing through the agar plate particularly well and therefore the technique was not 
suitable for testing susceptibility of different mutants.  
Following the unsuccessful disc diffusion assays, liquid culture was tried to test the 
susceptibility of the different Yej mutants, this was carried out using a plate reader. A 96 
well plate was filled with LB containing different concentrations of polymyxin B and the 
antibiotic colistin and the wells were inoculated with E. coli BW25113. The plates were 
incubated at 37 °C for 48 hours with constant shaking and an OD600 reading was taken 
every 30 mins. Once a suitable concentration for polymyxin B and colistin were identified, 
roughly decreases in OD600 of 40-50% in stationary phase, these concentrations were tested 
on the Keio collection knockout mutants.  
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Using the same setup in the plate reader polymyxin B was tested at 10 and 15 µg/ml and 
colistin was used at 40 and 45 µg/ml with either E. coli BW25113, E. coli ΔyejA or E. coli 
ΔtolC. TolC is an outer membrane efflux protein that is a major factor in the protection 
against antibiotics that damage membranes (Zgurskaya et al., 2011) and therefore made it 
a good control in these experiments.  
The E. coli ΔyejA and E. coli ΔtolC mutants grown in LB without any polymyxin B or colistin 
grew in a very similar manner to the wild type, E. coli BW25113 (Figure 5.12). This indicates 
that the mutations are not having any effect on the growth of the E. coli in these 
conditions. However, at 10 and 15 µg/ml polymyxin B and 40 and 45 µg/ml colistin growth 
of the E. coli ΔyejA and E. coli ΔtolC mutants was completely abolished, a very strong 
phenotype.  
An unusual phenotype displayed in the plate reader graphs is the increased lag phase in the 
growth of the E. coli BW25113 wild type to 10-12hrs after inoculation (Figure 5.12). This 
was thought to be the time required to upregulate the expression of the Yej transporter.  
In an attempt to replicate the plate reader results susceptibility tests were carried out with 
10 µg/ml polymyxin B in 100 ml shake flasks. Shake flasks were incubated at 37 °C for 48 
hrs with shaking at 150 rpm, OD600 readings were taken at the stated times.  
Interestingly the lag in the growth phase of the E. coli BW25113 wild type could not be 
replicated in the shake flasks (Figure 5.13). However, a new phenotype was seen where 
there is a small lag in the growth of the E. coli ΔyejA mutant on LB alone with no added 
polymyxin B. Although this result could not be repeated in subsequent experiments (Figure 
5.14).  
The difference seen between the plate reader and shake flask assays could be explained by 
the different amounts of aeration in each technique. The shake flask assays naturally aerate 
the liquid to a greater extent than the plate reader does, it is possible that this lower 
aeration in the plate reader induces a stress response allowing the E. coli BW25113 wild 
type strain to overcome the negative effects of the polymyxin B.  
The plates used in the plate reader experiments are coated to give them a slightly negative 
charge, as CAMPs are cationic their function could be impaired by the negatively charged 
plates. This could be another reason that the E. coli BW25113 wild type could withstand 




Figure 5.12. Growth of ΔyejA and ΔtolC mutants is completely abolished in the presence 
of polymyxin B or colistin. 
(A) shows cell growth with 0, 10 or 15 µg/ml polymyxin B, (B) shows cell growth with 0, 40 
or 45 µg/ml colistin. BW25113 is the wild-type control strain, there is a lag in growth of 10-
12 hrs in the presence of both polymyxin B and colistin. ΔyejA and ΔtolC mutants are 






Figure 5.13. 10 µg/ml polymyxin B abolishes growth of E. coli BW25113, E. coli ΔyejA and 
E. coli ΔtolC. 
1, 2, 3 = repeats; NP = No polymyxin B. BW25113-1 was thought to be contaminated at 
8:14pm. There was no cell growth in any of the flasks which contained 10 µg/ml polymyxin 
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Figure 5.14. E. coli ΔyejA phenotype seen in plate reader assays could not be replicated in 
shake flasks. 
1, 2, 3 = repeats. E. coli BW25113, E. coli ΔyejA, E. coli ΔdppA, E. coli ΔoppA and E. coli ΔtolC 
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6. Discussion and Future Work 
CAMPs are important components of the innate immune system, the first line of defence 
against invading pathogens, and are conserved throughout biology (Pasupuleti, 
Schmidtchen and Malmsten, 2012). CAMPs are able to disrupt the integrity of bacterial 
cells by forming pores in the membrane. This causes the bacterial cell to leak and the 
bacteria to die, however bacteria have developed a number of resistance mechanisms to 
these CAMPs, including the use of the ABC transporters Sap and Yej (Parra-Lopez, Baer and 
Groisman, 1993; Eswarappa et al., 2008; Wimley, 2010; Shelton et al., 2011; Wang et al., 
2016). ABC transporters which import substrates contain SBPs, in the case of the Sap and 
Yej transporters, these are SapA and YejA respectively. The SBPs define the specificity of 
the transporter as they capture the substrates in the extracellular environment and make 
them available to the transmembrane components for transport (Locher, 2009). SapA and 
YejA are members of the Cluster C SBPs, these SBPs are structurally distinct from others as 
they contain an extra domain, giving rise to larger binding pockets which can accommodate 
larger substrates (Berntsson et al., 2010). Genetic and/or biochemical data have shown 
that Sap and Yej are important in the defence of bacteria against CAMPs. It is believed that 
SapA and YejA are able to recognise and bind CAMPs, transporting them to the cytoplasm 
before they have the chance to integrate into the bacterial cell membrane (Groisman et al., 
1992; Parra-Lopez, Baer and Groisman, 1993; Mason et al., 2006; Eswarappa et al., 2008; 
Shelton et al., 2011; Wang et al., 2016). However, CAMPs are large (20-30 residue) peptides 
that often contain secondary structure. How then do SapA and YejA accommodate these 
large and potentially structured CAMPs? 
We aimed to determine whether SapA and YejA bind CAMPs and if so how. A number of 
different strategies were employed to express soluble SapA at high enough concentrations 
to carry out biochemical and structural work, unfortunately this was not possible. YejA 
from E. coli on the other hand was cloned, expressed and purified successfully and was 
therefore taken forward in this study and its specificity investigated.  
6.1 SapA is an insoluble protein  
Several different constructs were created with the aim of producing high yields of soluble 
SapA. An E. coli SapA construct, which targeted production of SapA to the cytoplasm of the 
cell, was trialled with no success. Due to the predicted disulphide bonds in the SapA protein 
the next constructs contained a vector derived PelB leader sequence which targeted SapA 
to the periplasm where disulphide bond formation occurs. SapA from different species, S. 
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Typhimurium LT2 and H. influenzae, were also included to broaden the scope of the trials. 
Again, there was no success. Finally, an E. coli SapA construct was produced which 
contained the native leader sequence, again targeting the production of SapA to the 
periplasm with no soluble protein being produced.  
As well as creating different constructs different growth and protein production conditions 
were tested. Many different IPTG concentrations and growth temperatures were trialled, 
but little to no soluble SapA was produced. Lowering the IPTG concentration can increase 
the production of soluble protein in the cell by reducing the burden on the cell and 
therefore helps to ensure the protein being produced is properly processed (Donovan, 
Robinson and Click, 1996). Reducing the growth temperature of the cells can slow the rate 
of protein production and increase protein solubility, again by ensuring the correct 
processing of the protein (Schein and Noteborn, 1988).  
Although SapA was not taken forwards in this work, phylogenetic and bioinformatic 
analysis was carried out on the protein. The phylogenetic tree (Figure 3.1) shows SapA and 
DppA proteins positioned close together, indicating similarity between the two sets of 
proteins. SapA was also predicted to contain two disulphide bonds (Figure 3.2, 3.3), which 
are conserved in DppA. From sequence alignments (Figure 3.2) an aspartate residue is 
predicted to “cap” the binding site in E. coli SapA, this residue limits the length of the 
peptides bound by the SBPs which contain the capping aspartate and is a characteristic 
feature of SBPs binding shorter peptides. This analysis strongly suggested to us that SapA 
was a dipeptide binding protein, similar to DppA, and was therefore incapable of binding 
full length CAMPs. 
The difficulties of producing soluble SapA could be caused by protein misfolding. Misfolded 
proteins can aggregate into larger structures which are often insoluble, this type of 
aggregation can be caused by environmental stress, chemical modifications and 
destabilising mutations (Vendruscolo, 2012). Newly synthesised proteins, such as SapA 
upon addition of IPTG to the cells, are particularly vulnerable to misfolding and aggregation 
(Winkler et al., 2010). Aggregation can be caused by exposed hydrophobic regions of 
misfolded proteins interacting with hydrophobic regions of other misfolded proteins which 
leads to aberrant protein-protein interactions (Vabulas et al., 2010). Recombinant SapA 
was produced in the cytoplasm a location in which the formation of disulphide bonds is 
compromised. As disulphide bonds are often important for structure it is possible that 
producing SapA in the cytoplasm led to exposed hydrophobic regions, contributing to 
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protein misfolding, aggregation and insolubility. The misfolding could also have resulted 
from the large quantity and high rate of protein production as aggregation is a 
concentration dependent process (Vabulas et al., 2010).  
Molecular chaperones interact with most proteins as they are being translated and prevent 
premature folding/misfolding and aggregation (Vabulas et al., 2010). This is important for 
SapA with either a PelB leader sequence or native leader sequence as it passes through the 
Sec translocase to enter the periplasm. The Sec translocase only allows the passage of 
unfolded proteins, therefore SapA must be unfolded to pass through. SecB, the chaperone 
of the Sec translocase, maintains proteins in their unfolded state (du Plessis, Nouwen and 
Driessen, 2011). However, the rate of SapA production is vastly increased by the addition of 
IPTG to the cells which could overwhelm SecB as SecB production has not been increased 
accordingly with SapA production. This could lead to an accumulation of misfolded SapA in 
the cytoplasm as it cannot pass through the Sec translocase. Overproduction of SapA 
therefore overloads the capacity of the cell to support protein folding to the native 
structure.  
If the work on SapA had continued a number of other techniques would have been trialled 
in the quest for soluble protein. Fusion to maltose binding protein, a solubility tag, would 
have been used to try and increase the quantity of soluble SapA. Maltose binding protein is 
able to promote the solubility of aggregation-prone proteins and so would be a good 
option to try with SapA (Pryor and Leiting, 1997). There are other solubility tags which 
could have been tested in addition to the maltose binding protein, for example the 
glutathione S-transferase (GST) tag and the SUMO tag (Marblestone et al., 2006).   
6.2 EcYejA has a large binding pocket and binds peptides with an EPRYAFN 
motif 
EcYejA was crystallised and its structure determined by X-ray diffraction methods.  This led 
to the discovery of a ligand bound in the binding site of EcYejA. This was unexpected as 
during the purification process EcYejA had been treated with 2 M guanidine hydrochloride 
which is commonly used to remove any pre-bound ligands (Lanfermeijer et al., 1999). This 
suggested that the ligand was bound post-purification. The ligand was discovered to be 
LGEPRYAFNFN, and therefore derived from the N-terminal region of EcYejA itself. From the 
crystal structure of EcYejA it was clear to see that this N-terminal region is a loop packed 
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onto the surface of EcYejA and is not present in other Cluster C SBPs, such as BsAppA, 
StOppA and EcMppA, when superposed onto each other.  
The interactions between EcYejA and LGEPRYAFNFN (GEP) feature key side chain residues, 
mainly Arg5 and Asn9 of GEP. These residues form a number of hydrogen bonds with 
residues of EcYejA that serve to anchor GEP in the binding pocket (Figure 4.15A, 4.16B). 
Other side chains of GEP appear not to contribute significantly to the binding of GEP to 
EcYejA, it is backbone interactions that contribute most to binding. An emphasis on 
backbone interactions is not unusual with Cluster C peptide transporter SBPs as this allows 
the SBP to accommodate peptides of varying sequence but usually of a defined length. This 
strategy allows the cell to produce a single transporter to transport all the dipeptides 
encountered in the periplasm rather than producing a transporter for each specific 
dipeptide available, drastically reducing the work load of the cell. However, some Cluster C 
peptide transporter SBPs are highly specific, for example the transport of murein tripeptide 
by MppA. In this case hydrogen bonds and salt bridges are formed between side chains of 
the murein tripeptide and MppA, helping to make the interaction highly specific (Maqbool 
et al., 2011). To reduce the work load of the cell in this case MppA is an orphan SBP, 
meaning it is not found in an operon with a cognate transporter and so uses the OppBCDF 
transporter to transport murein tripeptide (Park et al., 1998). EcYejA contains components 
of both of these systems, specific side chain interactions, some backbone interactions and 
its own cognate transporter.  
LlOppA has the ability to bind a large range of peptide chain lengths (4-35 residues) but 
prefers peptides containing branched chain amino acids and at least one isoleucine. In the 
structure hydrogen bonds are mainly formed between LlOppA and the backbone of the 
bound peptides demonstrating that LlOppA has limited preference for sequence order, 
components and length. However, the isoleucine side chain sits in a hydrophobic pocket 
and is well defined in the electron density, indicating that it anchors the peptides to LlOppA 
and that specific position of isoleucine is highly important, the peptide chain can extended 
either way and for however long as long as the isoleucine of the peptide is anchored in the 
hydrophobic pocket (Berntsson et al., 2009). It is possible that Arg5 and Asn9 of the GEP 
peptide are anchoring it to EcYejA in a similar mechanism to that of LlOppA, therefore as 
long as those residues are present in the peptide at the correct spacing, EcYejA will bind 
the peptide.  
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EcYejA is very similar to LlOppA structure wise as it contains a large internal cavity, lacks 
the capping aspartate residue and substrates are possibly anchored by key side chain 
residues. However, specificity wise, EcYejA is more similar to MppA as it binds one specific 
peptide but can tolerate slight variations on the ends of that peptide.  
To determine other ligands of EcYejA, thermal shift assays were used where several 
different potential ligands were tested including; CAMPs, peptides of varying length, 
Microcin C like peptides and LGEPRYAFNFN based peptides. Only LGEPRYAFNFN was able 
to produce a large increase in the melting temperature of EcYejA that was indicative of 
binding.  
CAMPs have many different structures and sequences, it is possible that EcYejA does not 
have the ability to bind and recognise all of the different CAMPs (Pasupuleti, Schmidtchen 
and Malmsten, 2012). However, every effort was made to carefully select CAMPs that had 
been previously linked with YejA and resistance, for example Polymyxin B, Melittin and LL-
37 (Eswarappa et al., 2008; Wang et al., 2016). These were all tested for binding in thermal 
shift assays and none were shown to bind EcYejA. This indicates that EcYejA probably does 
not bind full length CAMPs. Although in this study no biochemical evidence has been found 
for EcYejA binding CAMPs, the genetic studies previously carried out clearly show the Yej 
transporter as a key component in resistance to CAMPs (Eswarappa et al., 2008; Wang et 
al., 2016). The work carried out here and the data from previous studies therefore indicate 
that the Yej transporter is important in resistance to CAMPs via a mechanism that does not 
involve the binding of full length CAMPs by YejA.  
It is unsurprising that the heptapeptide (MRTGNAD) analogues of Microcin C did not bind 
EcYejA in thermal shift assays. There has been work trying to identify the determinants of 
the specificity of YejA for Microcin C. It was found that Microcin C analogues must have a 
minimum peptide chain length of 6 residues together with an N-terminal formyl-methionyl-
arginyl sequence for transport to take place (Gaston et al., 2011). As a result, it was unlikely 
that any of the Microcin C analogues tested in this work would show binding to EcYejA, but 
they were tested to add breadth to the ligands trialled.  
Native ESI mass spectrometry and MALDI MS/MS was used to show binding of 
LGEPRYAFNFN to EcYejA. Related ligands from the N-terminus of EcYejA were also shown 
to bind to EcYejA, all of which contained a core motif of VLGEPRYAFN, this indicated some 
specificity of EcYejA. This was then probed further with more thermal shift assays which 
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determined the core motif to actually be EPRYAFN. The thermal shift assays also indicated, 
in general, that as the length of the ligand increased the shift in melting temperature 
increased accordingly. The largest peptide shown to bind EcYejA in this work was 15 
residues. 
It is not surprising that Arg5 of GEP is present in the conserved motif in view of its large 
contribution, 5 side chain hydrogen bonds, to the anchoring of GEP to EcYejA. Asn9 was 
also conserved throughout the ligands identified via mass spectrometry, again from the 
structure of EcYejA it is evidently a key residue in anchoring GEP to EcYejA with 3 side chain 
hydrogen bonds to the protein. It is possible that if shorter peptides had been present in 
the mass spectrometry solution containing Arg and Asn at the correct spacing, they would 
have bound. For example, the peptide RYAFN or RXXXN might have bound as they both 
contain Arg and Asn in the correct register. Interestingly, LGEPR and YAFNFN were shown 
to not bind EcYejA via thermal shift assays. Neither of these peptides contains both the Arg 
or Asn residues, lending more weight to the hypothesis that Arg and Asn are essential for 
EcYejA binding.  
From the mass spectrometry data it is clear that there are a range of EcYejA derived 
peptides in the solution. However, to produce any of these peptides EcYejA must have 
been cut at least twice (Figure 6.1). Figure 6.1 shows all of the different cut sites on EcYejA 
to produce all of the different peptides identified via native ESI-MS as being in complex 
with EcYejA.  
A known periplasmic peptidase, DegP, has been found to cleave between paired 
hydrophobic residues which could account for some of the cleavage sites indicated in 
Figure 6.1 (Jones et al., 2002). However, not much is known about the specificity of other 
periplasmic proteases and whether they would cleave YejA to produce the seen peptides.  
The transmembrane glycoprotein MUC1 undergoes self-cleavage in its extracellular domain 
to generate two subunits that specifically recognise and bind each other in a strong 
noncovalent interaction (Levitin et al., 2005). It is possible that YejA does something similar 
and self-cleaves in its N-terminal region to produce EPRYAFN containing peptides which it 
then goes on to bind.  
Inteins are another example of self-cleaving proteins, they excise themselves from a native 







Peptides shown to be in complex 
with EcYejA 
VLGEPRYAFNF 
   VLGEPRYAFNFN 
               FAVLGEPRYAFN 
            VLGEPRYAFNFNHFD 
              VLGEPRYAFNFNHFDY 
            AVLGEPRYAFNFNHFDY 
        AFAVLGEPRYAFNFNHFDY 
 
Figure 6.1. Cleavage sites on EcYejA to produce VLGEPRYAFN containing peptides. 
The sequence of the N-terminal region of EcYejA can be seen at the top of the figure, red 
lines indicate the cleavage sites required to produce all peptides found in complex with 
EcYejA. At the bottom of the figure is a table detailing all of the VLGEPRYAFN containing 
peptides found in complex with EcYejA. All peptides in the table have been aligned via the 




(Warren, Coolbaugh and Wood, 2013). It is possible that the EPRYAFN containing peptides 
are actually excising themselves from YejA, rather than a peptidase or YejA self-cleaving to 
remove them.  
It would be interesting to obtain accurate KD information for EcYejA and the different 
ligands identified via the mass spectrometry work, this would help further pinpoint the 
specificity of EcYejA. For example, it could help determine whether both the anchoring Arg 
and Asn contribute equally to the binding of ligands, whether there is an optimal peptide 
length and whether there is an optimal sequence.   
Whilst other ABC peptide importers are made up of 5 protein components, the Yej 
transporter is only made up of 4, with the YejF protein being a fused homodimeric NBD. 
This indicates that the role of the Yej transporter might be atypical, with the YejF 
component carrying out an additional perhaps unusual function such as signalling or 
protection. The ABC-F proteins contain two NBDs on a single polypeptide chain, much like 
YejF, but are not always associated with a transporter nor are they in operons encoding 
transporters. However, some ABC-F proteins do associate with TMDs to transport 
substrates, but it is clear that this is not the role of all ABC-F proteins. ABC-F proteins have 
been shown to drive dissociation of antibiotics bound to the ribosome to rescue translation 
in the cell via a mechanism of protein-mediated drug displacement (Sharkey, Edwards and 
O’Neill, 2016). It is possible that the YejF is able to dissociate from the transporter and carry 
out some similar role within the bacterial cell, possibly triggering resistance to CAMPs after 
they have been sensed in the periplasm.  
6.3 New model for stress-based sensing in E. coli 
From the data collected during this body of work we hypothesise that the transport of 
Microcin C by YejA is a subsidiary function of the transporter and that the true substrate of 
YejA is peptides containing the EPRYAFN motif. We propose that CAMPs enter the 
periplasm where they activate peptidases as a stress response to the presence of the 
CAMPs (Figure 6.2). These peptidases cleave the N-terminus of YejA to produce peptides 
with the core EPRYAFN motif which are bound by YejA and transported to the cytoplasm 
through the Yej transporter. The transport of these peptides activates YejF which then 
dissociates and possibly activates an LPS modifying enzyme, or other CAMP resistance 




Figure 6.2. Hypothetical mechanism of action for the Yej transporter. 
CAMPs are detected in the periplasm which activates peptidases. The peptidases then 
cleave the N-terminus of YejA releasing EPRYAFN containing peptides which are bound by 
YejA. Transport of these peptides activates YejF which then dissociates from the membrane 





When harvested the cells expressing EcYejA would have been in the stationary phase of 
growth. Stationary phase cells commonly induce a cellular stress response due to the 
exhaustion of the external environment and the accumulation of toxic side products from 
catabolism (Pletnev et al., 2015). This stress response could have activated peptidases and 
could explain the presence of the EPRYAFN containing peptides in the binding site of EcYejA 
without a CAMP stimulus. A way of testing this hypothesis would be to harvest the cells in 
the log phase of growth and carry out native ESI-MS and MALDI-MS/MS to identify any 
bound ligands.  
Pull down assays and tandem affinity purification could be used to investigate the 
interactions YejF makes with other proteins in the cell. These techniques work by fusing a 
tag to the protein of interest, in this case YejF, binding that protein to a column and then 
flowing cellular extract over the column. Proteins which interact with the protein of 
interest elute with the protein of interest when it is removed from the column (Puig et al., 
2001). Mass spectrometry could then be carried out on the eluted proteins to identify 
them.  
Activation of YejF could be caused by binding of ATP or ATP hydrolysis as it is a nucleotide 
binding domain and already contains two ATP binding sites which bind and hydrolyse ATP 
as the substrate is transported (Locher, 2009). ATP therefore seems like an obvious choice 
of activation molecule. To test this hypothesis non-hydrolysable ATP analogues could be 
used and downstream effects monitored.  
6.4 Conclusion 
The initial aims of this project were to characterise proteins which are thought to bind 
CAMPs with a view to developing new drugs to help tackle antibiotic resistance. Although it 
was not possible to show any involvement of either SapA or YejA with CAMPs in this work, 
solving the structure of YejA in a closed conformation and further binding experimentation 
with this protein has provided useful information which could be used in drug design.  
A new peptide drug could be designed based on the knowledge gained from the structure 
of YejA, possibly containing the EPRYAFN motif, which binds very tightly to YejA and is not 
transported or does not activate YejF. This peptide drug would then bind the majority of 
YejA, preventing YejA from binding EPRYAFN containing peptides which are transported 
and do activate YejF. By preventing the stress-based signalling system functioning correctly 
192 
 
CAMP resistance mechanisms would not be activated and would therefore leave naturally 









ABC – ATP Binding Cassette 
CAMP – Cationic Antimicrobial Peptide 
CD – Circular Dichroism 
CV – Column Volume 
DNA – Deoxyribonucleic Acid 
EcYejA – E. coli YejA 
HRV – Human rhinovirus 
IPTG – Isopropyl β-D-1-thiogalactopyranoside 
LB – Luria-Bertani broth 
MALDI-MS/MS – matrix-assisted laser desorption/ionisation mass spectrometry mass 
spectrometry 
Native ESI – Native electrospray ionisation 
NBD – Nucleotide Binding Domain 
PAGE – Polyacrylamide Gel Electrophoresis 
PCR – Polymerase Chain Reaction 
SBP – Substrate Binding Protein 
SEC – Size exclusion chromatography 
SEC-MALLS – Size Exclusion Chromatography Multi-Angle Laser Light Scattering 
SDS – Sodium Dodecyl Sulphate 
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